Document:

exhibit101-original

                                                                     Exhibit 10.1                                             CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED     BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY     CAUSE COMPETITIVE HARM TO RADIUS HEALTH, INC. IF PUBLICLY DISCLOSED                                                                                                                CONFIDENTIAL                                  LICENSE AGREEMENT                      This License Agreement (this “Agreement”), dated as of July 23, 2020 (the “Effective Date”), is   made by and between Radius Pharmaceuticals, Inc., organized under the laws of Delaware having business   offices at 950 Winter Street, Waltham, MA 02451 (“Radius”), and Berlin-Chemie AG – Menarini Group,   organized under the laws of Germany having business offices at Glienicker Weg 125, 12849 Berlin,  Germany (“Licensee”).  Radius and Licensee are sometimes hereinafter referred to each as a “Party” and   collectively as the “Parties.”          WHEREAS, Radius is engaged in the development of elacestrant (RAD1901), a selective estrogen  receptor degrader, and controls certain patent rights and know-how with respect thereto;          WHEREAS, Licensee desires to obtain exclusive rights under the Radius Patent Rights and Radius  Know-How in order to commercialize pharmaceutical products containing elacestrant (RAD1901)  including the Licensed Product (all capitalized terms as hereinafter defined);          WHEREAS, on the Effective Date, the Parties will enter into the Transition Services Agreement  (as hereinafter defined) pursuant to which Radius will conduct certain Development (as hereinafter defined)  activities relating to the Licensed Product, including submission of a Regulatory Filing in the United States,  until Licensee elects to take over such Development or until completion of the services contemplated in the  Transition Services Agreement; and          WHEREAS, the Parties desire to enter into an agreement pursuant to which Radius will grant an  exclusive license to Licensee under the Radius Patent Rights and Radius Know-How for Licensee to  Develop, Manufacture and Commercialize Licensed Compound and Licensed Products in the Territory (all  capitalized terms as hereinafter defined), all on the terms set forth below.          NOW, THEREFORE, the Parties hereby agree as follows:    Section 1.  Definitions.          For the purpose of this Agreement, the following terms and phrases (and cognates) will have the  meanings set forth below:          1.1   “Accounting Standards” means, with respect to Radius, U.S. Generally Accepted   Accounting Principles, and, with respect to Licensee, IFRS (International Financial Reporting Standards),   in each case, consistently applied.          1.2   “Affiliate” of a Person means any other Person which (directly or indirectly) is controlled   by, controls or is under common control with such Person.  For the purposes of this definition, the   term “control” (including, with correlative meanings, the terms “controlled by” and “under common   control with”) as used with respect to any Person means (a) in the case of a corporate entity, direct or   indirect ownership of voting securities entitled to cast at least fifty percent (50%) of the votes in the election   of directors, (b) in the case of a non-corporate entity, direct or indirect ownership of at least fifty   percent (50%), including ownership by trusts with substantially the same beneficial interest, of the equity   interests with the power to direct the management and policies of such Person, provided that if local law 

 

                                                                LICENSE AGREEMENT   restricts foreign ownership, control will be established by direct or indirect ownership of the maximum  ownership percentage that may, under such local law, be owned by foreign interests, or (c) the power to  direct the management or policies of a Person, whether through ownership of voting securities, by contract  or otherwise.          1.3   “Calendar Quarter” means the respective periods of three (3) consecutive calendar months   ending on March 31, June 30, September 30 and December 31.          1.4   “Calendar Year” means each successive period of twelve (12) months commencing on   January 1 and ending on December 31.          1.5   “Change of Control” means with respect to a Party, (a) completion of a merger,   reorganization, amalgamation, arrangement, share exchange, consolidation, tender or exchange offer,   private purchase, business combination, recapitalization or other transaction involving a Party as a result of   which the stockholders of such Party immediately preceding such transaction hold less than fifty percent   (50%) of the outstanding shares, or less than fifty percent (50%) of the outstanding voting power,   respectively, of the ultimate company or entity resulting from such transaction immediately after   consummation thereof (including a company or entity which as a result of such transaction owns the then-  outstanding securities of a Party or all or substantially all of a Party’s assets, either directly or through one  or more subsidiaries), (b) the adoption of a plan relating to the liquidation or dissolution of a Party, other  than in connection with a corporate reorganization (without limitation of clause (a), above); (c) any sale,  lease, exchange, contribution or other transfer (in one transaction or a series of related transactions) to a  Third Party of all or substantially all the assets of a Party (determined on a consolidated basis); or (d) the  sale or disposition to a Third Party of assets or businesses that constitute fifty percent (50%) or more of the  total revenue or assets of a Party (determined on a consolidated basis).          1.6   “China” means People’s Republic of China, including Hong Kong SAR, Macau SAR and   Taiwan.          1.7   “Clinical Studies” means any study in which human subjects are dosed with a drug,   whether approved or investigational, including any Phase 1, 2, 3 or 4 clinical study.          1.8   “Combination” means a Combination Product or Combination Therapy.          1.9   “Combination Product” means a Licensed Product that includes at least one additional   active ingredient other than Licensed Compound.  Drug delivery vehicles, adjuvants, and excipients will   not be deemed to be “active ingredients”, except in the case where such delivery vehicle, adjuvant, or   excipient is recognized as an active ingredient in accordance with 21 C.F.R. § 210.3(b)(7) (as amended), or  any foreign counterpart.          1.10  “Combination Therapy” means a therapy comprised of a Licensed Product and one or more   other therapeutically or prophylactically active ingredients, whether priced and sold in a single package   containing such multiple products, packaged separately but sold together for a single price, or sold under   separate price points but labeled for use together, including all dosage forms, formulations, presentations,   and package configurations.  Drug delivery vehicles, adjuvants, and excipients will not be deemed to be   “active ingredients”, except in the case where such delivery vehicle, adjuvant, or excipient is recognized as   an active ingredient in accordance with 21 C.F.R. § 210.3(b)(7) (as amended), or any foreign counterpart.          1.11  “Commercially Reasonable Efforts” means [*].                                           2   

 

                                                                LICENSE AGREEMENT          1.12  “Commercialize”, “Commercializing” or “Commercialization” means activities directed to   obtaining pricing and reimbursement approvals, carrying out Phase 4 clinical studies for, marketing,   promoting, distributing, importing, exporting, offering for sale or selling any pharmaceutical product,   including any Licensed Product.          1.13  “Commercialization Budget” means the budget for conducting Commercialization of any   Licensed Product in the Territory pursuant to the Commercialization Plan during a given Calendar Year   and the two (2) succeeding Calendar Quarters, which budget will be updated and amended concurrently   with the Commercialization Plan in accordance with Section 5.1(b).          1.14  “Commercialization Plan” means the plan setting forth the activities and timelines relating   to the Commercialization of any Licensed Product in the Territory during a given Calendar Year and the   [*] ([*]) succeeding Calendar Quarters, including the Commercialization Budget and annual Net Sales   forecasts for the Territory, as updated and amended from time to time in accordance with the procedures   set forth in this Agreement.  Licensee will provide an initial Commercialization Plan to Radius within [*]   ([*]) months after the Effective Date of this Agreement.          1.15  “Companion Diagnostic” means any product or service, in each case approved, cleared or   authorized by the competent Regulatory Authority in the Territory, that: (a) identifies a person having a   disease or condition or a molecular genotype or phenotype that predisposes a person to such disease or   condition, in each case, for which a Licensed Compound or Licensed Product could be used to treat or   prevent such disease or condition; or (b) is used to select a therapeutic or prophylactic regimen, wherein at   least one (1) potential such therapeutic or prophylactic regimen involves a Licensed Compound or Licensed   Product, and where the selected regimen is determined to likely be effective or to be safe for a person, based   on the use of such product or service.          1.16  “Confidential Information” means all Know-How, marketing plans, strategies and   customer lists, and other information or material that are disclosed or provided by a Party or its Affiliates   to the other Party or its Affiliates, regardless of whether any of the foregoing are marked “confidential”   or “proprietary” or communicated to the other by the disclosing Party or its Affiliates in oral, written,   graphic, or electronic form.          1.17  “Confidentiality Agreement” means the Confidential Disclosure Agreement, dated as of   January 23, 2019, by and between Radius and an Affiliate of Licensee.          1.18  “Controlled” means, with respect to any Know-How, patent rights or other intellectual   property right, the possession (whether by ownership or license, other than by a license or sublicense   granted pursuant to this Agreement) by a Party or its Affiliates of the ability to grant to the other Party a   license or access as provided herein to such item, without violating the terms of any agreement or other   arrangement with any Third Party or, other than under the Duke License Agreement or the Eisai License   Agreement, being obligated to pay any royalties or other consideration therefor, in existence as of the time   such Party or its Affiliates would first be required hereunder to grant the other Party such license or access.   For clarity, the Duke Patent Rights and Eisai IP are “Controlled” by Radius unless and until assigned by  Radius to Licensee.          1.19  “Develop”, “Developing” or “Development” means non-clinical and clinical drug   development activities reasonably related to the development and submission of information to a   Regulatory Authority, including toxicology, pharmacology and other discovery and pre-clinical efforts, test   method development and stability testing, manufacturing process development and improvement, process   validation, process scale-up, formulation development, delivery system development, quality assurance and   quality control development, statistical analysis, Clinical Studies, regulatory affairs, and Regulatory                                          3   

 

                                                                LICENSE AGREEMENT   Approvals (and specifically excluding activities directed to obtaining pricing and reimbursement  approvals).          1.20  “Development Budget” means the budget for conducting Development of the Licensed   Compounds and Licensed Products pursuant to the Development Plan, which budget will be updated and   amended concurrently with the Development Plan in accordance with Section 4.1(c).          1.21  “Development Plan” means the plan setting forth the activities and timelines relating to the   Development of the Licensed Compounds and Licensed Products in the Field in the Territory, including all   of the activities and timelines through the achievement of Regulatory Approval in the Major Market   Countries for at least one (1) Licensed Product as a monotherapy for each Indication reflected in such   Development Plan, including as applicable with respect to any Combination Products. An initial draft of  the Development Plan for the Territory excluding the United States will be provided to Radius within [*]  ([*]) months after the Effective Date and shall be attached hereto as Exhibit A-1.          1.22  “Diligent Efforts” has the meaning set forth in the Transition Services Agreement.          1.23  “Duke License Agreement” means the Patent License Agreement dated as of December 8,   2017, between Radius and Duke University (“Duke”), as such agreement may be amended or restated from   time to time.          1.24  “Duke Patent Rights” has the meaning set forth in the preamble to Exhibit F.          1.25  “Duke Patent Prosecution and Maintenance Costs” has the meaning set forth in Clause 1.3   of Exhibit F.          1.26  “Eisai Know-How” means [*].          1.27  “Eisai IP” means the Eisai Know-How, Eisai Patents, and Eisai’s undivided interest in the   Joint Patents.          1.28  “Eisai License Agreement” means the License Agreement dated as of June 29, 2006,   between Radius and Eisai Co., Ltd. (“Eisai”), as such agreement may be amended or restated from time to   time.          1.29  “Eisai Patents” means all patents and patent applications which are or become owned by   Eisai and/or its Affiliates, or to which Eisai and/or its Affiliates, otherwise have, now or in the future, the   right to grant licenses, and which generically or specifically claim Compound and/or Product, a use for   Compound and/or Product, a process for manufacturing Compound and/or Product, or an intermediate use   in such process. Included within the definition of Eisai Patents are all continuations, continuations-in-part,   divisions, patents of addition, reissues, re-examinations, renewals or extensions thereof and all   Supplementary Protection Certificates. Also included within the definition are any improvements on   Compound and/or Product or intermediates or manufacturing process required or useful for production of   Compound and/or Product which are developed by or for Eisai and/or its Affiliates, or to which Eisai and/or   its Affiliates otherwise has the right to grant licenses, now or in the future, during the term of this   Agreement. Eisai Patents also includes any patent application covering an invention solely owned by Eisai   in accordance with Article 6.4 of the Eisai License Agreement. The Eisai Patents existing as of the Effective   Date as set forth in Exhibit C-2.           1.30  “EMA” means the European Medicines Agency and any successor agency thereto.                                           4   

 

                                                                LICENSE AGREEMENT          1.31  “European Union” or “E.U.” means the European Union and all its then-current member   countries but including in any case France, Germany, Italy, Spain and the United Kingdom regardless of   whether they are then-current member countries.          1.32  “Euro” or “EUR” means Euros, the currency of the European Union.          1.33  “Executive Officers” means (a) for Radius, [*]; and (b) for Licensee, [*]. In the event that   the position of any of the Executive Officers identified in this Section  1.33 no longer exists due to a  corporate reorganization, corporate restructuring or the like that results in the elimination of the identified  position, the applicable Executive Officer will be replaced with another executive officer with  responsibilities and seniority comparable to the eliminated Executive Officer.          1.34  “FDA” means the United States Food and Drug Administration or any successor agency   thereto.          1.35  “Field” means [*].          1.36  “First Commercial Sale” means, with respect to any Licensed Product in a given country   or region in the Territory, the first sale of such Licensed Product in such country or region. Notwithstanding   the foregoing, sales for Clinical Studies purposes or compassionate or similar use will not be considered to   constitute a First Commercial Sale. For clarity, First Commercial Sale will be determined on a Licensed  Product-by-Licensed Product and country-by-country (or region-by-region) basis, as applicable.          1.37  “Generic Product” means, with respect to a particular Licensed Product in a country, a   generic pharmaceutical product that: (a) (i) contains the same active ingredient as the Licensed Compound   in such Licensed Product; and (ii) is approved for use in such country by a Regulatory Authority through   an Abbreviated New Drug Application (as permitted in the United States of America pursuant to the Federal  Food, Drug, and Cosmetic Act, as amended, and the regulations promulgated thereunder, pursuant to Article  10.1 of Directive 2001/83/EC of the European Parliament and Council of 6 November 2001, as amended,  or any enabling legislation thereof, or pursuant to any similar abbreviated route of approval in any other  countries in the Territory); or (b) (i) contains the same active ingredient as the Licensed Compound in such  Licensed Product; and (ii) is approved for use in such country by a Regulatory Authority through a  regulatory pathway referencing clinical data first submitted by a Party or its Affiliates or Sublicensees for  obtaining Regulatory Approval for such Licensed Product.          1.38  “Good Clinical Practice” means the current standards for clinical trials for pharmaceuticals,   as set forth in the ICH guidelines and applicable regulations promulgated thereunder, as amended from time   to time, and such standards of good clinical practice as are required by any organizations and Governmental   Authorities in countries in which a Licensed Product is intended to be sold to the extent such standards are   not less stringent than United States Good Clinical Practice.          1.39  “Good Laboratory Practice” means the current standards for laboratory activities for   pharmaceuticals, as set forth in the FDA’s Good Laboratory Practice regulations or the Good Laboratory  Practice principles of the Organization for Economic Co-Operation and Development, as amended from  time to time, and such standards of good laboratory practice as are required by any organizations and  Governmental Authorities in countries in which a Licensed Product is intended to be sold, to the extent  such standards are not less stringent than United States Good Laboratory Practice.          1.40  “Good Manufacturing Practice” means the part of quality assurance which ensures that   products are consistently produced and controlled in accordance with the quality standards appropriate to   their intended use as defined in 21 C.F.R. § 210 and 211, European Directive 2003/94/EC, Eudralex 4,                                          5   

 

                                                                LICENSE AGREEMENT   Annex 16 (in each case as amended), and applicable United States, EU, Canadian and ICH Guidance or  regulatory requirements for a Licensed Product.          1.41  “Governmental Authority” means any United States federal, state or local or any foreign   government, or political subdivision thereof, or any multinational organization or authority or any authority,   agency or commission entitled to exercise any administrative, executive, judicial, legislative, police,   regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division   thereof), or any governmental arbitrator or arbitral body.          1.42  “ICH” means the International Conference on Harmonization of Technical Requirements   for Registration of Pharmaceuticals for Human Use.          1.43  “In-License Agreements” means the Duke License Agreement and Eisai License   Agreement.          1.44  “IND” means an Investigational New Drug application, Clinical Study Application,   Clinical Trial Exemption, or similar application or submission for approval to conduct human clinical   investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of   such Regulatory Authority (which in countries of the E.U. and in other markets may include an   “Investigational Medicinal Product Dossier” or “IMPD” filed or to be filed as part of the application to the   relevant Regulatory Authority).          1.45  “Indication” means a disease (a) for which a Licensed Product is indicated for treatment   and (ii) that is described in the Licensed Product label as required by the Regulatory Approval granted by   the applicable Regulatory Authority. An Indication is only distinct from another Indication (a) if the   diseases associated with such Indications are listed in two (2) different blocks of the ICD-10 and (b)   Regulatory Approvals are based, in whole or in part, on separate clinical studies.          1.46  “Japan” means Japan, including its territories and possessions.          1.47  “Joint Inventions” has the meaning set forth in Clause 1.10 of Exhibit G.          1.48  “Joint Patent Agreement” has the meaning set forth in Clause 1.10 of Exhibit G.          1.49  “Joint Patents” has the meaning set forth in Clause 1.10 of Exhibit G.          1.50  “Know-How” means know-how, trade secrets, chemical and biological materials,   formulations, information, documents, studies, results, data and regulatory approvals, data (including from   Clinical Studies), filings and correspondence (including DMFs), including biological, chemical,   pharmacological, toxicological, pre-clinical, clinical and assay data, manufacturing processes and data,   specifications, sourcing information, assays, and quality control and testing procedures, whether or not   patented or patentable.          1.51  “Knowledge” means the actual knowledge of a Party or any of its Affiliates without any   duty of inquiry.          1.52  “Law” means any federal, state, provincial, local, international or multinational law,   statute, standard, ordinance, code, rule, regulation, resolution or promulgation, or any order, writ, judgment,   injunction, decree, stipulation, ruling, determination or award entered by or with any Governmental   Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any   similar provision having the force or effect of law.                                          6   

 

                                                                LICENSE AGREEMENT          1.53  “Licensed Compound” means the compound known as elacestrant (RAD1901), as further   described on Exhibit B, the backup compounds listed on Schedule 1.53, and in each case, any modification,  improvement, derivative or Structural Analog thereof, including any metabolite, salt, ester, free acid form,  free base form, crystalline form, amorphous form, pro-drug form, racemate, chelate, polymorph, tautomer,  solvate, or optical isomer thereof.          1.54  “Licensed Product” means any pharmaceutical product containing any Licensed   Compound (alone or with other active ingredients), in all forms, presentations, formulations and dosage   forms. For clarification, Licensed Product will include any Combination.           1.55  “Licensee-Eisai Joint Invention” has the meaning set forth in Clause 1.4 of Exhibit G.          1.56  “Licensee-Eisai Joint Patent” has the meaning set forth in Clause 1.10 of Exhibit G.          1.57  “Licensee-Invented Patents” has the meaning set forth in the preamble to Exhibit G.          1.58  “Loss of Market Exclusivity” means an event where, with respect to any Licensed Product   in any country one or more Generic Products are being marketed in such country.          1.59  “Loss of Market Exclusivity Initial Threshold” means, on a Licensed Product-by-Licensed   Product and country-by-country basis, (a) Loss of Market Exclusivity has occurred for such Licensed  Product in such country, and (b) average quarterly total aggregate sales in value of such Licensed Product  sold in that country during any Calendar Quarter following introduction of such Generic Product in such  country have fallen by at least [*] ([*]) in that country as compared to the average quarterly total aggregate  sales in value of such Licensed Product sold in such country during the last [*] ([*]) full Calendar Quarters  prior to the Calendar Quarter in which such Generic Product was first introduced.          1.60  “MAA” means (a) a marketing authorization application filed with (i) the EMA under the   centralized EMA filing procedure or (ii) a Regulatory Authority in any country of the European Union if   the centralized EMA filing procedure is not used or (b) any other equivalent or related regulatory   submission, in either case to gain approval to market a Licensed Product in any country in or outside the   European Union, in each case including, for clarity, amendments thereto and supplemental applications.          1.61  “Major Market Countries” means each of China, France, Germany, Italy, Spain, the United   States and the United Kingdom.          1.62  “Manufacture” or “Manufacturing” means activities related to the manufacture,   formulation and packaging of any compound or product, including any Licensed Compounds and Licensed   Products, including related quality control and quality assurance and product release activities.          1.63  “NDA” means a New Drug Application filed with the FDA (including amendments and   supplements thereto) to obtain Regulatory Approval in the U.S., or any corresponding applications or   submissions filed with the relevant Regulatory Authorities to obtain Regulatory Approvals in any other   country or region in the Territory (including any MAA).          1.64  “Net Sales” means the aggregate amount billed, invoiced or otherwise charged by   Licensee, its Affiliates or Sublicensees for the sale of the Licensed Products to a Third Party in the Territory,   less the following deductions related to Licensed Products, to the extent such deductions are actually paid   or incurred, and are reasonable and customary: [*]. Net Sales will be determined from the books and records   of Licensee, its Affiliates and Sublicensees maintained in accordance with the Accounting Standards. Net   Sales for any Combination will be calculated on a country-by-country basis by multiplying actual Net Sales                                          7   

 

                                                                LICENSE AGREEMENT   of such Combination by the fraction A/B, where A is the gross invoice price for the Licensed Product  contained in such Combination if such Licensed Product is sold separately in finished form in such country,  and B is the gross invoice price for such Combination in such country. If such Licensed Product is not sold  separately in finished form in such country, the Parties will determine Net Sales for such Licensed Product  by mutual agreement based on the relative contribution of such Licensed Product and each such other active  ingredients in such Combination in accordance with the above formula, and will take into account in good  faith any applicable allocations and calculations that may have been made for the same period in other  countries.          1.65  “Patent Challenge” means any challenge in a legal or administrative proceeding to the   patentability, validity or enforceability of any of the Radius Patent Rights (or any claim thereof), including   by: (a) filing or pursuing a declaratory judgment action in which any of the Radius Patent Rights is alleged   to be invalid or unenforceable; (b) citing prior art against any of the Radius Patent Rights (other than art   required to be cited under a duty of candor to a patent office), filing a request for or pursuing a re- examination of any of the Radius Patent Rights (other than with Radius’s written agreement), or becoming  a party to or pursuing an interference; or (c) filing or pursuing any re-examination, opposition, cancellation,  nullity or other like proceedings against any of the Radius Patent Rights; but excluding any challenge raised  as a defense against a claim, action or proceeding asserted by Radius or its Affiliates against Licensee or  its Affiliates or Sublicensees.          1.66  “Person” means an individual, sole proprietorship, partnership, limited partnership, limited   liability partnership, corporation, limited liability company, business trust, joint stock company, trust,   beneficiary or trustee of any trust, incorporated association, joint venture, or similar entity or organization,   including a government or political subdivision or department or agency of a government.          1.67  “Phase 3 Clinical Study” means a clinical study of a product on a sufficient number of   subjects that is designed to establish that a pharmaceutical product is safe and efficacious for its intended   use, and to determine warnings, precautions, and adverse reactions that are associated with such   pharmaceutical product in the dosage range to be prescribed, which trial is intended to support Regulatory   Approval of such product, as described in 21 C.F.R. 312.21(c) (as amended or any replacement thereof), or   a similar clinical study prescribed by the Regulatory Authorities in a foreign country.          1.68  “Pivotal Study” means, with respect to any Licensed Product, a clinical study that at the   time of initiation (or any later point, if applicable), is expected or otherwise designed to provide the basis   for submitting an application for Regulatory Approval for such Licensed Product thereof, including but not   limited to a Phase II/III clinical study or Phase IIb clinical study.          1.69  “Prosecute” or “Prosecution” means in relation to any patent rights, (a) to prepare and file   patent applications, including re-examinations or re-issues thereof, and represent applicants or assignees   before relevant patent offices or other relevant Governmental Authorities during examination, re- examination and re-issue thereof, in appeal processes and interferences, or any equivalent proceedings,  (b) to defend all such applications against Third Party oppositions or other challenges, (c) to secure the  grant of any patents arising from such patent application, (d) to maintain in force any issued patent  (including through payment of any relevant maintenance fees), (e) obtain and maintain patent term  extension or supplemental protection certificates or their equivalents, and (f) to make all decisions with  regard to any of the foregoing activities.          1.70  “Prosecuting Party” has, with respect to a Joint Patent, the meaning set forth in Clause 1.10   of Exhibit G.          1.71  “Radius-Eisai Joint Invention” has the meaning set forth in the preamble to Exhibit G.                                          8   

 

                                                                LICENSE AGREEMENT          1.72  “Radius-Eisai Joint Patent” has the meaning set forth in the preamble to Exhibit G. The   Radius-Eisai Joint Patents existing as of the Effective Date are set forth in Exhibit C-3.          1.73  “Radius-Invented Patent Prosecution and Maintenance Costs” has the meaning set forth in   Clause 1.9 of Exhibit G.           1.74  “Radius-Invented Patents” has the meaning set forth in the preamble to Exhibit G. The   Radius-Invented Patents existing as of the Effective Date are set forth in Exhibit C-3.          1.75  “Radius Know-How” means (a) all Know-How Controlled by Radius or any of its   Affiliates as of the Effective Date and that is solely related to the Licensed Compounds or Licensed   Products, and (b) all Know-How within the TSA Inventions.          1.76  “Radius Patent Rights” means (a) the patents and patent applications listed in Exhibit C-1,   C-2 and C-3 attached hereto, plus any conversion, continuation, division or substitution thereon, any   reissues, reexaminations or extensions thereof, any continuation-in-part application or patent that is entitled   to the priority date of, and is directed specifically to subject matter specifically described in, at least one of   the patents or patent applications described above, and any foreign counterparts of any of the foregoing,   and (b) all patents and patent applications that specifically claim or cover the TSA Inventions, plus any   conversion, continuation, division or substitution thereon, any reissues, reexaminations or extensions   thereof, any continuation-in-part application or patent that is entitled to the priority date of, and is directed   specifically to subject matter specifically described in, at least one of the patents or patent applications   described above, and any foreign counterparts of any of the foregoing. For the sake of clarity, the Radius   Patent Rights include the Duke Patent Rights, the Eisai Patents, the Joint Patents and the Radius-Invented   Patents.          1.77  “Regulatory Approval” means, with respect to a country or region in the Territory,   approvals, licenses, registrations or authorizations from the relevant Regulatory Authority necessary in   order to import, distribute, market or sell a pharmaceutical product (including any Licensed Product) in   such country or region, but not including any pricing or reimbursement approvals. Regulatory Approvals  include approvals by the relevant Regulatory Authority of an NDA.          1.78  “Regulatory Authority” means the FDA, the EMA, and any other analogous government   regulatory authority or agency involved in granting approvals (including any required pricing or   reimbursement approvals) for the Development, Manufacture or Commercialization of any pharmaceutical   product (including any Licensed Product) in the Territory.          1.79  “Regulatory Exclusivity” means any exclusive marketing rights or data exclusivity rights   conferred by any Regulatory Authority with respect to a Licensed Product other than patent rights,   including, without limitation, rights conferred in the U.S. under the Hatch-Waxman Act or the FDA   Modernization Act of 1997 (including pediatric exclusivity), orphan drug exclusivity, or rights similar   thereto outside the U.S.          1.80  “Regulatory Filing” means any documentation comprising or relating to or supporting any   filing or application with any Regulatory Authority with respect to any compound or product (including   any Licensed Compound or Licensed Product), or its use or potential use in humans, including any   documents submitted to any Regulatory Authority and all supporting data, including INDs and NDAs, and   all correspondence with any Regulatory Authority with respect to such compound or product (including   minutes of any meetings, telephone conferences or discussions with any Regulatory Authority).          1.81  [*].                                          9   

 

                                                               LICENSE AGREEMENT         1.82  “Structural Analog” means a compound covered by the chemical structure set forth on  Schedule 1.82.         1.83  “Sublicensee” means any Affiliate of Licensee or any Third Party that is granted a license  or sublicense by Licensee in accordance with Section 2.2 with respect to the Licensed Compound or  Licensed Product.         1.84  “Territory” means worldwide.         1.85  “Third Party” means any Person other than Licensee or Radius or any of their respective  Affiliates.         1.86  “Transfer Inventory” means the Licensed Compounds and Licensed Products and other  materials and data listed on a schedule to be mutually agreed by the Parties in the Transition Services  Agreement in the quantities as set forth therein, in the form in which it exists as of the Effective Date and  to the extent such can be transferred in compliance with applicable Laws and in accordance with the relevant  informed consents.         1.87  “TSA Inventions” has the meaning set forth in the Transition Services Agreement.         1.88  “United States” or “U.S.” means the United States of America, including its territories and  possessions, and the District of Columbia.         1.89  “US$” means US dollars, the currency of the U.S.         The following additional defined terms have the meanings set forth in the section indicated:         Defined Term                         Section        Additional Payment                   Section 7.5(e)(iii)        Affected Party                       Section 11.3        Agreement                            Introductory Paragraph        Alternative Product                  Section 2.3(b)        Bankruptcy Event                     Section 11.3        Claim                                Section 10.6(c) 10.6(c)        CREATE Act                           Section 8.1(g)        CRE Considerations                   Section  1.11        Disclosing Party                     Section 9.1(a)        Effective Date                       Introductory Paragraph        Existing Licensed Product Contracts  Section 3.3        Generic Step-Down Rate               Section 7.3(c)(ii)        Hatch-Waxman Time Period             Section 8.2(b)        Indemnitee                           Section  10.6(c)        Indemnitor                           Section  10.6(c)        Issuing Party                        Section 9.2(c)        Licensee                             Introductory Paragraph        Licensee Indemnitees                 Section 10.6(b)        Losses                               Section 10.6(a)        Milestone Events                     Section 7.2(a)        Milestone Payments                   Section 7.2(a)        Non-Publishing Party                 Section 9.2(e)                                         10               

 

                                                               LICENSE AGREEMENT         Party                                Introductory Paragraph        Publishing Party                     Section 9.2(e)        Radius                               Introductory Paragraph        Radius Indemnitees                   Section 10.6(a)        Receiving Party                      Section 9.1(a)        Release                              Section 9.2(c)        Reversion IP                         Section 11.7(f)        Reviewing Party                      Section 9.2(c)        Sublicense                           Section 2.2(b)        Term                                 Section 11.1        Transition Services Agreement        Section 3.4        U.S. Know-How Step-Down Rate         Section 7.3(c)(i)        Withholding Action                   Section 7.5(e)(ii)    Section 2.  License Grants.         2.1   License Grants.                (a)   Subject to the terms and conditions of this Agreement, Radius, on behalf of itself   and its Affiliates, hereby grants to Licensee a non-transferable (except in accordance with Section 12.1),   exclusive (even as to Radius), royalty-bearing license, with the right to sublicense in accordance with   Section 2.2 only, under the Radius Patent Rights and Radius Know-How, to Develop, have Developed,   make, have made, use, sell, offer for sale, Commercialize, import and export one or more Licensed   Compound(s) and Licensed Product(s) in the Field in the Territory.                (b)   Notwithstanding the exclusive license granted to Licensee in Section 2.1(a),  Radius and its Affiliates will retain the non-exclusive rights under the Radius Patent Rights and Radius  Know-How to (i) make, have made, use and have used Licensed Compounds, and Licensed Products for  non-clinical and clinical research purposes, and (ii) to exercise its rights and perform its obligations under  the Transition Services Agreement. The licenses granted in this Section 2.1 will not grant or create (by  implication, estoppel or otherwise) any license or right under any Radius Patent Rights or Radius Know- How to Develop, Manufacture or Commercialize any molecule that is not a Licensed Compound or  Licensed Product. The foregoing retained rights are sublicensable by Radius to Third Parties only with  the prior written consent of Licensee, which consent will not be unreasonably withheld, conditioned or  delayed.         2.2   Sublicenses.                (a)   Licensee may grant sublicenses (or any options to a sublicense) of the rights  granted by Radius to Licensee hereunder (i) to its Affiliates without prior written consent, and (ii) to Third  Parties only with the prior written consent of Radius.                (b)  Each sublicense (or any option to a sublicense) granted by a Licensee to a Third  Party pursuant to this Section 2.2 (each a “Sublicense”) will (i) be in writing; (ii) be subject and   subordinate to, and consistent with, the terms and conditions of this Agreement; (iii) require the applicable   Sublicensee to comply with all applicable terms of this Agreement (except for the payment obligations,   for which Licensee will remain responsible) and contain such obligations as to permit Licensee to comply   with its obligations under this Agreement and to permit Radius to comply with Radius’ obligations under   the In-License Agreements. Licensee will provide Radius with a copy of each agreement containing any   Sublicense or any amendment or modification to any Sublicense within [*] ([*]) days of execution. No                                         11               

 

                                                                LICENSE AGREEMENT    Sublicense will diminish, reduce or eliminate any obligation of Licensee under this Agreement, and   Licensee will remain responsible for its obligations under this Agreement and will be responsible for the   performance of the relevant Sublicensee as if such Sublicensee were “Licensee” hereunder. Each   Sublicense granted by Licensee to any rights licensed to it hereunder will terminate immediately upon the   termination of the license from Radius to Licensee with respect to such rights.          2.3   Exclusivity and Alternative Products.                 (a)   Exclusivity. Beginning on the Effective Date until the date that is [*], except   pursuant to the terms of this Agreement, neither Licensee nor any of its Affiliates shall (alone or with or   for any Third Party) [*]. To Licensee’s Knowledge, as of the Effective Date, neither Licensee nor any of   its Affiliates owns or otherwise in-licenses any compound or product that qualifies as an Alternative   Product hereunder.                 (b)  For purposes hereof, “Alternative Product” means [*].          2.4   License Limitations and In-License Agreements.                 (a)   Except as expressly set forth in this Agreement, no licenses or other rights are   granted or created hereunder to use any patent right, Know-How or other intellectual property rights   owned or in-licensed by Radius or any of its Affiliates. All licenses and other rights are or will be granted   only as expressly provided in this Agreement, and no other licenses or other rights are or will be created   or granted hereunder by implication, estoppel or otherwise.                (b)   Radius represents to Licensee, and Licensee acknowledges, that sublicenses   granted to Licensee under Section 2.1(a) are subject to the rights and obligations of Radius under the In-  License Agreements. Radius will comply with all applicable provisions of the In-License Agreements,   and will perform and take such actions as may be required to allow Radius to comply with its obligations   thereunder. In addition, Radius shall not amend or modify the In-License Agreements in a way that would   have a material adverse effect on Licensee’s rights and obligations hereunder without Licensee’s consent.   Licensee shall perform under this Agreement and shall take all reasonable actions required by Radius to   permit Radius to comply with Radius’ obligations under the In-License Agreements.    Section 3.  Transfer of Radius Know-How; Transfer Inventory; Existing Licensed Product               Agreements; Transition Services.          3.1   Radius Know-How. During the [*] ([*]) day period following the Effective Date, Radius   will provide to Licensee one (1) electronic copy of all documents, data or other information in Radius’s or   its Affiliates possession or Control as of the Effective Date to the extent that such documents, data or other   information describe or contain Radius Know-How and the relevant know-how of Radius’ licensors and  Third Party providers concerning the Licensed Compound and the Licensed Product. During the term of   the Transition Services Agreement, Radius will continue to deliver to Licensee all Radius Know-How with   respect to Licensed Compound and Licensed Product in Radius’s or its Affiliates possession or Control.          3.2   Transfer Inventory. As set forth in the Transition Services Agreement, Radius will transfer   to Licensee, at Licensee’s sole cost (including both for the transfer and Radius’ and its Affiliates’ fully   burdened manufacturing costs therefor), all Transfer Inventory in accordance with a schedule to be mutually   agreed by the Parties; provided, however, that such transfer timeline may be reasonably extended for items   that, despite Diligent Efforts by Radius, are not practicable to transfer within such time period, in which  case Radius will continue to use Diligent Efforts to transfer such items as promptly as practicable after such  period.                                          12   

 

                                                                LICENSE AGREEMENT          3.3   Existing Licensed Product Agreements. Radius has entered into certain contracts, listed on   an exhibit to the Transition Services Agreement, with Third Parties, which contracts relate solely to the  Development, Manufacture or Commercialization of any Licensed Compound or Licensed Product (the  “Existing Licensed Product Contracts”). Upon Licensee’s request, Radius will use Diligent Efforts (subject,   as applicable, to the applicable terms thereof, including any consent of the counterparty thereto) to obtain,   as applicable, the consent of the counterparty to assign and to assign the Existing Licensed Product   Contracts to Licensee. After such assignment, Licensee will be solely responsible for the performance of  the obligations (including payment obligations), which arise on or after the relevant assignment date, under  the Existing Licensed Product Contracts.          3.4   Transition Services Agreement. On the Effective Date, the Parties will execute the   transition services agreement in a form substantially identical to the one attached hereto as Exhibit D (the   “Transition Services Agreement”), pursuant to which Radius will perform certain clinical, regulatory and   other activities in the interest of Licensee relating to the Licensed Compounds, Licensed Products and, to   the extent applicable, Companion Diagnostic.    Section 4.  Development.          4.1   Development Plan; Amendments; Development Responsibilities.                 (a)   Development Plan. Except as set forth in the Transition Services Agreement, the   global Development of the Licensed Compounds and Licensed Products, including pre-clinical   Development activities, if any, will be governed by the Development Plan. Licensee agrees to exercise   Commercially Reasonable Efforts to conduct all Development activities relating to the Licensed Products   as a monotherapy in the Major Market Countries in accordance with the Development Plan (except for   those activities for which Radius is responsible under the Transition Services Agreement) at Licensee’s   sole cost and expense. Additionally, during the Term Licensee will continue evaluating the opportunity to   Develop Combinations, provided that Licensee shall not be under any obligation to Develop   Combinations. The outcome of such evaluations will be shared with Radius. Licensee may not Develop,   Commercialize, or otherwise exploit any Combination Product without Radius’ prior written consent, not   to be unreasonably withheld.                (b)   Transition Services. The Parties acknowledge that pursuant to the Transition   Services Agreement, Radius is responsible for performing the Services (as defined in the Transition   Services Agreement) in accordance with the Development Plan and with the Services Schedules (as   defined in the Transition Services Agreement), and the Transition Services Agreement provides for the   reimbursement by Licensee of the costs incurred by Radius in performing such Services in accordance   with the Development Budget set forth therein. Within [*] ([*]) months after the Effective Date of this   Agreement, Licensee will provide Radius with a Development Plan relating to the Licensed Product as a   monotherapy for the registration of the Licensed Product outside the U.S.. Licensee may amend the   Development Plan during the Term; provided that any such amendment is consistent with the Parties’   respective Development obligations set forth in Section 4.2 and in the Transition Services Agreement with   the aim at allowing the Licensed Product to enter into the market as soon as practicable in such Major   Market Countries. The Development Plan will include overall total estimated budget figures for the initial   Development Budget as described in Section 4.1(b). The Development Plan will include general study   design parameters, specific staffing requirements and the funding budget for each stage of clinical   Development for each Indication in the Development Plan, and will be consistent with the terms of this   Agreement. The terms of and activities set forth in the Development Plan will at all times be designed to   be in compliance with all applicable Laws and to be conducted in accordance with professional and ethical   standards customary in the pharmaceutical industry.                                          13   

 

                                                               LICENSE AGREEMENT               (c)   Development Budget. The Development Budget included in the Development  Plan will set forth the estimated budgeted amounts for Development costs and expenses under the  Development Plan. Within [*] ([*]) months after the Effective Date of this Agreement, Licensee will share   with Radius a Development Budget relating to the Development Plan of Licensed Product monotherapy   for the seeking of Regulatory Approval of the Licensed Product in the Major Market Countries outside of   the United States. Licensee may amend the Development Budget for the Major Market Countries during   the Term, always with the aim at allowing the Licensed Product to enter into the market as soon as   practicable in such Major Market Countries. Concurrently with the annual update of the Development   Plan in accordance with Section 4.2(c), Licensee also will prepare an updated Development Budget   covering the next Calendar Year and the two (2) succeeding Calendar Quarters thereafter and a forecast   of the annual development budgets through receipt of Regulatory Approval for each Indication reflected   in such Development Budget.                (d)  Updates to Development Plan. Should the Development Services be transferred   to Licensee pursuant to the provisions of the Transition Services Agreement and Radius receives notices   from Eisai which indicates that Eisai does not believe performance of the Development Plan is consistent   with the obligations to use Commercially Reasonable Efforts in Developing Licensed Compound and/or   Licensed Product in the Territory, Radius shall inform Licensee and the Parties shall immediately meet to   discuss in good faith on possible actions or conducts that the Parties would consider to be an acceptable   remediation of such inconsistency versus Eisai’s indications and in order to prevent any possible   complaint by Eisai.         4.2   Development Efforts; Manner of Performance; Reports.                (a)   Licensee Development Efforts. Without limiting the foregoing sentence and   except as set forth in the Transition Services Agreement, Licensee will use Commercially Reasonable   Efforts to seek and attempt to obtain Regulatory Approval for Licensed Products as monotherapy in each   of the Major Market Countries. Without limiting the generality of the foregoing, and except as set forth in   the Transition Services Agreement, Licensee will use Commercially Reasonable Efforts to execute and   perform, or cause to be performed, the Development Plan, in accordance with the timelines set forth   therein. Licensee will conduct its Development activities in good scientific manner and in compliance   with applicable Law, including Laws regarding environmental, safety and industrial hygiene, any   applicable anti-corruption or anti-bribery laws or regulations, and Good Laboratory Practice, Good   Clinical Practice, current standards for pharmacovigilance practice, and all applicable requirements   relating to the protection of human subjects.                (b)   Cost and Expense. Licensee will be responsible for the costs and expenses for all   Development activities under this Agreement in compliance with the Development Plan and Development   Budget and will keep Radius reasonably informed as to the progress of such activities.                (c)   Development Reports and Updates. Licensee will, through receipt of Regulatory   Approval for each Indication reflected in the Development Plan and with respect to its own Development   activities, (i) provide to Radius each Calendar Quarter, a written progress report that includes, as   applicable, information regarding accrual, site initiation, progress on protocol writing, meeting requests   and briefing documents, in the case of clinical or regulatory activities, and in other cases such information   as is reasonably necessary to convey a reasonably comprehensive understanding of the status of the   applicable Development activity, (ii) annually, together with the progress report delivered during the   Calendar Quarter that includes the anniversary of the Effective Date, Licensee shall provide Radius with   a copy of the then-current Development Plan and Development Budget and (iii) upon the request of   Radius, no more than once per Calendar Year, representatives of Licensee shall participate in a telephone   conference with Radius’ representatives to provide an oral update on and answer Radius’ questions                                         14               

 

                                                               LICENSE AGREEMENT   regarding Licensee’s progress in the Development of the Licensed Compounds and Licensed Products  (including to discuss the information in (i) and (ii) above). In addition to the foregoing, Licensee will   provide notice to Radius if Licensee elects to suspend or no longer proceed with Developing or   Commercializing any Licensed Compounds or Licensed Products for any Indication.               (d)   Compliance Audits. With respect to any facility or site at which Licensee  conducts Development activities pursuant to this Agreement or the Development Plan, Radius will have  the right, at its expense, upon reasonable written notice to Licensee (and if applicable, such Affiliate), and  during normal business hours, to inspect such site and facility and any records relating thereto once per  year, or more often with reasonable cause, to verify Licensee’s compliance with the terms of this  Agreement pertaining to Development of the Licensed Compounds and Licensed Products pursuant to all  applicable Laws, including Good Laboratory Practices, Good Clinical Practices and current standards for  pharmacovigilance practice. Such inspection will be subject to the confidentiality provisions set forth in  Section 9.         4.3   Regulatory Submissions and Regulatory Approvals.                (a)   Regulatory Responsibilities. As of the Effective Date, except as set forth in the  Transition Services Agreement, Licensee will be responsible, at its sole cost and expense, to use its  Commercially Reasonable Efforts to seek and attempt to (i) obtain all Regulatory Approvals for the  Licensed Product in monotherapy in the Field in the Major Market Countries, (ii) following Regulatory  Approval to continue active, diligent marketing efforts throughout the life of this Agreement, and (iii)  following Regulatory Approval, to obtain and retain any governmental approvals to manufacture and/or  sell Licensed Products for all relevant activities of Licensee and Sublicensees. Further, for the sake of  clarity, Licensee shall use Commercially Reasonable Efforts to make commercially reasonable amounts  of Licensed Products available.               (b)   Transfer of Regulatory Filings. As soon as reasonably practicable after the  Effective Date, but with an effort to avoid any adverse impact on or disruption to the activities under the  Transition Services Agreement, at Licensee’s cost, Radius will use Commercially Reasonable Efforts to  transfer and assign to Licensee Radius’s entire right, title, and interest in and to all INDs, other Regulatory  Filings, and other regulatory documentation in the Territory with respect to all Licensed Compounds and  Licensed Products, in each case, that is in the possession and control of Radius, excluding any drug master  files maintained by Radius or a Third Party solely with respect thereto.               (c)   Ownership of Regulatory Approvals. Licensee will own all regulatory  submissions, including all applications, for Regulatory Approvals for the Licensed Products in the Field  in the Territory filed after the Effective Date.               (d)   Pricing and Reimbursement Approvals. Licensee will be responsible for and have  the exclusive right to seek and attempt to obtain pricing and reimbursement approvals for the Licensed  Products in the Field in the Territory, provided that Licensee will keep Radius reasonably informed with  regard to any pricing or reimbursement approval proceedings for the Licensed Products in the Field in the  Territory.   Section 5.  Commercialization.         5.1   Commercialization Plan and Budget.                (a)   Commercialization Plan. The Commercialization of the Licensed Products in the  Field in the Territory will be governed by the Commercialization Plan. The Commercialization Plan will                                         15               

 

                                                                LICENSE AGREEMENT    be updated annually as provided in Section 5.2(c). Any updated Commercialization Plan will include at a   minimum, a situation analysis and an overall strategy for the Commercialization of the Licensed Products   in the Field throughout the Territory (including branding, positioning, promotional materials, market   preparation, field force size, etc.), strategies for detailing and promotion of the Licensed Products in the   Territory, the Commercialization Budget, Net Sales and market forecasts for the Territory, and an   anticipated timeline for Commercialization of the Licensed Products throughout the Territory. The terms   of and activities set forth in the Commercialization Plan will at all times be designed to be in compliance   with all applicable Laws and to be conducted in accordance with professional and ethical standards   customary in the pharmaceutical industry. Notwithstanding the foregoing, Licensee shall be free to   reasonably update, change and modify the Commercialization Plan; such updates, changes and   modifications shall be shared with Radius.                (b)   Commercialization Budget. The Commercialization Budget included in any   updated Commercialization Plan will be a written budget setting forth the budgeted amounts for costs with   respect to activities set forth in the Commercialization Plan during the then-current Calendar Year and the   two (2) succeeding Calendar Quarters thereafter, broken down by Calendar Quarter. Such   Commercialization Budget also will include a breakout of costs by functional area or category (and may   set forth budgets for Commercialization activities in the Territory on a regional basis, rather than a   country-by-country basis, defining the regions in a manner consistent with Licensee’s internal   procedures). Notwithstanding the foregoing, Licensee shall be free to reasonably update, change and   modify the Commercialization Budget and will keep Radius reasonably informed as to such updates,   changes and modifications.          5.2   Commercialization Efforts; Manner of Performance; Reports.                 (a)   Commercialization Efforts. Licensee will use Commercially Reasonable Efforts   to Commercialize Licensed Products in the Territory in each of the Major Market Countries. Without   limiting the generality of the foregoing, Licensee will use Commercially Reasonable Efforts to execute   and to perform, or cause to be performed, the Commercialization Plan.                (b)   Cost and Expense. Licensee will be responsible, at its sole cost and expense, for   all Commercialization activities under this Agreement or the Commercialization Plan and will keep   Radius reasonably informed as to the progress of such activities.                (c)   Commercialization Reports. During the Term and following the First   Commercial Sale of a Licensed Product, Licensee will provide to Radius (i) annually, a copy of the then-  current Commercialization Plan and Commercialization Budget and (ii) upon the request of Radius no   more than once per Calendar Year, representatives of Licensee will provide an oral update on Licensee’s   progress in the Commercialization of the Licensed Compounds and Licensed Products. Further, Licensee   will provide notice to Radius if Licensee elects to suspend or no longer proceed with Commercializing   any Licensed Compounds or Licensed Products.    Section 6.  Manufacturing.          6.1   Except to the extent otherwise provided in the Transition Services Agreement, Licensee  will be solely responsible, at its cost and expense, for Manufacturing and supplying the requirements for  the Development and Commercialization of the Licensed Compounds and Licensed Products in the  Territory.    Section 7.  Licensee Payments.                                          16   

 

                                                                LICENSE AGREEMENT          7.1   Initial License Fee. Licensee will pay to Radius within [*] ([*]) days after the Effective   Date a one-time payment of thirty million US dollars (US$30,000,000). Such payment will be non-  refundable and non-creditable and not subject to set-off.          7.2   Milestone Payments.                 (a)   As set forth in the following table, Licensee will make the following payments   (the “Milestone Payments”) to Radius upon achievement of each of the milestone events set forth in the    tables below (the “Milestone Events”) by Licensee or its Affiliates or Sublicensees. Each Milestone    Payment will be payable by Licensee to Radius within [*] ([*]) days after the achievement of the    corresponding Milestone Event. Such payments will be non-refundable and non-creditable and not subject    to set-off (except as provided in Section 11.9).    Development and Commercialization Milestones     No.     Development Milestone Event                      Milestone Payment     1       [*]                                              [*]     2       [*]                                              [*]     3       [*]                                              [*]       If, [*], then (i) Milestone Payment 2 set forth above will become payable [*], and (ii) Milestone Payment 3  set forth above will become payable upon [*].    If, [*], then (i) Milestone Payment No. 2 set forth above will be [*] and will become payable upon [*], and  (ii) Milestone Payment No. 3 set forth above will be [*] and will become payable upon [*].    Sales Milestones    Sales Milestone Event                                Milestone Payment    Total Net Sales of Licensed Products in the Territory in a Calendar [*]   Year equal to or greater than [*]    Total Net Sales of Licensed Products in the Territory in a Calendar [*]   Year equal to or greater than [*]    Total Net Sales of Licensed Products in the Territory in a Calendar [*]   Year equal to or greater than [*]    Total Net Sales of Licensed Products in the Territory in a Calendar [*]   Year equal to or greater than [*]    Total Net Sales of Licensed Products in the Territory in a Calendar [*]   Year equal to or greater than [*]                                              17   

 

                                                                LICENSE AGREEMENT                (b)   Each of the Milestone Payments will be payable only once upon the first   achievement of the corresponding Milestone Event, regardless of the number of Licensed Products that   achieve such Milestone Event or the number of times the Milestone Event is achieved.                (c)   Multiple Total Net Sales Milestone Payments as set forth above shall be payable   by Licensee in a given Calendar Year in the event two (2) or more Net Sales Milestones Events are   achieved in the same Calendar Year. By way of example, [*]          7.3   Royalties.                 (a)   Royalties. Licensee will pay to Radius royalties at the graduated royalty rates   specified in the following table with respect to the aggregate annual Net Sales of all Licensed Products in   the Territory in a Calendar Year:    Aggregate Annual Worldwide Net Sales of All Licensed   Products in a Calendar Year                              Royalty Rate    Portion of aggregate Annual Net Sales up to and including [*] [*]    Portion of aggregate Annual Net Sales greater than [*] up to   and including [*]                                            [*]    Portion of aggregate Annual Net Sales greater than [*] up to   and including [*]                                            [*]    Portion of aggregate Annual Net Sales by Licensee, its   Affiliates and Sublicensees greater than [*]                 [*]       The applicable royalty rate will be calculated as provided in this Section 7.3(a) by reference to the aggregate   annual worldwide Net Sales of all Licensed Products. [*].                 (b)  Royalty Term. The royalties due under Section 7.3(a) will be payable on Net Sales    from the First Commercial Sale of a particular Licensed Product until the latest of, on a country-by-country    basis, [*].                 (c)   Royalty Reductions.                      (i)   U.S. Sales. If royalties are payable under this Section 7.3 on Net Sales of   a particular Licensed Product for use in the United States after the expiration of all U.S. Radius Patent   Rights (including any applicable patent term extension) claiming the use, sale, offer for sale or importation   of such Licensed Product, then the royalties payable on Net Sales of such Licensed Product for use in the   United States will be calculated as set forth in Section 7.3(a), provided that the portion of the royalties   payable on Net Sales of such Licensed Product for use in the United States will be reduced, subject to   Section 7.3(c)(iv), by [*] ([*]) (the “U.S. Know-How Step-Down Rate”) after the date of expiration of all   such U.S. Radius Patent Rights. For clarity, there will be no reduction on royalties payable on Net Sales of   Licensed Products for use in any country or region in the Territory other than in the United States.                      (ii) Reduction for Generic Competition. Subject to Section 7.3(c)(iv), on a  Licensed Product-by-Licensed Product and country-by-country basis, upon the First Commercial Sale of  any Generic Product, as from the first Calendar Quarter this Section 7.3(c)(ii) applies, the applicable royalty                                          18   

 

                                                                LICENSE AGREEMENT   rates for annual Net Sales of such Licensed Product otherwise due in such country pursuant to  Section 7.3(a): (1) for all countries of the Territory excluding US - will be reduced by [*] ([*]) (the “Generic   Step-Down Rate”); (2) for US, will be reduced to [*] ([*]) of the amount for US under Section 7.3(a);   provided, however, that the royalties payable on Net Sales for a Licensed Product in the United States shall   not be reduced by more than [*] ([*]) in the aggregate pursuant to Sections 7.3(c)(i) and 7.3(c)(ii) with   respect to the amount originally due under Section 7.3(a), unless in case of Loss of Market Exclusivity  occurs in United States. (For the sake of clarity, further to the event set forth under Section 7.3(c)(i) above,  the royalty due for the US to Radius under Section 7.3(a) will be reduced by [*]; upon the First Commercial  Sale of any Generic Product in the US the royalty due for the US will be further reduced so that the total   royalty due for the US will be [*] of the amount due for the US under Section 7.3(a)). Additionally, in the   event of Loss of Market Exclusivity with respect to a Licensed Product in a country, as from the first   Calendar Quarter this Section 7.3(c)(ii) applies the applicable royalty rates for annual Net Sales of such   Licensed Product otherwise due in such country pursuant to Section 7.3(a) will be reduced by [*].                      (iii) Third Party Payments. Without prejudice to Section 7.3(c)(iv), on a  Licensed Product-by-Licensed Product and country-by-country basis, in the event that Licensee determines  in good faith that patents controlled by a Third Party would be infringed by the manufacturing, use or sale  of such Licensed Product in such country under this Agreement, Licensee may credit any amounts due to  such Third Party in such country against the royalties due and payable by Licensee to Radius on the Net  Sales for such Licensed Product in such Calendar Quarter in such country.                     (iv)  Cumulative Reductions Floor. On a Licensed Product-by-Licensed   Product and country-by-country basis, in no event will the royalties otherwise due to Radius for any   Licensed Product in a Calendar Quarter in a given country during the royalty term for such Licensed Product   be reduced by more than [*] ([*]) of the amount that would otherwise be due in such Calendar Quarter for   such Licensed Product in such country but for the reductions set forth in Section 7.3(c)(i), Section 7.3(c)(ii),   or Section 7.3(c)(iii). [*].                (d)    Only One Royalty. Only one royalty will be due with respect to the sale of the   same unit of Licensed Product. Only one royalty will be due hereunder on the sale of a Licensed Product   even if the manufacture, use, sale, offer for sale or importation of such Licensed Product infringes more   than one claim of the Radius Patent Rights.                (e)    No Other Deductions. Without prejudice to Section 7.5(e), there will be no other   deductions or reductions to any royalties payable to Radius hereunder, except to the extent provided by   Section 7.3(c). All royalty payments will be non-refundable and non-creditable and not subject to set-off   (except as provided in Section 11.9).                (f)   Products Containing the Licensed Compound. Should, during the Term, any   product containing the Licensed Compound which does not fall within the definition of Generic Product   but which has received Regulatory Approval for the same indication(s) as the Licensed Product, lawfully   enter the market in a given country(ies) of the Territory (and without infringing any of the Radius Patent   Rights), the Parties shall promptly meet in order to discuss in good faith how to cope with this new scenario   with the aim at preserving the commercial viability of the Licensed Product in the concerned country(ies).           7.4   Duke License Agreement and Eisai License Agreement Payments. For clarity, except for   what is expressly provided for hereunder, Radius will be solely responsible for any and all payments,  including all royalty and milestone payments provided for in the Duke License Agreement and Eisai  License Agreement.          7.5   Payment Terms.                                          19   

 

                                                               LICENSE AGREEMENT               (a)   Manner of Payment. All payments to be made by Licensee to Radius hereunder   will be made in United States dollars by wire transfer to such bank account as Radius may designate.   Licensee shall promptly establish and consistently employ a system of specific nomenclature and type   designations for Licensed Products to permit identification and segregation of various types where  necessary, and shall require Sublicensees to use the same nomenclature and type designations.               (b)   Reports and Royalty Payments. For as long as royalties are due under  Section 7.3(a), Licensee will furnish to Radius (i) within [*] days after the end of each Calendar Quarter,  a written report, showing the amount of Net Sales of Licensed Products and royalty due for such Calendar  Quarter. Royalty payments for each Calendar Quarter will be due within [*] ([*]) days following the end  of the relevant Calendar Quarter. The report will include, at a minimum, the following information for the  applicable Calendar Quarter, each listed by product and by country of sale: (i) the number of units of  Licensed Products sold by Licensee and its Affiliates and Sublicensees on which royalties are owed to  Radius hereunder; (ii) the gross amount received for such sales; (iii) deductions (a) taken from Net Sales  as specified in the definition thereof and (b) made pursuant to Section 7.5(e); (iv) Net Sales; (v) the  royalties and Milestone Payments owed to Radius, listed by category; and (vi) the computations for any  applicable currency conversions pursuant to Section 7.5(d). All such reports will be treated as Confidential  Information of Licensee.               (c)   Records and Audits. Licensee will keep, and will cause each of its Affiliates and  Sublicensees, as applicable, to keep adequate books and records of accounting for the purpose of  calculating all amounts due to Radius hereunder. For the [*] ([*]) years following the end of the Calendar  Year to which each will pertain, such books and records of accounting (including those of Licensee’s  Affiliates and Sublicensees, as applicable) will be kept at each of their principal place of business and will  be open for inspection at reasonable times and upon reasonable notice by an independent certified  accountant selected by Radius, and which is reasonably acceptable to Licensee, for the sole purpose of  inspecting the amounts due to Radius under this Agreement. In no event will such inspections be  conducted hereunder more frequently than once every [*] ([*]) months. Such accountant must have  executed and delivered to Licensee and its Affiliates and Sublicensees, as applicable, a confidentiality  agreement as reasonably requested by Licensee, which will include provisions limiting such accountant’s  disclosure to Radius to only the consolidated results and basis for such results of such inspection. The  results of such inspection, if any, will be binding on both Parties. Any underpayments will be paid by  Licensee within [*] ([*]) days of notification of the results of such inspection. Any overpayments will be  fully creditable against amounts payable in subsequent payment periods. Radius will pay for such  inspections, except that in the event there is any upward adjustment in amounts payable for any Calendar  Year shown by such inspection of more than [*] ([*]) of the amount paid, Licensee will reimburse Radius  for any reasonable out-of-pocket costs of such accountant. Any underpayments or overpayments under  this Section 7.5(c) will be subject to the currency exchange provisions set forth in Section 7.5(d) as applied  to the Calendar Quarter during which the payment obligations giving rise to such underpayment or  overpayment were incurred by Licensee.               (d)   Currency Exchange. With respect to Net Sales invoiced in United States dollars,  the Net Sales and the amounts due to Radius hereunder will be expressed in United States dollars. With  respect to Net Sales invoiced in a currency other than United States dollars, the Net Sales will be expressed  in the domestic currency of the entity making the sale, together with the United States dollars equivalent,  calculated based on standard methodologies employed by Licensee for consolidation purposes for the  Calendar Quarter for which remittance is made for royalties. For purposes of calculating Net Sales as set  forth in Section 7.3(a), the aggregate Net Sales with respect to each Calendar Quarter within a Calendar  Year will be calculated based on the currency exchange rates for the Calendar Quarter in which such Net  Sales occurred, in a manner consistent with the exchange rate procedures set forth in the immediately  preceding sentence.                                         20               

 

                                                                LICENSE AGREEMENT                (e)   Taxes.                     (i)   If Licensee is required by the Law of any jurisdiction to deduct, or  withhold any tax from any sum payable to Radius according to Sections 7.1.-7.3 above, such deduction or  withholding of any tax will be deducted by Licensee as required by Law from such sum payable and shall  be paid by Licensee to the proper tax authority. Official receipts indicating proof of payment of any  withholding taxes shall be secured by Licensee and made available to Radius upon request.                     (ii)  If, as a result of a Withholding Action by Licensee (including any assignee  or successor), withholding is required by applicable Law and the amount of such withholding exceeds the  amount of withholding that would have been required if Licensee had not committed the Withholding  Action, then Licensee shall pay an additional amount to Radius such that, after withholding from the  payment contemplated by this Agreement and such additional amount, Radius receives the same amount as  it would have received from Licensee absent such Withholding Action by Licensee. If as a result of a  Withholding Action by Radius (including any assignee or successor) the amount of withholding under the  Law of the applicable jurisdiction exceeds the amount of such withholding that would have been required  in the absence of such Withholding Action by Radius, Licensee shall not be required to pay any additional  amount to Radius and any additional amount shall be paid to the proper tax authority according to Section  7.5(e)(i). A “Withholding Action” is defined as (a) a permitted assignment or sublicense of this Agreement   (in whole or in part) by a Party to an Affiliate or a Third Party or the exercise by a Party of its rights under  this Agreement (in whole or in part) through an Affiliate, or (b) a redomiciliation or change of tax residency  of a Party.                      (iii) If, as a result of a change in Law after the Effective Date, any withholding   or deduction of tax is imposed on any payment made by Licensee to Radius (other than as contemplated by   Section 7.5(e)(ii)), Licensee shall pay additional amounts to Radius, such that, after giving effect to the tax   withholding, Radius receives the payment net of the tax withholding plus [*] (“Additional Payment”). In   order to receive the Additional Payment, Radius shall provide reasonable evidence to Licensee that Radius  is unable to use the relevant amount to obtain double taxation relief by crediting it from its own corporation  tax liability. Should Radius be able to partially or fully recover any amounts withheld or deducted that  caused the Additional Payment, then the Additional Payment shall be reduced accordingly.                     (iv)  The Parties will cooperate with each other in seeking exemption or   reduction in the deduction or withholding of any tax under any double taxation or other similar treaty or   agreement in force and in seeking to receive a refund of any withholding tax or to claim a foreign tax credit.   If permitted and based on Licensee’s reasonable interpretation of German (and any other applicable) Law   in consultation with Radius, and taking into account that Radius agrees to provide any documents relating   to a claim for the benefits of the bilateral income tax treaty between the United States and Germany,   including with respect to the 0% tax rate for “royalties”, Licensee shall not withhold on any payments made   to Radius pursuant to this Agreement.                      (v)   In addition, the Parties will cooperate in accordance with applicable Laws   to minimize indirect taxes (such as value added tax, sales tax, consumption tax and other similar taxes) in   connection with this Agreement.                 (f)   Blocked Payments. In the event that, by reason of applicable Law in any country,    it becomes impossible or illegal for Licensee to transfer, or have transferred on its behalf, payments owed    to Radius hereunder, Licensee will promptly notify Radius of the conditions preventing such transfer and    such payments will be deposited in local currency in the relevant country to the credit of Radius in a    recognized banking institution designated by Radius or, if none is designated by Radius within a period                                          21   

 

                                                                LICENSE AGREEMENT    of [*] ([*]) days, in a recognized banking institution selected by Licensee, as the case may be, and   identified in a written notice given to Radius.                (g)   Interest Due. Licensee will pay Radius interest on any payments that are not paid   on or before the date such payments are due under this Agreement at a rate of [*] calculated on the total   number of days payment is delinquent.          7.6   Mutual Convenience. The royalty and other payment obligations set forth hereunder have   been agreed to by the Parties for the purpose of reflecting and advancing their mutual convenience,   including the ease of calculating and paying royalties and other amounts to Radius. Licensee hereby   stipulates to the fairness and reasonableness of such royalty and other payments obligations and covenants   not to allege or assert, nor to allow any of its Sublicensees or Affiliates to allege or assert, nor further to   cause or support any other Third Parties to allege or assert, that any such royalty or other payments   obligations are unenforceable or illegal in any way.    Section 8.  Patent Prosecution, Infringement and Extensions, Trademarks.          8.1   Prosecution and Maintenance.                (a)   The Prosecution and maintenance of all Duke Patent Rights shall be governed by  Exhibit F and the Prosecution and maintenance of all Eisai Patents, Joint Patents, Radius-Invented Patents  and Licensee-Invented Patents shall be governed by Exhibit G. The provisions in this Section 8.1 shall  supplement Exhibit F and Exhibit G.                (b)  For so long as Licensee Prosecutes the patents and patent applications within the  Radius Patent Rights pursuant to Exhibit F and Exhibit G, Radius shall promptly cooperate with Licensee’s  reasonable requests for data, affidavits, and other information and assistance. Any reasonable and  documented out-of-pocket costs and expenses incurred by Radius in connection with such requests shall be  shared equally between the Parties; provided, however, that any expenses incurred in connection with such  requests shall be shared equally between the Parties until [*]; provided that upon and following [*],  Licensee shall bear [*].                (c)   For so long as Licensee Prosecutes the patents and patent applications within the   Radius Patent Rights and Licensee-Invented Patents pursuant to Exhibit F and Exhibit G, any reasonable   and documented out-of-pocket costs incurred by Radius only in connection with the review of, and   comments on, papers relating to the Prosecution of such patents and patent applications within the Radius   Patent Rights and Licensee-Invented Patents that are provided by Licensee to Radius in accordance with   Clause 1.2 of Exhibit F and Clauses 1.8 and 1.10 of Exhibit G shall be shared equally between the Parties;   provided, however, that any expenses incurred in connection with such review and comments shall be   shared equally between the Parties until [*] and that upon and following [*], Licensee shall bear [*]; and   provided, further, that Licensee’s obligation to bear such costs shall be limited to [*].                (d)   For so long as Licensee Prosecutes the patents and patent applications within the  Radius Patent Rights and Licensee-Invented Patents, Licensee will have final decision-making authority  with respect to the Prosecution of the patents and patent applications within the Radius Patent Rights and  Licensee-Invented Patents that it Prosecutes in accordance with Exhibit F and Exhibit G; provided,  however, that Licensee may not use such final decision-making authority in a manner inconsistent with the  Duke License Agreement or the Eisai License Agreement.               (e)   In no event will any of the patents and patent applications within the Radius Patent  Rights and Licensee-Invented Patents be permitted to lapse or be abandoned in any country without Radius                                          22   

 

                                                                LICENSE AGREEMENT   first being given an opportunity to assume full responsibility for the continued Prosecution of such patents  or patent applications. Licensee will provide Radius with written notice of any decision not to continue the  Prosecution of any patent application or patent within the Radius Patent Rights or the Licensee-Invented  Patents in any country at least [*] ([*]) days prior to any filing deadline or pending lapse or abandonment   thereof. Any such patent application(s) and patent(s) will remain a “Radius Patent Right” hereunder.               (f)    Patent Extensions; Orange Book Listings; Patent Certifications.                      (i)   Patent Term Extension. If elections with respect to obtaining patent term   extension or supplemental protection certificates or their equivalents in any country with respect to any   Licensed Product becomes available, upon Regulatory Approval or otherwise, as between the Parties and   subject to Exhibits F and G, Licensee will have the first right in accordance to file and maintain any such   patent term extension or supplemental protection certificates or their equivalent for the Radius Patent   Rights.                      (ii)  Data Exclusivity and Orange Book Listings. With respect to data  exclusivity periods (such as those periods listed in the Orange Book (including any available pediatric  extensions) or periods under national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83, and  all equivalents in any country), [*], in consultation with [*], will seek and maintain all such data exclusivity  periods that may be available for any of the Licensed Products. [*] will determine which Radius Patent  Rights and Licensee-Invented Patents, if any, will be listed in the Orange Book or any similar patent listing  in any country with respect to the Licensed Products.                     (iii) Notification of Patent Certification. Each Party will notify and provide the  other with copies of any allegations of alleged patent invalidity, unenforceability or non-infringement of a  Radius Patent Right and Licensee-Invented Patents pursuant to a Paragraph IV Patent Certification by a  Third Party filing an Abbreviated New Drug Application, an application under §505(b)(2) of the United  States Federal Food, Drug, and Cosmetic Act (as amended or any replacement thereof), or any other similar  patent certification by a Third Party, and any foreign equivalent thereof.                (g)   CREATE Act. Notwithstanding anything to the contrary in this Agreement, each  Party will have the right to invoke the Cooperative Research and Technology Enhancement Act of 2004,  35 U.S.C. § 103(c)(2)-(c)(3) (the “CREATE Act”) when exercising its rights under this Agreement, but   only with the prior written consent of the other Party in its sole discretion. In the event that a Party intends   to invoke the CREATE Act, once agreed to by the other Party as required by the preceding sentence, it will   notify the other Party and the other Party will cooperate and coordinate its activities with such Party with   respect to any filings or other activities in support thereof. The Parties acknowledge and agree that this   Agreement is a “joint research agreement” as defined in the CREATE Act.                 (h)  Cooperation. Each Party will reasonably cooperate with the other Party in the   Prosecution of the Radius Patent Rights. Such cooperation includes promptly executing all documents, or   requiring inventors, subcontractors, employees and consultants and agents of such Party and its Affiliates,   and for Licensee, Sublicensees, to execute all documents, as reasonable and appropriate so as to enable   the Prosecution of any such Radius Patent Rights in any country. Furthermore, promptly at Licensee’s   request, Radius shall (i) fully cooperate, and, to the extent needed, cause its Affiliates and use Diligent   Efforts to have Eisai and Duke fully cooperate, with Licensee’s reasonable requests that Radius (or Eisai   or Duke) execute and deliver documents, and do filings and take other actions in the future in order for   Licensee to carry out the purposes of the Agreement, such cooperation not to be unreasonably denied or   delayed, and (ii) fully cooperate, and, to the extent needed, cause its Affiliates and use Diligent Efforts to   have Eisai and Duke fully cooperate, with all reasonable requests of Licensee in order for Licensee to   record the license hereby granted by Radius to Licensee under the Radius Patent Rights promptly                                          23   

 

                                                                LICENSE AGREEMENT    following execution, and Radius shall do so by executing (including, where needed, notarization and   legalization) and delivering such instruments, and/or taking such other actions, or by using Diligent Efforts   to have Eisai and Duke execute (including, where needed, notarization and legalization) and deliver such   instruments, and/or take such other actions, at Licensee’s sole expense, as reasonably requested by   Licensee for purposes of such recordal.          8.2   Enforcement and Defense.                (a)   The enforcement and defense of all Duke Patent Rights shall be governed by   Exhibit F and the enforcement and defense of all Eisai Patents, Joint Patents, Radius-Invented Patents and   Licensee-Invented Patents shall be governed by Exhibit G. The provisions in this Section 8.2 supplement   Exhibit F and Exhibit G.                (b)   Subject to the provisions of Exhibit F and Exhibit G, in case of an actual or  suspected infringement of any Radius Patent Right and/or any Licensee-Invented Patent, or in case the  validity or enforceability of any Radius Patent Right and/or any Licensee-Invented Patent is challenged in  any action or proceeding (other than any interferences, oppositions, reissue proceedings or reexaminations)  or Radius or Licensee receives a notice of Paragraph IV Patent Certification as described in Section  8.1(f)(iii), if Licensee elects not to settle, defend or bring any action for infringement within [*] ([*]) months   after becoming aware of such suspected infringement or action or proceeding (and in all events at least [*]   ([*]) days before the end of the applicable Hatch-Waxman Time Period, as defined below), then, subject to   the provisions in Exhibit F and Exhibit G, Radius may defend or bring such action at its own expense, in   its own name and entirely under its own direction and control, subject to the following: Licensee will  reasonably assist Radius in any action or proceeding being defended or prosecuted if so requested, and will  join such action or proceeding if requested by Radius. Licensee will have the right to participate in any such   action or proceeding with its own counsel at its own expense. For purposes of this Agreement, “Hatch-  Waxman Time Period” means the applicable period of time during which a patent holder or licensee has   the right to file an infringement suit to maintain certain rights and privileges upon receipt of Paragraph IV   Patent Certification by a Third Party filing an Abbreviated New Drug Application or an application under   § 505(b)(2) of the United States Food, Drug, and Cosmetic Act (as amended), or any other similar patent   certification by a Third Party, or any foreign equivalent thereof.                 (c)   Withdrawal. If either Party brings an action or proceeding under this Section 8.2  and subsequently ceases to pursue or withdraws from such action or proceeding, it will promptly notify the  other Party and the other Party may substitute itself for the withdrawing Party under the terms of this  Section 8.2.          8.3   Patent Marking. Licensee will mark, and will cause all of its Affiliates and Sublicensees to   mark, Licensed Products with all Radius Patent Rights in accordance with applicable Law, which marking   obligation will continue for as long as required under applicable Law.          8.4   Trademarks. Licensee shall have the right to select the trademark(s) and/or logo(s) under   which to Commercialize Licensed Products in the Field in the Territory. Licensee shall be responsible for   the registration, maintenance and defense of such trademarks used in connection with the   Commercialization of any Licensed Product in the Field in the Territory, as well as all expenses associated   therewith.    Section 9.  Confidential Information and Publicity.          9.1   Confidentiality.                                          24   

 

                                                                LICENSE AGREEMENT                 (a)   Confidential Information. Except as expressly provided herein, each of the   Parties agrees that, for itself and its Affiliates, and during the Term and for a period of [*] ([*]) years   thereafter, a Party and its Affiliates (the “Receiving Party”) receiving Confidential Information of the    other Party or its Affiliates (the “Disclosing Party”) will (i) not disclose such Confidential Information to    any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly    permitted below, and (ii) not use such Confidential Information for any purpose except those licensed or    otherwise authorized or permitted by this Agreement.                 (b)  Exceptions. The obligations in Section 9.1(a) will not apply with respect to any   portion of the Confidential Information that the Receiving Party can show by competent proof:                     (i)   is publicly disclosed by the Disclosing Party, either before or after it is  disclosed to the Receiving Party hereunder;                     (ii)  was lawfully known to the Receiving Party or any of its Affiliates, without  any obligation to keep it confidential or any restriction on its use, prior to disclosure by the Disclosing  Party;                     (iii) is subsequently disclosed to the Receiving Party or any of its Affiliates by  a Third Party lawfully in possession thereof and without any obligation to keep it confidential or any  restriction on its use;                     (iv)  is published by a Third Party or otherwise becomes publicly available or  enters the public domain, either before or after it is disclosed to the Receiving Party; or                     (v)   has been independently developed by employees or contractors of the  Receiving Party or any of its Affiliates without the aid, application or use of Confidential Information of  the Disclosing Party.                (c)   Authorized Disclosures. The Receiving Party may disclose Confidential   Information belonging to the Disclosing Party to the extent (and only to the extent) such disclosure is   reasonably necessary in the following instances:                     (i)   subject to Section 9.2, by either Party in order to comply with applicable  Laws (including any securities Laws or regulation or rules of a securities exchange) or with a legal or  administrative proceeding;                     (ii)  by either Party, in connection with prosecuting or defending litigation,  making regulatory filings, and Prosecuting Radius Patent Rights in accordance with Section 8;                     (iii) by Licensee, to its Affiliates, potential and future Sublicensees, permitted  acquirers or assignees under Section 12.1, subcontractors, investment bankers, investors, lenders, and their  and each of Licensee and its Affiliates’ respective directors, employees, contractors, agents, attorneys and  other professional advisors; and                     (iv)  by Radius, to its Affiliates, permitted acquirers or assignees under  Section 12.1, subcontractors, investment bankers, investors (including royalty purchasers), lenders, and  their and each of Radius and its Affiliates’ respective directors, employees, contractors, agents, attorneys  and other professional advisors; provided that (A) with respect to Section 9.1(c)(i) or 9.1(c)(ii), where  reasonably possible and to the extent permitted by any applicable Law, the Receiving Party will notify the  Disclosing Party of the Receiving Party’s intent to make any disclosure pursuant thereto sufficiently prior                                          25   

 

                                                                LICENSE AGREEMENT   to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may  deem appropriate to protect the confidentiality of the information to be disclosed, and (B) with respect to  Sections 9.1(c)(iii) and 9.1(c)(iv), each of those named people and entities must be bound prior to disclosure   by confidentiality and non-use restrictions or obligations at least as restrictive as those contained in this   Section 9 (other than investment bankers, investors and lenders, who must be bound prior to disclosure by   commercially reasonable obligations of confidentiality). Further, with respect to Section 9.1(c)(i), in the   event either Party intends to make a disclosure pursuant thereto, to the extent permitted by applicable Law,   the other Party will have a reasonable time period to review and comment on the proposed disclosure or   filing that relates to this Agreement (including the right to request redaction of material terms to the extent   permitted by any applicable Laws), and the Party intending to make such disclosure will consider in good   faith any reasonable comments thereon provided by the other Party.          9.2   Terms of this Agreement; Publicity.                 (a)   Terms of this Agreement. The Parties agree that the terms of this Agreement will    be treated as Confidential Information of both Parties, and thus may be disclosed only as permitted by this   Section 9.                 (b)  Restrictions. No Party to this Agreement will originate any publicity, news   release or other public announcement, written or oral, relating to this Agreement, the transactions   contemplated hereby or the terms hereof, or the existence of any arrangement between the Parties, without   the prior written consent of the other Party, such consent not to be unreasonably withheld, delayed, or   conditioned, whether named in such publicity, news release or other public announcement or not, except   as required by applicable Laws.                 (c)   Review. In the event either Party (the “Issuing Party”) desires to issue any    publicity, new release or other public announcement relating to this Agreement or the transactions    contemplated hereby or the terms hereof, the Issuing Party will provide the other Party (the “Reviewing    Party”) with a copy of the proposed release, announcement or statement (the “Release”). The Issuing Party    will specify with each such Release, taking into account the urgency of the matter being disclosed, a    reasonable period of time within which the Reviewing Party may provide any comments on such Release    and if the Reviewing Party fails to provide any comments during the response period called for by the    Issuing Party, the Reviewing Party will be deemed to have consented to the issuance of such Release;    provided, however, that as it relates to the disclosure of the results of any clinical trial conducted by    Licensee or any health or safety matter related to a Licensed Product, Radius acknowledges that    announcements may need to be made on extremely short notice, and although Licensee will endeavor to    provide Radius adequate time for such a review, Licensee will be free to make necessary public disclosures   as promptly as it deems necessary and appropriate. If the Reviewing Party provides any comments, the   Parties will consult on such Release and work in good faith to prepare a mutually acceptable Release. If    the Reviewing Party does not provide its consent, not to be unreasonably withheld, conditioned or delayed,    to the issuance of the Release, the Issuing Party will not issue the Release except as required by Law or    as otherwise expressly set forth herein. Each Party may subsequently publicly disclose any information   previously contained in any Release so consented to. If either Party concludes that a copy of this   Agreement must be filed with the United States Securities and Exchange Commission or similar   regulatory agency in a country other than the United States, at least [*] ([*]) days in advance of any such   filing such Party will provide the other Party with a copy of this Agreement showing any provisions hereof   as to which the Party proposes to request confidential treatment, will provide the other Party with an   opportunity to comment on any such proposed redactions and to suggest additional redactions, and will   take such Party’s reasonable and timely comments into consideration before filing the Agreement.                                           26   

 

                                                               LICENSE AGREEMENT               (d)   Press Release Regarding Execution of the Agreement. The Parties agree to issue  the joint press release in Exhibit E promptly following the Effective Date.               (e)   Publication of Clinical Data. Unless otherwise required by any applicable Law,  each Party agrees that it shall not publish or present to the public the results of non-clinical scientific  studies or clinical trials related to the Licensed Product without the opportunity for prior review by the  other Party. If a Party (the “Publishing Party”) wishes to publish or to present to the public such results,  then it shall provide the other Party (the “Non-Publishing Party”) the opportunity to review any of the   Publishing Party’s proposed abstracts, manuscripts or presentations (including verbal presentations)   which relate to the Licensed Product at least [*] ([*]) days prior to its intended submission for publication  and agrees, upon request, not to submit any such abstract or manuscript for publication until the other  Party is given a reasonable period of time to secure patent protection for any material in such publication  which it believes to be patentable. Both Parties understand that a reasonable commercial strategy may  require delay of publication of information or filing of patent applications. The Parties agree to review  and consider delay of publication and filing of patent applications under certain circumstances. Neither  Party shall have the right to publish or present to the public Confidential Information of the other Party,  except as permitted under Section 9. Nothing contained in this Section 9.2(e) shall prohibit the inclusion   of the results of non-clinical scientific studies or clinical trials related to the Licensed Product necessary   for a patent application.         9.3   Relationship to the Confidentiality Agreement. This Agreement supersedes the  Confidentiality Agreement, provided that all “Confidential Information” disclosed or received by the  parties thereunder will be deemed “Confidential Information” hereunder and will be subject to the terms  and conditions of this Agreement.         9.4   Use of Name. Licensee shall, and shall require its Affiliates to, refrain from using and to  require Sublicensees to refrain from using the name, mark, logo, image or any adaption thereof of Duke or  its employees in publicity or advertising without the prior written approval of Duke. Reports in scientific  literature and presentations of joint research and development work are not publicity. Notwithstanding this  provision, without prior written approval of Duke, Licensee and Sublicensees may state publicly that  Licensed Products were developed by Licensee based upon an invention(s) developed at Duke University  and/or that the Duke Patent Rights were licensed from Duke University. However, in no event, shall  Licensee or Sublicensee represent, either directly or indirectly, that any Licensed Product is a product of  Duke. For purposes of this Section 9.4 only, “Licensed Product” means any product that contains the  Licensed Compound and, but for this Agreement, comprises an infringement (including contributory or  inducement), of an issued or unexpired claim contained in the Duke Patent Rights in the country in which  any such product or product is made, used, imported, offered for sale or sold.   Section 10. Warranties; Limitations of Liability; Indemnification and Disclaimers.         10.1  Radius Representations and Warranties. Radius covenants, represents and warrants to  Licensee that as of the Effective Date:                (a)   Radius is duly organized, validly existing and in good standing under the laws of  the jurisdiction in which it is organized, and it has full right and authority to enter into this Agreement and  to grant the licenses and other rights to Licensee as herein described.               (b)   Radius Controls the Radius Patent Rights and the Radius Know-How and has full  right and authority to grant the licenses and rights under the Radius Patent Rights and the Radius Know- How to Licensee as provided for hereunder.                                         27               

 

                                                               LICENSE AGREEMENT               (c)   This Agreement has been duly authorized by all requisite corporate action, and  when executed and delivered will become a valid and binding contract of Radius enforceable against  Radius in accordance with its terms.               (d)   The execution, delivery and performance of this Agreement does not conflict  with any other agreement, contract, instrument or understanding, oral or written, to which Radius is a  party, or by which it is bound, nor will it violate any applicable Laws.               (e)   All necessary consents, approvals and authorizations of all Governmental  Authorities and other Persons required to be obtained by Radius in connection with the execution and  delivery of this Agreement and the performance of its obligations hereunder have been obtained.               (f)   Attached hereto as Exhibit C is a complete and accurate list of all patent rights  owned or in-licensed by Radius or any of its Affiliates that the manufacture, use, sale, offer for sale or  importation of the Licensed Compounds or any Licensed Product would infringe. All patent rights listed  on Exhibit C are Radius Patent Rights hereunder. To Radius’s Knowledge, no Third Party action or  proceeding has been commenced or threatened in writing, alleging that any of the issued claims included  in the Radius Patent Rights are invalid or unenforceable.               (g)   No lien on or security interest exists in, upon, and to the Radius Patent Rights and  Radius Know How and it will not, nor will it permit any of its Affiliates to, directly or indirectly, create,  assume or suffer to exist any lien on or security interest in all or any portion of the Radius Patent Rights  and/or Radius Know How for so long and during the period that this Agreement remains in full force and  effect or that the Radius Patent Rights and the Radius Know How remain subject to the license to Licensee.               (h)   To Radius’s Knowledge, all information and data that exists as of the Effective  Date that is material to the Development, Manufacture or Commercialization of Licensed Compounds or  Licensed Products and is in the possession or control of Radius or its Affiliates as of the Effective Date  has been included in the electronic data room made available to Licensee by Radius prior to the Effective  Date, and such information or data contained in such data room is true and correct (subject to any  redactions to such information or data) in all material respects as well as the information delivered to  Licensee upon Licensee’s request is true and correct in all material respects as of the date such requests  for information were made by Licensee.         10.2  Licensee Representations and Warranties. Licensee covenants, represents and warrants to  Radius that as of the Effective Date:                (a)   Licensee is duly organized, validly existing and in good standing under the laws  of the state or jurisdiction in which it is organized, and it has full right and authority to enter into this  Agreement and to accept the rights and licenses granted as herein described.               (b)   This Agreement has been duly authorized by all requisite corporate action, and  when executed and delivered will become a valid and binding contract of Licensee enforceable against  Licensee in accordance with its terms.               (c)   The execution, delivery and performance of this Agreement does not conflict  with any other agreement, contract, instrument or understanding, oral or written, to which Licensee is a  party, or by which it is bound, nor will it violate any applicable Laws.                                          28               

 

                                                               LICENSE AGREEMENT               (d)   All necessary consents, approvals and authorizations of all Governmental  Authorities and other Persons required to be obtained by Licensee in connection with the execution and  delivery of this Agreement and the performance of its obligations hereunder have been obtained.         10.3  Ethical Business Practices.                (a)   Either Party agrees to conduct its own activities contemplated herein in a manner  which is consistent with both applicable Laws and good business ethics. In the performance of this  Agreement either Party and its Affiliates and its and their employees and agents (i) will not offer to make,  make, promise, authorize or accept any payment or giving anything of value, including, without limitation,  bribes, either directly or indirectly to any public official, Regulatory Authority or anyone else for the  purpose of influencing, inducing or rewarding any act, omission or decision in order to secure an improper  advantage, or obtain or retain business and (ii) will comply with all applicable anti-corruption and anti- bribery Laws. Either Party will notify the other Party immediately upon becoming aware of any breach of  its obligations under this Section. Either Party warrants to the other Party that none of its or its Affiliates’  officer, director, partner, owner, principal, employee or agent is an official or employee of a governmental  agency or instrumentality or a government owned company in a position to influence action or a decision  regarding its activities contemplated in this Agreement.               (b)   In the event that either Party has reason to believe that a breach of this  Section 10.3 by the other Party or its Affiliates has occurred or may occur, either Party is entitled to audit  the other Party and its Affiliates, which will fully cooperate in connection with any such audit.               (c)   Either Party will promptly notify the other Party in the event of any government  investigation or inquiry related to compliance with applicable anti-corruption and anti-bribery Laws in  connection with this Agreement and will allow the other Party to participate to the extent permitted by  any applicable Law.               (d)   Either Party expressly understands and agrees that any breach of this Section 10.3  is considered a material breach of this Agreement entitling the other Party to terminate this Agreement in  accordance with Section 11.2.         10.4  Disclaimer.                (a)   EXCEPT AS EXPRESSLY SET FORTH HEREIN, NEITHER RADIUS NOR  LICENSEE MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EITHER  EXPRESS OR IMPLIED, WITH RESPECT TO ANY RADIUS PATENT RIGHTS OR RADIUS  KNOW-HOW, ANY LICENSED COMPOUNDS, OR ANY LICENSED PRODUCTS, INCLUDING  ANY   WARRANTIES OF VALIDITY OR ENFORCEABILITY OF ANY PATENTS, TITLE,  QUALITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, PERFORMANCE  OR NONINFRINGEMENT OF ANY THIRD PARTY PATENTS OR OTHER INTELLECTUAL  PROPERTY RIGHTS.                 (b)  Licensee acknowledges that Duke makes no representations or warranties that  any claim within the Duke Patent Rights is or will be held valid, patentable or enforceable, or that the  manufacture, importation, use, offer for sale, sale or other distribution of any Licensed Products will not  infringe upon any patent or other rights. Additionally, Licensee acknowledges that DUKE MAKES NO  REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR  IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF  MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND ASSUMES NO  RESPONSIBILITIES WHATEVER WITH RESPECT TO DESIGN, DEVELOPMENT,                                         29               

 

                                                               LICENSE AGREEMENT   MANUFACTURE, USE, SALE OR OTHER DISPOSITION BY LICENSEE OR SUBLICENSEES OF  LICENSED PRODUCTS. LICENSEE AND SUBLICENSEES ASSUME THE ENTIRE RISK AS TO  PERFORMANCE OF LICENSED PRODUCTS.               (c)   Without prejudice to Section 10.8 which applies as between Radius and Licensee,  Licensee acknowledges that EISAI SHALL NOT BE LIABLE TO LICENSEE FOR ANY SPECIAL,   CONSEQUENTIAL, EXEMPLARY, OR INCIDENTAL DAMAGES ARISING FROM ANY CLAIM   RELATING TO EISAI IP, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT   (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE   OF LICENSEE IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME.         10.5  Performance by Affiliates and Subcontractors. Each Party will have the right to utilize the  services of its Affiliates or Third Party subcontractors in connection with the performance of the activities  for which it is responsible under this Agreement, including with respect to Licensee, the Development Plan  or the Commercialization Plan; provided, however, that such Party will remain responsible under this  Agreement for the performance and compliance of such Affiliates and Third Party subcontractors. The  Party utilizing such subcontractors also will ensure that such Affiliate or Third Party is subject to obligations  protecting and limiting use and disclosure of Confidential Information, the Licensed Compounds, Licensed  Products, patent rights and Know-How at least to the same extent as set forth under this Agreement.         10.6  Indemnification.                (a)   Licensee Indemnity. Licensee hereby agrees to indemnify, defend and hold  Radius and its Affiliates, and their respective employees, directors, agents and consultants, and their  respective successors, heirs and assigns and representatives (“Radius Indemnitees”) harmless from and   against all claims, liability, threatened claims, damages, expenses (including reasonable attorneys’ fees),   suits, proceedings, losses or judgments, whether for money or equitable relief, of any kind, including but   not limited to death, personal injury, illness, product liability or property damage or the failure to comply   with applicable Law (collectively, “Losses”), arising from any Third Party claim due to (i) the   Development, Commercialization (including promotion, advertising, offering for sale, sale or other   disposition), transfer, importation or exportation, Manufacture, labeling, handling or storage, or use of, or   exposure to, any Licensed Compound or Licensed Products by or for Licensee or any of its Affiliates,   Sublicensees, subcontractors, agents and consultants or any other person; or (ii) any material breach of   any obligation, representation or warranty of Licensee hereunder; or (iii) Licensee’s (or its Affiliates’ and   Sublicensees’) negligence, recklessness or willful misconduct; or (iv) the use or practice by Licensee of  any invention related to the Duke Patent Rights (but without prejudice to Licensee right under Section  7.3(c)(iii), to the extent applicable), except, in each case, to the extent that such Losses arise from  (A) infringement or misappropriation of patent or other intellectual property rights or know-how by any  Radius Indemnitees, (B) the negligence, recklessness or willful misconduct of any Radius Indemnitees, or  (C) any material breach of any obligation, representation or warranty of Radius hereunder; or (D) to the  extent the Losses are indemnifiable by Radius under Section 10.6(b).                (b)  Radius Indemnity. Radius hereby agrees to indemnify, defend and hold Licensee,  its Affiliates and Sublicensees, and their respective employees, directors, agents and consultants, and their  respective successors, heirs and assigns and representatives (“Licensee Indemnitees”) harmless from and   against all Losses arising from any Third Party claim due to (i) the Development, transfer, importation or   exportation, Manufacture, labeling, handling or storage, or use of, or exposure to, any Licensed   Compounds or Licensed Products by or for Radius or any of its Affiliates, sublicensees (excluding   Licensee), subcontractors, agents and consultants; or (ii) any material breach of any obligation,   representation or warranty of Radius hereunder; or (iii) Radius’s (or its Affiliates’ and sublicensees’)  negligence, recklessness or willful misconduct, except , in each case, to the extent that such Losses arise                                         30               

 

                                                                LICENSE AGREEMENT    from (A) infringement or misappropriation of patent or other intellectual property rights or know-how by   any Licensee Indemnitees, (B) the negligence, recklessness or willful misconduct of any Licensee   Indemnitees, or (C) any material breach of any obligation, representation or warranty of Licensee   hereunder; or (D) to the extent the Losses are indemnifiable by Licensee under Section 10.6(a).                (c)   Indemnification Procedure. A claim to which indemnification applies under   Section 10.6(a) or Section 10.6(b) will be referred to herein as a “Claim”. If any Person (each,    an “Indemnitee”) intends to claim indemnification under this Section 10.6, the Indemnitee will notify the    other Party (the “Indemnitor”) in writing promptly upon becoming aware of any claim that may be a Claim    (it being understood and agreed, however, that the failure by an Indemnitee to give such notice will not    relieve the Indemnitor of its indemnification obligation under this Agreement except and only to the extent   that the Indemnitor is actually prejudiced as a result of such failure to give notice). Subject to Section 11.9,   the Indemnitor will have the right to assume and control the defense of such Claim at its own expense   with counsel selected by the Indemnitor and reasonably acceptable to the Indemnitee. The Indemnitee or    its licensor (in the case of Radius) will have the right to participate and to retain its own counsel, with the    fees and expenses to be paid by the Indemnitee, if representation of such Indemnitee by the counsel    retained by the Indemnitor would be inappropriate due to actual or potential differing interests between    such Indemnitee and any other party represented by such counsel in such proceedings. If the Indemnitor    does not assume the defense of such Claim as aforesaid, the Indemnitee, at Indemnitor’s expense, may    defend such Claim but will have no obligation to do so. The Indemnitee will not settle or compromise any    Claim without the prior written consent of the Indemnitor, and the Indemnitor will not settle or    compromise any Claim in any manner which would have an adverse effect on the Indemnitee’s interests,    or otherwise create an obligation or admission of liability for Indemnitee without the prior written consent    of the Indemnitee, which consent, in each case, will not be unreasonably withheld. The Indemnitee will    reasonably cooperate with the Indemnitor at the Indemnitor’s expense and will make available to the    Indemnitor all pertinent information under the control of the Indemnitee, which information will be subject    to Section 9.          10.7  Insurance. During the Term and for at least [*] ([*]) years thereafter, Licensee will maintain   at its sole cost and expense, an adequate liability insurance or self-insurance program (including product   liability insurance) to protect against potential liabilities and risk arising out of activities to be performed   under this Agreement and upon such terms (including coverages, deductible limits and self-insured   retentions) as are customary in the pharmaceutical industry for the activities to be conducted by Licensee   under this Agreement. The coverage limits set forth herein will not create any limitation on Licensee’s  liability to Radius under this Agreement. Additionally, Licensee shall specify Duke as an additional insured   in its above coverage for all product liability claims with respect to any Licensed Products manufactured,   used, sold, licensed or otherwise distributed by or on behalf of Licensee.          10.8  Limitation of Liability. EXCEPT IN CASE OF FRAUD, GROSS NEGLIGENCE,   WILLFUL MISCONDUCT AND INDEMNIFICATION UNDER SECTIONS 10.6(a)       and 10.6(b)   ABOVE AND INDEMNIFICATION UNDER SECTION 2.2 OF EXHIBIT F,   NO PARTY WILL BE   LIABLE TO THE OTHER PARTY FOR ANY INCIDENTAL, SPECIAL, INDIRECT OR   CONSEQUENTIAL DAMAGES.    Section 11. Term, Termination and Survival.          11.1  Term. This Agreement will commence as of the Effective Date and, unless sooner   terminated in accordance with the terms hereof or by mutual written agreement of the Parties, will continue   on a country-by-country and Licensed Product-by-Licensed Product basis until the end of the period during  which royalties are due hereunder on Net Sales of such Licensed Product in such country (the “Term”).   Upon the end of such period for such Licensed Product in such country, the license grant contained in                                          31   

 

                                                                LICENSE AGREEMENT   Section 2.1 will become perpetual, irrevocable, non-terminable, royalty free and fully paid up with respect  to such Licensed Product in such country.          11.2  Termination for Material Breach. Either Party will have the right to terminate this   Agreement upon delivery of written notice to the other Party in the event of any material breach in the   performance by such other Party of any term or condition under this Agreement, provided that such   termination will not be effective if such breach has been cured within [*] ([*]) days after written notice  thereof is given by the terminating Party to such other Party specifying the nature of the alleged breach..          11.3  Bankruptcy. To the extent permitted by Law, upon the filing or institution of bankruptcy,   reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of   the assets for the benefit of creditors (a “Bankruptcy Event”) by either Party, Radius, in the case of a   Bankruptcy Event by Licensee, or Licensee, in the case of a Bankruptcy Event by Radius, may terminate   this Agreement; provided, however, that, in the case of any involuntary bankruptcy proceeding, such right   to terminate will only become effective if the subject Party consents to the involuntary bankruptcy or such   proceeding is not dismissed within [*] ([*]) days after the filing thereof. Each Party will retain and may  fully exercise all of its rights and elections under the U.S. Bankruptcy Code and foreign equivalents,  including that upon commencement of a bankruptcy proceeding by or against such Party undergoing a  bankruptcy proceeding (the “Affected Party”) under the U.S. Bankruptcy Code or foreign equivalents, the   non-Affected Party will be entitled to complete duplicates of or complete access to, as such non-Affected   Party deems appropriate, any Know-How and patent and other intellectual property rights and all   embodiments hereof licensed or to be transferred to such non-Affected Party hereunder by the Affected   Party. Such Know-How, rights and embodiments will be promptly delivered to the non-Affected Party   (a) upon any such commencement of a bankruptcy proceeding and upon written request thereof by the non-  Affected Party, unless the Affected Party elects to continue to perform all of its obligations under   this Agreement, or (b) if not delivered under the foregoing clause (a), upon the rejection of this Agreement   by or on behalf of the Affected Party upon written request therefore by the non-Affected Party. This   Section 11.3 is without prejudice to any rights the non-Affected Party may have arising under the U.S.   Bankruptcy Code, foreign equivalents or other Law. Without prejudice to the foregoing, notwithstanding   anything to the contrary in this Agreement or otherwise, the Parties agree that in the event that this   Agreement is terminated or rejected by a Party or its receiver or trustee under applicable bankruptcy laws   due to such Party’s Bankruptcy Event, then all rights and licenses granted under or pursuant to this   Agreement by such Party to the other Party are, and shall otherwise be deemed to be, for purposes of   Section 365(n) of the United States Bankruptcy Code and any similar law or regulation in any other country,   licenses of rights to “intellectual property” as defined under Section 101(35A) of the United States  Bankruptcy Code. The Parties agree that all intellectual property rights licensed hereunder, including  without limitation, any patents or patent applications of or Controlled by a Party in any country covered by  the license grants under this Agreement, are part of the “intellectual property” as defined under  Section 101(35A) of the United States Bankruptcy Code subject to the protections afforded the non- terminating Party under the Section 365(n) of the United States Bankruptcy Code, and any similar law or  regulation in any other country.          11.4  Termination by Radius for Cessation. Radius shall have the right to terminate this   Agreement if, no Development, Manufacture or Commercialization activity, in each case to the extent to   be performed by Licensee hereunder, is conducted by Licensee, its Affiliates or Sublicensees [*], and such   cessation is not due to any action by any Regulatory Authority that prevents, limits or otherwise adversely   affects any such Development, Manufacture or Commercialization activity, including for safety or CMC   issues.          11.5  Termination by Radius for Patent Challenge.                                          32   

 

                                                               LICENSE AGREEMENT               (a)   Radius will have the right to terminate this Agreement in full upon written notice  to Licensee in the event that Licensee or any of its Affiliates or Sublicensees directly or indirectly asserts  a Patent Challenge; provided that with respect to any such Patent Challenge by any non-Affiliate  Sublicensee, Radius will not have the right to terminate this Agreement under this Section 11.5 if Licensee  (i) causes such Patent Challenge to be terminated or dismissed or (ii) terminates such Sublicensee’s  sublicense to the Radius Patent Rights being challenged by the Sublicensee, in each case within [*] ([*])  days of Radius’s notice to Licensee under this Section 11.5. In the event Licensee or any of its Affiliates  intends to assert a Patent Challenge in any forum, not less than [*] ([*]) days prior to making any such  assertion, Licensee will provide to Radius a complete written disclosure of each basis known to Licensee  and its Affiliates for such assertion.               (b)   Licensee acknowledges and agrees that this Section 11.5 is reasonable, valid and  necessary for the adequate protection of Radius’s interest in and to the Radius Patent Rights, and that  Radius would not have granted to Licensee the licenses under those Radius Patent Rights, without this  Section 11.5. Radius will have the right, at any time in its sole discretion, to strike this Section 11.5 (or  any portion thereof) from this Agreement, and Radius will have no liability whatsoever as a result of the  presence or absence of this Section 11.5 (or any struck portion thereof).         11.6  Discretionary Termination by Licensee. Licensee will have the right to terminate this  Agreement in full or on a country-by-country basis at its discretion for any reason by delivering written  notice to Radius, such termination to be effective [*] days ([*]) days following the date of such notice,  provided that (a) any such termination will not be effective before [*]; and (b) Licensee has paid to Radius  all Milestone Payments and royalties due and payable up to the effective date of termination.          11.7  Effect of Termination. Upon termination of this Agreement pursuant to Section 11.2, 11.3,  11.4, 11.5 or 11.6:               (a)   Except as may otherwise be agreed in writing by the Parties, Licensee will be  responsible at its own expense for an orderly wind-down, in accordance with accepted pharmaceutical  industry norms and ethical practices, of any then on-going Clinical Studies hereunder for which it has  responsibility.               (b)   Should Licensee or any of its Affiliates or Sublicensees have any inventory of  any Licensed Product, each of them will have [*] [*]) months thereafter in which to, at Radius’s sole  discretion, either (i) dispose of such inventory (subject to the payment to Radius of any royalties or other  amounts due hereunder thereon) or (ii) transfer such inventory to Radius at Licensee’s cost.               (c)   All licenses and other rights granted by Radius to Licensee hereunder will  terminate and such licenses and other rights will revert to Radius, and Licensee and its Affiliates and  Sublicensees will have no further rights to use any Radius Patent Rights or Radius Know-How (except as  expressly set forth in Sections 11.7(a) and 11.7(b)). Each Party will promptly return to the other Party (or  as directed by such other Party destroy and certify to such other Party in writing as to such destruction)  all of such other Party’s Confidential Information and any materials, Licensed Compound and Licensed  Products provided by or on behalf of such other Party hereunder that are in such Party’s (or its Affiliates’  or in the case of Licensee’s Sublicensees’) possession or control, save that such Party will have the right  to retain (A) one (1) copy of intangible Confidential Information of such other Party for legal purposes,  and (B) any of the foregoing under which such Party retains any license or other right hereunder. Subject  to Sections 11.7(a) and 11.7(b), Licensee and its Affiliates and Sublicensees will not continue to Develop,  Manufacture or Commercialize any Licensed Compounds or Licensed Products.                                          33               

 

                                                               LICENSE AGREEMENT               (d)   All Regulatory Approvals, Regulatory Filings, regulatory documents and  regulatory communications owned (in whole or in part) or otherwise controlled by Licensee and its  Affiliates and Sublicensees concerning any Licensed Compounds and Licensed Products will be assigned  to Radius, and Licensee will provide to Radius one (1) copy of the foregoing and all documents contained  in or referenced in any such items, together with the raw and summarized data for any Clinical Studies  (and where reasonably available, electronic copies thereof). In the event of failure to obtain assignment,  Licensee hereby consents and grants to Radius the right to access and reference (without any further action  required on the part of Licensee, whose authorization to file this consent with any Regulatory Authority  is hereby granted) any such item.               (e)   At Radius’s election, Licensee will use reasonable efforts to assign to Radius or  its designee all then-existing Manufacturing contracts with Third Party contract manufacturers in  connection with the Manufacture of any Licensed Compounds and Licensed Products. After such  assignment, Radius will be solely responsible for the performance of the obligations under such  Manufacturing contracts.               (f)   Licensee will grant (without any further action required on the part of Licensee)  to Radius and its Affiliates a worldwide, perpetual and irrevocable, nontransferable (except in connection  with a permitted assignment of this Agreement in accordance with Section 12.1), royalty-free and fully  paid-up, license, with the right to grant sublicenses through multiple tiers, in the Territory on an exclusive  (even as to Licensee) basis, under all Reversion IP that (x) is owned or in-licensed by Licensee (or any of  its Affiliates or Sublicensees), to the extent permissible under the relevant in-license agreement, as of the  date of notice of termination, (y) is actually being used to Develop, Manufacture or Commercialize the  Licensed Compound or any Licensed Products as of the date of notice of termination, and (z) only to the  extent necessary to Develop, Manufacture and Commercialize, and for the sole purpose of Developing,  Manufacturing, and Commercializing, in each case, the Licensed Compound or any Licensed Products  (along with other active ingredients in any Licensed Products); in all cases in the Territory and in the  Field. At Radius’s written request, the Parties will enter into commercially reasonable Prosecution and  enforcement and defense terms for the Reversion IP in a form substantially similar to the terms contained  herein for the benefit of Licensee. For purposes hereof, “Reversion IP” means any patent rights or Know-  How owned or in-licensed by Licensee or any of its Affiliates or Sublicensees that specifically claim or  cover the Licensed Compound or any Licensed Products, or their method of manufacture or use.                (g)   Upon Radius’s request, Licensee agrees to discuss in good faith and reasonably   cooperate with Radius with respect to the assignment and transfer to Radius of Licensee’s and its   Affiliates’ right, title and interest in and to any agreements between Licensee or any of its Affiliates and   Third Parties that relate solely to the Development, Manufacture or Commercialization of any Licensed   Compound or Licensed Product (including any Third Party licenses or sublicenses) and for any such   agreement that does not relate solely to the Development, Manufacture or Commercialization of Licensed   Compounds or Licensed Products, the assignment (or license, if applicable) to Radius of only such   portions of such agreements relating thereto.                (h)   Only in case this Agreement is terminated by Radius for (i) Licensee’s breach of   this Agreement pursuant to Section 11.2 or (ii) Licensee’s Patent Challenge pursuant to Section  11.5,  Licensee will assign (or, if applicable, will cause its Affiliates or Sublicensees to assign) to Radius all of  Licensee’s (and such Affiliates’ or Sublicensees’) worldwide right, title and interest in and to any  registered or unregistered trademarks or internet domain names that are specific to and solely used for any  Licensed Products (it being understood that the foregoing will not include any trademarks or internet  domain names that contain the corporate or business name(s) of Licensee or any of its Affiliates or  Sublicensees).                                         34               

 

                                                                LICENSE AGREEMENT         11.8  Survival. In addition to the termination consequences set forth in Section 11.7, the   following provisions will survive expiration or termination of this Agreement for any reason: Sections 2.2   (mutatis mutandis with respect to licenses granted to Radius under Section 11.7(f)), 7.6, 10.3, 10.6, 11.1  (last sentence, in the case of expiration of this Agreement) and 11.3 (excluding the first sentence thereof),  this Section 11.8, the last sentence of Section 2.2(b), and all of Section 1, Section 9 and Section 12.  Expiration or termination of this Agreement for any reason will not relieve the Parties of any liability or  obligation which accrued hereunder prior to the effective date of such termination or expiration, nor  preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity,  with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any  obligation. All other rights and obligations will terminate upon termination or expiration of this Agreement.          11.9  Right to Set-off. Notwithstanding anything to the contrary in this Agreement (other than   the last sentence of Section 7.1), each Party has the right at all times to retain and set off against all amounts  due and owing to the other Party, as determined in a final judgment or award, any damages or awards  recovered by such Party for any Losses incurred by such Party.    Section 12. General Provisions.          12.1  Assignment.                 (a)   This Agreement may not be assigned by either Party, nor may either Party   delegate its obligations or otherwise transfer licenses or other rights created by this Agreement, except as   expressly permitted hereunder or otherwise without the prior written consent of the other Party, which   consent will not be unreasonably withheld, delayed or conditioned; provided that without consent either   Party may assign this Agreement in its entirety to an Affiliate, or in connection with a Change of Control   of the assigning Party. Each Party will provide prompt written notice to the other Party of any such   permitted assignment.                (b)   Notwithstanding anything to the contrary in Section 12.1(a) or elsewhere in this   Agreement, Radius may sell, transfer or assign its rights to any Third Party to receive payments under   Section 7, and Radius may disclose Confidential Information of Licensee to one or more Third Party(ies)   in connection with any such assignment to enable the Third Party(ies) to evaluate and monitor any such   purchase, transfer or assignment, provided that such Third Party(ies) are subject to confidentiality   obligations consistent with those set forth in Section 9. Radius will provide prompt written notice to   Licensee of any such sale, transfer or assignment of its rights to any Third Party to receive payments under   Section 7, provided however that in no event Licensee shall be obligated to make a payment to any Third   Party if such payment may be in violation of any applicable Law.                (c)   Any attempted assignment, delegation or transfer in violation of this Section 12.1   will be void ab initio. Any permitted assignee will assume all assigned obligations of its assignor under   this Agreement. The terms and conditions of this Agreement will inure to the benefit of, and be binding   upon, the legal representatives, successors and permitted assigns of the Parties.          12.2  Severability. If any one or more of the provisions contained in this Agreement is held   invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining   provisions contained herein will not in any way be affected or impaired thereby, unless the absence of the   invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties will in such an   instance use their reasonable commercial efforts to replace the invalid, illegal or unenforceable provision(s)   with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this   Agreement.                                          35   

 

                                                                LICENSE AGREEMENT          12.3  Cumulative Remedies. All rights and remedies of the Parties hereunder will be cumulative   and in addition to all other rights and remedies provided hereunder or available by agreement, at Law or   otherwise.          12.4  Amendment; Waiver. This Agreement may not be modified, amended or rescinded, in   whole or part, except by a written instrument signed by the Parties; provided that any unilateral undertaking   or waiver made by one Party in favor of the other will be enforceable if undertaken in a writing signed by   the Party to be charged with the undertaking or waiver. No delay or omission by either Party hereto in  exercising any right or power occurring upon any noncompliance or default by the other Party with respect  to any of the terms of this Agreement will impair any such right or power or be construed to be a waiver  thereof. A waiver by either of the Parties of any of the covenants, conditions or agreements to be performed  by the other will not be construed to be a waiver of any succeeding breach thereof or of any other covenant,  condition or agreement herein contained.          12.5  Notices. Except as otherwise provided herein, all notices under this Agreement will be sent   by certified mail or by overnight courier service, postage prepaid, to the following addresses of the   respective Parties:                If to Licensee, to:     Berlin-Chemie AG                                       Glienicker Weg 125, 12849 Berlin                                       Attention: President of the Board of Director                 With a required copy to: Berlin-Chemie AG                                       Glienicker Weg 125, 12849 Berlin                                       Attention:  Head of Legal Department                If to Radius, to:       Radius Pharmaceuticals, Inc.                                       950 Winter Street                                        Waltham, MA 02451                                        Attention:  Secretary                With a required copy to: Goodwin Procter LLP                                       100 Northern Avenue                                        Boston, MA 02210                                        Attention:  Sarah A. Solomon    or to such address as each Party may hereafter designate by notice to the other Party. A notice will be   deemed to have been given on the date it is received by all required recipients for the noticed Party.          12.6  Applicable Law. This Agreement will be governed by and construed in accordance with   the laws of the State of New York, without regard to its conflicts of law provisions; provided that any   dispute relating to the scope, validity, enforceability or infringement of any patent rights will be governed   by, and construed and enforced in accordance with, the substantive laws of the jurisdiction in which such   patent rights apply. Each Party agrees to submit to the exclusive jurisdiction of the United States District   Court and state courts located in New York, New York with respect to any claim, suit or action in law or   equity arising in any way out of this Agreement or the subject matter hereof.          12.7  Relationship of the Parties. Each Party is an independent contractor under this Agreement.   Nothing contained herein is intended or is to be construed so as to constitute Radius and Licensee as   partners, agents or joint venturers. Except as set forth herein with respect to Duke or Eisai or their Affiliates,   neither Party will have any express or implied right or authority to assume or create any obligations on                                          36   

 

                                                                LICENSE AGREEMENT   behalf of or in the name of the other Party or to bind the other Party to any contract, agreement or  undertaking with any Third Party. There are no express or implied third party beneficiaries hereunder  (except for Licensee Indemnitees other than Licensee and Radius Indemnitees other than Radius for  purposes of Sections 10.6(a) or 10.6(b), as applicable).          12.8  Entire Agreement. This Agreement (along with the Exhibits), and the Transition Services   Agreement, contains the entire understanding of the Parties with respect to the subject matter hereof and   supersedes and replaces any and all previous arrangements and understandings, including the   Confidentiality Agreement, whether oral or written, between the Parties with respect to the subject matter   hereof.          12.9  Headings. The captions to the several Sections hereof are not a part of this Agreement, but   are merely guides or labels to assist in locating and reading the several Sections hereof.          12.10 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel   in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of   construction that any ambiguity in this Agreement will be construed against the drafting Party will not   apply.          12.11 Interpretation. Whenever any provision of this Agreement uses the term “including” (or   “includes”), such term will be deemed to mean “including without limitation” (or “includes without   limitations”). “Herein,” “hereby,” “hereunder,” “hereof” and other equivalent words refer to this Agreement   as an entirety and not solely to the particular portion of this Agreement in which any such word is used.   The term “or” means “and/or” hereunder. All definitions set forth herein will be deemed applicable whether   the words defined are used herein in the singular or the plural. Unless otherwise provided, all references to   Sections and Exhibits in this Agreement are to Sections and Exhibits of this Agreement. References to any   Sections include Sections and subsections that are part of the related Section (e.g., a section numbered   “Section 2.2” would be part of “Section 2”, and references to “Section 2.2” would also refer to material   contained in the subsection described as “Section 2.2(a)”).          12.12 Counterparts; Facsimiles. This Agreement may be executed in one (1) or more   counterparts, each of which will be deemed an original and all of which together will constitute one and the   same instrument. Facsimile or PDF execution (including electronic signature) and delivery of this   Agreement by either Party will constitute a legal, valid and binding execution and delivery of this   Agreement by such Party.                        [Remainder of this Page Intentionally Left Blank]                                               37   

 

           IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their  respective duly authorized representatives as of the Effective Date.                                       RADIUS PHARMACEUTICALS, INC.                                        By:   /s/ Kelly Martin                                                                 (Signature)                                       Name: Kelly Martin                                                               Title: Chief Executive Officer                                                    BERLIN-CHEMIE AG                                        By:   /s/ Pio Mei                                                                      (Signature)                                       Name: Pio Mei                                                                    Title: Member of Executive Board                                                   By:   /s/ Attilio Sebastio                                                            (Signature)                                       Name: Attilio Sebastio                                                           Title: Member of Executive Board                

 

                                                               LICENSE AGREEMENT                                   SCHEDULE 1.53                                  Backup Compounds   1902 genus:                                                                  1902 Selection Case genus:                                                                           

 

                                                               LICENSE AGREEMENT   1902 lead compounds:                                                                                                                                                                    

 

LICENSE AGREEMENT                                                                                                                                                                                                                                                                                                                                                       

 

LICENSE AGREEMENT                                                                                                                                                                                                                                                                                                                                   

 

LICENSE AGREEMENT                                                                                                                                                                              

 

                                                                LICENSE AGREEMENT                                    SCHEDULE 1.82                                   Structural Analog    1.    A compound represented by the following formula (I);                                                                               wherein                                                f g’              f’   g’         Z represents a bond, a C1-C4 alkylene group or –CR ’R -CH2-O- wherein R  and R independently   represent a C1-C6 alkyl group;          -T-NRaRb represents -NRaRb,                                    , or                                                         ;           A represents a 5- to 14-membered heteroarylene group which may have one or more substituents   or a C6-C14 arylene group which may have one or more substituents;                                               c         c        Y represents a C1-C4 alkylene group or –CH2-NR - wherein R  represents a C1-C6 alkyl group  which may have a substituent;          ring G is a ring or a fused ring system selected from the group consisting of;      

 

                                                                LICENSE AGREEMENT                   ,            ,             ,             ,               ,                   ,            ,             ,            ,             ,                   ,               ,             ,                         ,                 ,             ,             ,               ,               ,                ,             ,            ,             ,               ,                   ,             ,             ,             ,               , and                   ;   wherein each Rh is independently selected from hydrogen or CH3; Rg is hydrogen, C1-C3 alkyl, C1-C3   fluoroalkyl, CN, fluorine, chlorine or bromine; and each Re is independently selected from hydrogen,   halogen, OH, O(CO)R, O(CO)NR1R2, OPO3, OSO3,O(SO2)NR1R2, or wherein two adjacent Re together   form:             ,                 ,         , or                 ;     wherein each R3 is hydrogen, C1-C12 acyl, or C1-C12 acyloxy; and each R4 is independently hydrogen, C1-  C3 alkyl, fluorine or chlorine;      

 

                                                               LICENSE AGREEMENT         R’ represents 1 to 4 substituents independently selected from a hydrogen and a C1-C6 alkoxy  group;         a partial structure in formula (I) represented by the following formula:                                                                                    or                                             R’’ represents a hydroxyl group that may be further protected by a protecting group or a C1-C6  alkoxy group which may have a substituent; U and V are each independently selected from CRa’ or N; each  Ra’ is independently selected from:  H, C1-C3 alkyl, C1-C3 fluoroalkyl, phenyl (optionally substituted with     

 

                                                                LICENSE AGREEMENT     1-3 groups selected from fluorine, chlorine, C1-C3 alkyl, CN, OC1-C3 alkyl, OH), OH, OC1-3alkyl, CN,   fluorine, or chlorine; and           Ra and Rb are the same as or different from each other and each represents a hydrogen atom, a C1-  C6 alkyl group which may have one or more substituents, or a C3-C8 cycloalkyl group which may have   one or more substituents, or when Ra and Rb are bonded together, they may form, together with the nitrogen  atom that is adjacent to a Ra and Rb, a 4- to 10-membered single ring which may have one or more   substituents; and           L represents a single bond,         or a salt thereof.         

 

                                      EXHIBIT A-1                              INITIAL DEVELOPMENT PLAN    [*]        

 

                                     EXHIBIT B                               LICENSED COMPOUND   Elacestrant (RAD1901)                                                

 

                                                                   EXHIBIT C-1                                           DUKE PATENT RIGHTS                                  Application    Filing                              Patent   Issue   Type   Country     Title                              Appl. Type     Status                      Ownership                                     No.         Date                                No.     Date   1901 DUKE   Patent  United    Method of    61/971,627     3-28-    Provisional   Expired        --       --      Duke           States   Treating                     2017                                               University                    Cancer                    Using                    Selective                    Estrogen                    Receptor                    Modulators  Patent  United    Method of    14/512,061     10-10-      Non-        Issued     9421264     8-      Duke           States   Treating                     2014    Provisional                          23-   University                    Cancer                                                                   2016                    Using                    Selective                    Estrogen                    Receptor                    Modulators  Patent  United    Method of    62/129,379    3-6-2015  Provisional   Expired        --       --      Duke           States   Treating                                                                        University                    Cancer                    Using                    Selective                    Estrogen                    Receptor                    Modulators  Patent   PCT      Method of   PCT/US2015/     3-28-       PCT        Expired        --       --      Duke                    Treating       023216        2015                                               University                    Cancer                    Using                    Selective                    Estrogen                    Receptor                    Modulators  Patent  United    Method of    15/214,187     7-19-       Non-        Issued    10071066     9-      Duke           States   Treating                     2016    Provisional                          11-   University                    Cancer                                                                   2018                    Using                    Selective                    Estrogen                    Receptor                    Modulators  Patent  United    Method of    15/129,197    26-Sep-      Non-        Issued    10420734    24-      Duke           States   Treating                      16     Provisional                         Sep-   University            NP      Cancer                                                                    19                    Using                    Selective                    Estrogen                    Receptor                    Modulators                       

 

                                                                                         LICENSE AGREEMENT                                   Application    Filing                              Patent   Issue   Type   Country     Title                              Appl. Type     Status                      Ownership                                     No.         Date                                No.     Date   1901 DUKE   Patent  Canada    Method of     2943611       3-28-      CA NP       Pending        --       --      Duke                    Treating                     2015                                               University                    Cancer                     National                    Using                       Entry                    Selective                   9-22-                   Estrogen                     2016                    Receptor                    Modulators  Patent  Europe    Method of    15769394.6     3-28-      EP NP      Published       --       --      Duke                    Treating                     2015                                               University                    Cancer                     National                    Using                       Entry                    Selective                    10-                   Estrogen                   27/2016                    Receptor                    Modulators  Patent  Europe    Method of     Proposed     Proposed    EP Div      Proposed       --       --      Duke            DIV     Treating                                                                        University                    Cancer                    Using                    Selective                    Estrogen                    Receptor                    Modulators  Patent  United    Method of    16/041,416     20-Jul-     Non-      Abandoned       --       --      Duke           States   Treating                      18     Provisional                                University          CON 2     Cancer                    Using                    Selective                    Estrogen                    Receptor                    Modulators  Patent  United    Method of    16/549,828    23-Aug-      Non-      Published       --       --      Duke           States   Treating                      19     Provisional                                University          CON 3     Cancer                    Using                    Selective                    Estrogen                    Receptor                    Modulators  Patent  United    Method of    16/721,329    19-Dec-      Non-      Published       --       --      Duke           States   Treating                      19     Provisional                                University          CON 4     Cancer                    Using                    Selective                    Estrogen                    Receptor                    Modulators                       

 

                                                                                         LICENSE AGREEMENT                                                 EXHIBIT C-2                                                                                                  EISAI PATENT RIGHTS                                                     Filing   Appl.                          Issue  Type    Country      Title      Application No.                     Status   Patent No.           Ownership                                                     Date    Type                           Date   1901 EISAI COM   Patent  Australia  Selective      2003292625       25-     Nat'l   Issued    2003292625    20-    Eisai R&D                      Estrogen                       Dec-   Phase                           Nov-   Management                     Receptor                         03      of                             08      Co., Ltd.                     Modulator                               PCT    Patent   Canada    Selective       2512000         25-     Nat'l   Issued     2512000      9-     Eisai R&D                      Estrogen                       Dec-   Phase                           Aug-   Management                     Receptor                         03      of                             11      Co., Ltd.                     Modulator                               PCT    Patent   Europe    Selective      03782904.1       25-     Nat'l   Issued     1577288      23-    Eisai R&D                      Estrogen                       Dec-   Phase    in CH,                  Jul-  Management                     Receptor                         03      of    DE, GB,                  14      Co., Ltd.                     Modulator                               PCT     FR, LI,                                                                       NL                                                                    11/30/18   Patent   Poland    Selective          --            --      --     Issued      186710       --    Eisai R&D                      Estrogen                                                                     Management                     Receptor                                                                        Co., Ltd.                     Modulator    Patent    India    Selective   2829/DELNP/2005     25-     Nat'l   Issued      323625      24-    Eisai R&D                      Estrogen                       Dec-   Phase                           Oct-   Management                     Receptor                         03      of                             19      Co., Ltd.                     Modulator                               PCT    Patent   Japan     Selective      2004562947       25-     Nat'l   Issued     4500689      23-    Eisai R&D                      Estrogen                       Dec-   Phase                           Apr-   Management                     Receptor                         03      of                             10      Co., Ltd.                     Modulator                               PCT                                                     

 

                                                                                         LICENSE AGREEMENT                                                      Filing   Appl.                          Issue  Type    Country      Title      Application No.                     Status   Patent No.           Ownership                                                     Date    Type                           Date   1901 EISAI COM   Patent   United    Selective      11/158,245       22-     CIP     Issued     7,612,114    3-     Eisai R&D           States     Estrogen                       Jun-     of                            Nov-   Management                     Receptor                         05     PCT                             09      Co., Ltd.                     Modulator    Patent   United    Selective      12/544,965       20-     DIV     Issued     7,960,412    14-    Eisai R&D           States     Estrogen                       Aug-     of                            Jun-   Management                     Receptor                         09     '245                            11      Co., Ltd.                     Modulator    Patent   United    Selective      13/048,391       15-     DIV     Issued     8,399,520    19-    Eisai R&D           States     Estrogen                       Mar-     of                            Mar-   Management                     Receptor                         11     '965                            13      Co., Ltd.                     Modulator    Patent    PCT      Selective    PCT/JP03/16808     25-     PCT     Expired       --         --     Eisai Co.,                      Estrogen                       Dec-                                              Ltd.                     Receptor                         03                     Modulator                                                                 

 

                                                                   EXHIBIT C-3                                                                                         RADIUS-INVENTED PATENT RIGHTS                                                                                                                Issu                                                 Filin  Typ    Countr                                           Appl.                  Patent    e                     Title      Application No.     g                  Status                      Ownership    e       y                                               Type                   No.     Dat                                                 Date                                                                                            e    1901 THERAPEUTIC REGIMENS            United  Therapeuti                       12- Paten                                                   Provision                               Radius Health,          States  c               61/334,095      May-                Expired       --      --    t                                                        al                                       Inc.           PRV    Regimens                         10                    Therapeuti                       12-      Non- Paten                        PCT/US2011/0363                                                    Radius Health,           PCT    c                               May-    Provision   Expired       --      --    t                                 11                                                              Inc.                  Regimens                         10        al                    Therapeuti                       9-       Nat’l  Paten   United                                                     Abandone                     Radius Health,                  c               13/697,230      Nov-    Phase of                  --      --    t     States                                                         d                            Inc.                  Regimens                         12       PCT                                                           CON of          United  Therapeuti                       19-                                     31-       Radius  Paten                                                     US                   9,555,01         States  c               14/281,475      May-                 Issued              Jan-  Pharmaceutical   t                                                    13/697,23                  4          CON     Regimens                         14                                       17       s, Inc.                                                             0                   Therapeuti                       12-      Nat’l  Paten                                                              Abandone                     Radius Health,         Canada   c                2799183        May-    Phase of                  --      --    t                                                                    d                            Inc.                  Regimens                         11       PCT                                                                      Abandone                                                                        d                  Therapeuti                       12-      Nat’l                          20- Paten                                                                 all                       Radius Health,          Europe  c               11781299.0      May-    Phase of               2568806   Mar   t                                                                Validatio                        Inc.                  Regimens                         11       PCT                            -13                                                                         n                                                                     countries                   Therapeuti                       12-                                     18-       Radius  Paten   Europe                                           DIV of    Abandone                 c               16163037.1      May-                           3106159   Nov   Pharmaceutical   t      DIV                                            EP ‘299        d                  Regimens                         11                                      -16       s, Inc.                    Therapeuti                       12-     Nat’l                            8- Paten   Mexic                                                                                   Radius Health,                  c           MX/a/2012/013014    May-    Phase of     Issued    342898    Nov   t       o                                                                                         Inc.                  Regimens                         11       PCT                            -12                                                               

 

                                                                                         LICENSE AGREEMENT                                                                         Filin                                  Issu                                                            Appl.               Patent   Type   Country      Title      Application No.     g                Status               e      Ownership                                                              Type                No.                                                    Date                                  Date   1901 HF: MOT HOT FLASHES                      Treatment                     of                     vasomoto                    r           United    symptoms                        22-                                             Radius  Paten                                                     Provision  Expire          States    with           60/816,191      Jun-                           --       --   Pharmaceutical   t                                                          al         d            PRV      Selective                       06                                              s, Inc.                     estrogen                     receptor                     modulator                    s                     Treatment                     of                     vasomoto                    r                     symptoms                        22-      Non-                                   Radius  Paten                         PCT/US2007/0145                        Expire           PCT      with                           Jun-    Provision              --       --   Pharmaceutical   t                                   98                                d                     Selective                       07        al                                    s, Inc.                     estrogen                     receptor                     modulator                    s                     Treatment                     of                     vasomoto                    r                     symptoms                        22-      Nat'l                         2-       Radius  Paten                                                                         2,656,06          Canada    with           2,656,067       Jun-    Phase of   Issued              Jan-  Pharmaceutical   t                                                                              7                     Selective                       07     '598 PCT                       14        s, Inc.                     estrogen                     receptor                     modulator                    s                     Treatment                     of                     vasomoto                    r                                                           Validation                     symptoms                        22-                                    1-       Radius  Paten  Switzerlan                                            of                     with           07796378.3      Jun-               Issued   2037905   May    Pharmaceutical   t        d                                              2037905                     Selective                       07                                    -13       s, Inc.                                                             Patent                     estrogen                     receptor                     modulator                    s                     Treatment                     of                     vasomoto                    r                                                           Validation                     symptoms                        22-                                    1-       Radius  Paten                                                        of          Germany    with           07796378.3      Jun-               Issued   2037905   May    Pharmaceutical   t                                                       2037905                     Selective                       07                                    -13       s, Inc.                                                             Patent                     estrogen                     receptor                     modulator                    s                      

 

                                                                                         LICENSE AGREEMENT                                                     Filin                                  Issu                                                            Appl.               Patent   Type   Country      Title      Application No.     g                Status               e      Ownership                                                              Type                No.                                                    Date                                  Date   1901 HF: MOT HOT FLASHES                      Treatment                     of                     vasomoto                    r                     symptoms                        22-      Nat'l                         1-       Radius  Paten          Europe    with           07796378.3      Jun-    Phase of   Issued   2037905    May   Pharmaceutical   t                     Selective                       07     '598 PCT                       -13       s, Inc.                     estrogen                     receptor                     modulator                    s                     Treatment                     of                     vasomoto                    r                                                           Validation                     symptoms                        22-                                    1-       Radius  Paten                                                        of           Spain     with           07796378.3      Jun-               Issued   2037905   May    Pharmaceutical   t                                                       2037905                     Selective                       07                                    -13       s, Inc.                                                             Patent                     estrogen                     receptor                     modulator                    s                     Treatment                     of                     vasomoto                    r                                                           Validation                     symptoms                        22-                                    1-       Radius  Paten                                                        of           France    with           07796378.3      Jun-               Issued   2037905   May    Pharmaceutical   t                                                       2037905                     Selective                       07                                    -13       s, Inc.                                                             Patent                     estrogen                     receptor                     modulator                    s                     Treatment                     of                     vasomoto                    r                                                           Validation                     symptoms                        22-                                    1-       Radius  Paten    Great                                               of                     with           07796378.3      Jun-               Issued   2037905   May    Pharmaceutical   t      Britain                                          2037905                     Selective                       07                                    -13       s, Inc.                                                             Patent                     estrogen                     receptor                     modulator                    s                     Treatment                     of                     vasomoto                    r                                                           Validation                     symptoms                        22-                                    1-       Radius  Paten                                                        of           Ireland   with           07796378.3      Jun-               Issued   2037905   May    Pharmaceutical   t                                                       2037905                     Selective                       07                                    -13       s, Inc.                                                             Patent                     estrogen                     receptor                     modulator                    s                       

 

                                                                                         LICENSE AGREEMENT                                                     Filin                                  Issu                                                            Appl.               Patent   Type   Country      Title      Application No.     g                Status               e      Ownership                                                              Type                No.                                                    Date                                  Date   1901 HF: MOT HOT FLASHES                      Treatment                     of                     vasomoto                    r                                                           Validation                     symptoms                        22-                                    1-       Radius  Paten                                                        of            Italy    with           07796378.3      Jun-               Issued   2037905   May    Pharmaceutical   t                                                       2037905                     Selective                       07                                    -13       s, Inc.                                                             Patent                     estrogen                     receptor                     modulator                    s                     Treatment                     of                     vasomoto                    r           United    symptoms                        27-      Nat'l                        13-       Radius  Paten                                                                         8,933,13          States    with           12/308,640      Oct-    Phase of   Issued              Jan-  Pharmaceutical   t                                                                              0            NP       Selective                       09     '598 PCT                       15        s, Inc.                     estrogen                     receptor                     modulator                    s                                           Typ                                           Filing                              Paten    Issue   Ownershi         Country    Title    Application No.             Appl. Type      Status    e                                            Date                                 t No.   Date        p   1901 ER MUTANTS                     Method         United    s of                        29-                                                   Radius  Paten          States   Treatin     62/154,699      Apr-     Provisional      Expired      --     --    Pharmaceuti   t           PRV      g                            15                                                  cals, Inc.                    Cancer                     Method         United    s of                           30-                                                Radius  Paten          States   Treatin      62/155,451       Apr-    Provisional     Expired     --     --     Pharmaceuti   t           PRV      g                              15                                                cals, Inc.                    Cancer                     Method         United    s of                           6-                                                Radius  Paten          States   Treatin      62/252,085       Nov-    Provisional   Expired      --     --   Pharmaceutical   t           PRV      g                              15                                                s, Inc.                    Cancer                       

 

                                                                                         LICENSE AGREEMENT     Typ                                           Filing                              Paten    Issue   Ownershi         Country    Title    Application No.             Appl. Type      Status    e                                            Date                                 t No.   Date        p   1901 ER MUTANTS                     Method         United    s of                           10-                                                Radius  Paten          States   Treatin      62/265,696       Dec-    Provisional   Expired       --      --    Pharmaceuti   t           PRV      g                              15                                                cals, Inc.                    Cancer                     Method                   s of                           29-                                                Radius  Paten                                                      Non-          PCT      Treatin   PCT/US2016/30317    Apr-                  Expired       --      --    Pharmaceuti   t                                                     Provisional                    g                              16                                                cals, Inc.                    Cancer                     Method                                                         Nat'l phase                    s of                           29-                                                Radius  Paten                                                       of         Australia  Treatin      2016256470       Apr-                  Pending       --      --    Pharmaceuti   t                                                     PCT/US16/                    g                              16                                                cals, Inc.                                                            30317                    Cancer                     Method                                                         Nat'l phase                    s of                           29-                                                Radius  Paten                                                       of           Brazil   Treatin  BR 112017023233-2    Apr-                 Published      --      --    Pharmaceuti   t                                                     PCT/US16/                    g                              16                                                cals, Inc.                                                            30317                    Cancer                     Method                                                         Nat'l phase                    s of                           29-                                                Radius  Paten                                                       of          Canada    Treatin       2,984,195       Apr-                  Pending       --      --    Pharmaceuti   t                                                     PCT/US16/                    g                              16                                                cals, Inc.                                                            30317                    Cancer                     Method                                                         Nat'l phase                    s of                           29-                                                Radius  Paten                                                       of           China    Treatin    201680038908.9     Apr-                  Published     --      --    Pharmaceuti   t                                                     PCT/US16/                    g                              16                                                cals, Inc.                                                            30317                    Cancer                     Method                                                         Nat'l phase                    s of                           29-                                                Radius  Paten                                                       of          Europe    Treatin      16787290.2       Apr-                  Published     --      --    Pharmaceuti   t                                                     PCT/US16/                    g                              16                                                cals, Inc.                                                            30317                    Cancer                       

 

                                                                                         LICENSE AGREEMENT     Typ                                           Filing                              Paten    Issue   Ownershi         Country    Title    Application No.             Appl. Type      Status    e                                            Date                                 t No.   Date        p   1901 ER MUTANTS                     Method                   s of                           29-                                                Radius  Paten    Hong                                             OFF EP                    Treatin      18110956.1       Apr-                  Published     --      --    Pharmaceuti   t      Kong                                           16787290.2                    g                              16                                                cals, Inc.                    Cancer                     Method                                                         Nat'l phase                    s of                           29-                                                Radius  Paten                                                       of           Israel   Treatin        255148         Apr-                  Published     --      --    Pharmaceuti   t                                                     PCT/US16/                     g                              16                                                cals, Inc.                                                            30317                    Cancer                     Method                                                         Nat'l phase                    s of                           29-                                                Radius  Paten                                                       of           Japan    Treatin      2018-509731      Apr-                 Published      --      --    Pharmaceuti   t                                                     PCT/US16/3                   g                              16                                                cals, Inc.                                                             0317                    Cancer                     Method                                                         Nat'l phase                    s of                           29-                                                Radius  Paten    South                                              of                    Treatin    10-2017-7034603    Apr-                 Published      --      --    Pharmaceuti   t      Korea                                          PCT/US16/                    g                              16                                                cals, Inc.                                                            30317                    Cancer                     Method                                                         Nat'l phase                    s of                           29-                                                Radius  Paten                                                       of          Mexico    Treatin   MX/a/2017/013801    Apr-                  Pending       --      --    Pharmaceuti   t                                                     PCT/US16/                    g                              16                                                cals, Inc.                                                            30317                    Cancer                     Method                                                         Nat'l phase                    s of                           29-                                                Radius  Paten    New                                                of                    Treatin        737825         Apr-                  Pending       --      --    Pharmaceuti   t     Zealand                                         PCT/US16/                    g                              16                                                cals, Inc.                                                            30317                    Cancer                     Method                                                         Nat'l phase          Russian   s of                           29-                                                Radius  Paten                                                       of         Federatio  Treatin      2017140674       Apr-                  Pending       --      --    Pharmaceuti   t                                                     PCT/US16/             n      g                              16                                                cals, Inc.                                                            30317                    Cancer                       

 

                                                                                         LICENSE AGREEMENT     Typ                                           Filing                              Paten    Issue   Ownershi         Country    Title    Application No.             Appl. Type      Status    e                                            Date                                 t No.   Date        p   1901 ER MUTANTS                     Method                                                         Nat'l phase                    s of                           29-                                                Radius  Paten   Singapor                                            of        Abandon                   Treatin    11201708858W       Apr-                                --      --    Pharmaceuti   t        e                                            PCT/US16/        ed                    g                              16                                                cals, Inc.                                                            30317                    Cancer                     Method         Singapor                   s of                           29-                                                 Radius  Paten      e                    Treatin     10201903993U      Apr-     Divisional   Published                   Pharmaceuti   t     Division                   g                              16                                                cals, Inc.             al                    Cancer           United    Method          States   s of                           26-      CON of                                    Radius  Paten          CON      Treatin      15/794,774       Oct-    PCT/US16/    Published      --      --    Pharmaceuti   t          CON of    g                              17       30317                                    cals, Inc.           PCT      Cancer                                                                                             Filing                           Patent  Issue  Type     Country     Title      Application No.           Appl. Type     Status                     Ownership                                                    Date                              No.    Date   1901 COMBINATION W/ CDK 4/6 INHIBITOR                         Methods            United                                   15-                                                Radius                      for  Patent    States                  62/192,940       Jul-   Provisional   Expired      --     --    Pharmaceuticals,                      Treating            PRV                                      15                                                  Inc.                      Cancer                        Methods            United                                   10-                                                Radius                      for  Patent    States                  62/265,658      Dec-    Provisional   Expired      --     --    Pharmaceuticals,                      Treating            PRV                                      15                                                  Inc.                      Cancer                        Methods            United                                   15-                                                Radius                      for  Patent    States                  62/323,572      Apr-    Provisional   Expired      --     --    Pharmaceuticals,                      Treating            PRV                                      16                                                  Inc.                      Cancer                       

 

                                                                                         LICENSE AGREEMENT                                                      Filing                           Patent  Issue  Type     Country     Title      Application No.           Appl. Type     Status                     Ownership                                                    Date                              No.    Date   1901 COMBINATION W/ CDK 4/6 INHIBITOR                         Methods                                                     29-                                                Radius                      for                                     Non- Patent     PCT                PCT/US2016/30321    Apr-                  Expired      --     --    Pharmaceuticals,                      Treating                              Provisional                                                     16                                                  Inc.                      Cancer                        Methods                               Nat'l Phase                                                     29-                                                Radius                      for                                       of  Patent   Australia               2016256471       Apr-                  Pending      --     --    Pharmaceuticals,                      Treating                              PCT/US16/                                                     16                                                  Inc.                      Cancer                                  30321                        Methods                               Nat'l Phase                                                     29-                                                Radius                      for              BR                       of  Patent    Brazil                                  Apr-                 Published     --     --    Pharmaceuticals,                      Treating   112017023269-3             PCT/US16/                                                     16                                                  Inc.                      Cancer                                  30321                        Methods                               Nat'l Phase                                                     29-                                                Radius                      for                                       of  Patent   Canada                   2,984,200       Apr-                  Pending      --     --    Pharmaceuticals,                      Treating                              PCT/US16/                                                     16                                                  Inc.                      Cancer                                  30321                        Methods                               Nat'l Phase                                                     29-                                                Radius                      for                                       of  Patent    China                201680039059.9     Apr-                 Published     --     --    Pharmaceuticals,                      Treating                              PCT/US16/                                                     16                                                  Inc.                      Cancer                                  30321                        Methods                               Nat'l Phase                                                     29-                                                Radius                      for                                       of  Patent   Europe                  16787291.0       Apr-                 Published     --     --    Pharmaceuticals,                      Treating                              PCT/US16/                                                     16                                                  Inc.                      Cancer                                  30321                        Methods                                                     29-                                                Radius            Hong      for                                    OFF EP  Patent                           18110957.0       Apr-                 Published     --     --    Pharmaceuticals,            Kong      Treating                              16787291.0                                                     16                                                  Inc.                      Cancer                       

 

                                                                                         LICENSE AGREEMENT                                                      Filing                           Patent  Issue  Type     Country     Title      Application No.           Appl. Type     Status                     Ownership                                                    Date                              No.    Date   1901 COMBINATION W/ CDK 4/6 INHIBITOR                         Methods                               Nat'l Phase                                                     29-                                                Radius                      for                                       of  Patent    Israel                   255189         Apr-                  Pending      --     --    Pharmaceuticals,                      Treating                              PCT/US16/                                                     16                                                  Inc.                      Cancer                                  30321                        Methods                               Nat'l Phase                                                     29-                                                Radius                      for                                       of  Patent    Japan                  2018-509732      Apr-                 Published     --     --    Pharmaceuticals,                      Treating                              PCT/US16/                                                     16                                                  Inc.                      Cancer                                  30321                        Methods                               Nat'l Phase                                                     29-                                                Radius            South     for                                       of  Patent                         10-2017-7034606    Apr-                 Published     --     --    Pharmaceuticals,            Korea     Treating                              PCT/US16/                                                     16                                                  Inc.                      Cancer                                  30321                        Methods                               Nat'l Phase                                                     29-                                                Radius                      for                                       of  Patent   Mexico               MX/a/2017/013802    Apr-                  Pending      --     --    Pharmaceuticals,                      Treating                              PCT/US16/                                                     16                                                  Inc.                      Cancer                                  30321                        Methods                               Nat'l Phase                                                     29-                                                Radius            New       for                                       of  Patent                             737822         Apr-                  Pending      --     --    Pharmaceuticals,           Zealand    Treating                              PCT/US16/                                                     16                                                  Inc.                      Cancer                                  30321                        Methods                               Nat'l Phase                                                     29-                                                Radius           Russian    for                                       of  Patent                           2017140675       Apr-                  Pending      --     --    Pharmaceuticals,          Federation  Treating                              PCT/US16/                                                     16                                                  Inc.                      Cancer                                  30321                        Methods                               Nat'l Phase                                                     29-                                                Radius                      for                                       of  Patent  Singapore               11201708860S      Apr-                  Pending      --     --    Pharmaceuticals,                      Treating                              PCT/US16/                                                     16                                                  Inc.                      Cancer                                  30321                       

 

                                                                                         LICENSE AGREEMENT                                                      Filing                           Patent  Issue  Type     Country     Title      Application No.           Appl. Type     Status                     Ownership                                                    Date                              No.    Date   1901 COMBINATION W/ CDK 4/6 INHIBITOR                         Methods            United                                   24-                                                Radius                      for                                   CON of US  Patent    States                  16/580,914      Sep-                 Published     --     --    Pharmaceuticals,                      Treating                              15/794,861           CON 2                                     19                                                  Inc.                      Cancer              United    Methods                                                     26-     CON of                                     Radius            States    for  Patent                            15/794,861      Oct-    PCT/US16/   Abandoned      --     ..    Pharmaceuticals,            CON       Treating                                                     17       30321                                      Inc.           of PCT     Cancer                                                                                            Filin                                  Issu                                                                                 Paten Type     Country     Title    Application No.     g     Appl. Type    Status              e      Ownership                                                                                   t No.                                                   Date                                   Date   1901 COMBINATION W/ M-TOR INHIBITORS                      Method          United    s for                         15-                                               Radius  Paten           States   Treatin      62/192,944       Jul-   Provisional  Expired      --     --    Pharmaceutical   t            PRV      g                              15                                               s, Inc.                     Cancer                      Method          United    s for                         10-                                               Radius  Paten           States   Treatin      62/265,663       Dec-   Provisional  Expired      --     --    Pharmaceutical   t            PRV      g                              15                                               s, Inc.                     Cancer                      Method          United    s for                         15-                                               Radius  Paten           States   Treatin      62/323,576       Apr-   Provisional  Expired      --     --    Pharmaceutical   t            PRV      g                              16                                               s, Inc.                     Cancer                      Method                    s for                         29-                                               Radius  Paten                        PCT/US2016/3031              Non-           PCT      Treatin                       Apr-                Expired      --     --    Pharmaceutical   t                                  6                  Provisional                     g                              16                                               s, Inc.                     Cancer                       

 

                                                                                         LICENSE AGREEMENT                                                    Filin                                  Issu                                                                                 Paten Type     Country     Title    Application No.     g     Appl. Type    Status              e      Ownership                                                                                   t No.                                                   Date                                   Date   1901 COMBINATION W/ M-TOR INHIBITORS                      Method                               Nat'l phase                     s for                         29-        of                                     Radius  Paten         Australia  Treatin      2016256469       Apr-   PCT/US16     Pending      --     --    Pharmaceutical   t                     g                              16        /                                      s, Inc.                     Cancer                                 30316                      Method                               Nat'l phase                     s for                         29-        of                                     Radius  Paten                               BR           Brazil    Treatin                       Apr-   PCT/US16     Published    --     --    Pharmaceutical   t                           112017023228-6                     g                              16        /                                      s, Inc.                     Cancer                                 30316                      Method                               Nat'l phase                     s for                         29-        of                                     Radius  Paten          Canada    Treatin       2,984,357       Apr-   PCT/US16     Pending      --     --    Pharmaceutical   t                     g                              16        /                                      s, Inc.                     Cancer                                 30316                      Method                               Nat'l phase                     s for                         29-        of                                     Radius  Paten           China    Treatin    201680038907.4     Apr-   PCT/US16     Published    --     --    Pharmaceutical   t                     g                              16        /                                      s, Inc.                     Cancer                                 30316                      Method                               Nat'l phase                     s for                         29-        of                                     Radius  Paten          Europe    Treatin      16787289.4       Apr-   PCT/US16     Published    --     --    Pharmaceutical   t                     g                              16        /                                      s, Inc.                     Cancer                                 30316                      Method                    s for                         29-     OFF EP                                    Radius  Paten     Hong                     Treatin      18110955.2       Apr-   16787289.    Published    --     --    Pharmaceutical   t       Kong                     g                              16        4                                      s, Inc.                     Cancer                      Method                               Nat'l phase                     s for                         29-        of                                     Radius  Paten           Israel   Treatin        255261         Apr-   PCT/US16     Pending      --     --    Pharmaceutical   t                     g                              16        /                                      s, Inc.                     Cancer                                 30316                       

 

                                                                                         LICENSE AGREEMENT                                                    Filin                                  Issu                                                                                 Paten Type     Country     Title    Application No.     g     Appl. Type    Status              e      Ownership                                                                                   t No.                                                   Date                                   Date   1901 COMBINATION W/ M-TOR INHIBITORS                      Method                               Nat'l phase                     s for                         29-        of                                     Radius  Paten           Japan    Treatin      2017-556627      Apr-   PCT/US16     Published    --     --    Pharmaceutical   t                     g                              16        /                                      s, Inc.                     Cancer                                 30316                      Method                               Nat'l phase                     s for                         29-        of                                     Radius  Paten     South                     Treatin    10-2017-7034608    Apr-   PCT/US16     Published    --     --    Pharmaceutical   t      Korea                     g                              16        /                                      s, Inc.                     Cancer                                 30316                      Method                               Nat'l phase                     s for                         29-        of                                     Radius  Paten                        MX/a/2017/01379          Mexico    Treatin                       Apr-   PCT/US16     Pending      --     --    Pharmaceutical   t                                  4                     g                              16        /                                      s, Inc.                     Cancer                                 30316                      Method                               Nat'l phase                     s for                         29-        of                                     Radius  Paten     New                     Treatin        737819         Apr-   PCT/US16     Pending      --     --    Pharmaceutical   t      Zealand                     g                              16        /                                      s, Inc.                     Cancer                                 30316                      Method                               Nat'l phase           Russian   s for                         29-        of                                     Radius  Paten         Federatio  Treatin      2017140676       Apr-   PCT/US16     Pending      --     --    Pharmaceutical   t              n      g                              16        /                                      s, Inc.                     Cancer                                 30316                      Method                               Nat'l phase                     s for                         29-        of                                     Radius  Paten         Singapore  Treatin     11201708861V      Apr-   PCT/US16     Pending      --     --    Pharmaceutical   t                     g                              16        /                                      s, Inc.                     Cancer                                 30316                      Method                               Nat'l phase           United                     s for                         26-        of                                     Radius  Paten     States                                                    Abandone                    Treatin      15/794,910       Oct-   PCT/US16                               Pharmaceutical   t       CON                                                           d                     g                             2017       /                                      s, Inc.           of PCT                     Cancer                                 30316                       

 

                                                                                         LICENSE AGREEMENT                                                    Filin                                  Issu                                                                                 Paten Type     Country     Title    Application No.     g     Appl. Type    Status              e      Ownership                                                                                   t No.                                                   Date                                   Date   1901 COMBINATION W/ M-TOR INHIBITORS                      Method          United                     s For                         20-                                               Radius  Paten     States                                         CON of                     Treatin      16/545,859       Aug-                Published     --     --   Pharmaceutical   t       CON                                           15/794,910                     g                              19                                               s, Inc.          of 439320                     Cancer                                                                                           Filin  Typ    Countr                                           Appl.               Patent     Issue                     Title      Application No.    g                 Status                         Ownership    e       y                                              Type                 No.       Date                                                  Date   1901 POLYMORPHS                     Polymorph         United   ic Forms                        5-                                                Radius  Pate                                                   Provision         States   of             62/442,921      Jan-              Expired      --        --     Pharmaceutica  nt                                                       al           PRV     RAD1901-                        17                                                 ls, Inc.                   2HCL                    Polymorph                  ic Forms                        5-      Non                                       Radius  Pate    United                                                              103850    8/20/20                  of             15/863,850      Jan-   Provision   Issued                       Pharmaceutica  nt     States                                                                 08        19                   RAD1901-                        18       al                                       ls, Inc.                   2HCL                    Polymorph                  ic Forms                       28-                                                 Radius  Pate    United                                         Divisiona  Allowe                  of             16/456,314      Jun-                           --        --     Pharmaceutica  nt     States                                             l         d                   RAD1901-                        19                                                ls, Inc.                   2HCL                    Polymorph                                                                                                    Radius                   ic Forms                        6- Pate    United                                         Divisiona                                Pharmaceutica                  of             16/921,684      July-             Pending      --        --   nt     States                                             l                                         ls,                   RAD1901-                        20                                                                                                       Inc.                   2HCL                    Polymorph                  ic Forms                        5-      Non-                                      Radius  Pate                         PCT/US2018/012          PCT     of                             Jan-   Provision  Expired      --        --     Pharmaceutica  nt                                714                   RAD1901-                        18       al                                        ls, Inc.                   2HCL                       

 

                                                                                         LICENSE AGREEMENT                                                   Filin  Typ    Countr                                           Appl.               Patent     Issue                     Title      Application No.    g                 Status                         Ownership    e       y                                              Type                 No.       Date                                                  Date   1901 POLYMORPHS                     Polymorph                  ic Forms                        5-                                                 Radius  Pate   Austral                                          NP of                   of           AU 2018205285     Jan-              Pending      --        --     Pharmaceutica  nt       ia                                             PCT                   RAD1901-                        18                                                 ls, Inc.                   2HCL                    Polymorph                  ic Forms                        5-                                                 Radius  Pate                                                    NP of         Canada    of              3047411        Jan-              Pending       --        --    Pharmaceutica  nt                                                      PCT                   RAD1901-                        18                                                ls, Inc.                   2HCL                    Polymorph                  ic Forms                        5-                                                Radius  Pate                                                    NP of     Publish         China    of           201880006119.6    Jan-                            --        --    Pharmaceutica  nt                                                      PCT         ed                   RAD1901-                        18                                                ls, Inc.                    2HCL                    Polymorph                  ic Forms                        5-                                                 Radius  Pate                          EP 18736577.0             NP of     Publish         Europe   of                             Jan-                            --        --    Pharmaceutica  nt                              3565542                 PCT         ed                   RAD1901-                        18                                                ls, Inc.                   2HCL                    Polymorph                                                         OFF EP                   ic Forms                        5-                                                 Radius  Pate    Hong                                              EP                   of           62020005942.1     Jan-              Pending       --        --    Pharmaceutica  nt     Kong                                           18736577                  RAD1901-                        18                                                 ls, Inc.                                                            .0                   2HCL                    Polymorph                  ic Forms                        5-                                                Radius  Pate                                                    NP of     Publish         Israel   of             IL 267772       Jan-                           --         --    Pharmaceutica  nt                                                      PCT         ed                   RAD1901-                        18                                                 ls, Inc.                   2HCL                    Polymorph                  ic Forms                        5-                                                Radius  Pate                                                    NP of     Publish         Japan    of           JP 2019-536266    Jan-                            --        --    Pharmaceutica  nt                                                      PCT         ed                   RAD1901-                        18                                                ls, Inc.                    2HCL                       

 

                                                                                         LICENSE AGREEMENT                                                   Filin  Typ    Countr                                           Appl.               Patent     Issue                     Title      Application No.    g                 Status                         Ownership    e       y                                              Type                 No.       Date                                                  Date   1901 POLYMORPHS                     Polymorph                  ic Forms                        5-                                                 Radius  Pate    South                  KR 10-2019-              NP of     Publish                  of                             Jan-                            --        --    Pharmaceutica  nt     Korea                    7022624                 PCT         ed                   RAD1901-                        18                                                ls, Inc.                   2HCL                    Polymorph                  ic Forms                        5-                                                 Radius  Pate                         MX/a/2019/00774            NP of         Mexico    of                             Jan-              Pending       --        --    Pharmaceutica  nt                                 8                    PCT                   RAD1901-                        18                                                ls, Inc.                   2HCL                                                                                                   

 

                                                                                         LICENSE AGREEMENT                                    Application   Filing                         Patent   Issue   Type   Country      Title                            Appl. Type    Status                       Ownership                                      No.       Date                            No.     Date   1901 POLYMORPHS (PATTERN B)                      Polymorphic          United                                                                                    Radius                    Forms of                    4-Jul- Patent   States                 62/694,003            Provisional  Expired     --       --    Pharmaceuticals,                    RAD1901-                     18           PRV                                                                                        Inc.                    2HCL                      Polymorphic                                                          PCT                                        Radius                    Forms of     PCT/US2019/    3-Jul- Patent   PCT                                           30 mo.     Published     --     --     Pharmaceuticals,                    RAD1901-        040527       19                                                         4-Jan-21                                     Inc.                    2HCL                                                                               

 

                                                                                         LICENSE AGREEMENT                                                    Filing                         Patent  Issue   Type    Country      Title    Application No.          Appl. Type    Status                     Ownership                                                  Date                            No.    Date   1901 MOT OVARIAN CANCER                       Methods            United    for                          27-                                               Radius  Patent    States    Treating     62/400,495     Sep-    Provisional  Expired     --      --   Pharmaceuticals,            PRV       Ovarian                      16                                                 Inc.                      Cancer                       Methods                      for                          27-                                 PCT/US2017/               Non-                                  Radius Health,  Patent     PCT      Treating                    Sep-                 Expired     --      --                                     053834               Provisional                                 Inc.                      Ovarian                      17                      Cancer                       Methods                      for                          27-                                                                                                 Radius Health,  Patent   Australia  Treating   AU 2017336564    Sep-    NP of PCT    Pending      --    --                                                                                                       Inc.                      Ovarian                      17                      Cancer                       Methods                      for              BR          27-                                                                                                 Radius Health,  Patent    Brazil    Treating      11 2019       Sep-    NP of PCT   Published     --     --                                                                                                      Inc.                      Ovarian       004276-8       17                      Cancer                       Methods                      for                          27-                                                                                                 Radius Health,  Patent   Canada     Treating    CA 3036568      Sep-    NP of PCT    Pending      --    --                                                                                                       Inc.                      Ovarian                      17                      Cancer                       Methods                      for                          27-                                     CN                                                          Radius Health,  Patent    China     Treating                    Sep-    NP of PCT   Published     --     --                                 201780058319.1                                                       Inc.                      Ovarian                      17                      Cancer                       Methods                      for                          27-                                                                                                Radius Health,  Patent   Europe     Treating   EP 17857371.3    Sep-    NP of PCT   Published     --     --                                                                                                     Inc.                       Ovarian                      17                      Cancer                       

 

                                                                                         LICENSE AGREEMENT                                                    Filing                         Patent  Issue   Type    Country      Title    Application No.          Appl. Type    Status                     Ownership                                                  Date                            No.    Date   1901 MOT OVARIAN CANCER                       Methods                      for                          27-           Hong                                           OFF EP                                 Radius Health,  Patent              Treating     19129832.2     Sep-                 Pending      --     --            Kong                                         17857371.3                                   Inc.                      Ovarian                      17                      Cancer                       Methods                      for                          27-                                                                                                 Radius Health,  Patent    Israel    Treating     IL 265537      Sep-    NP of PCT    Pending      --     --                                                                                                      Inc.                      Ovarian                      17                      Cancer                       Methods                      for                          27-                                                                                                 Radius Health,  Patent    Japan     Treating   JP 2019-515854   Sep-    NP of PCT   Published     --     --                                                                                                      Inc.                      Ovarian                      17                      Cancer                       Methods                      for                          27-           South                 KR 10-2019-                                                     Radius Health,  Patent              Treating                    Sep-    NP of PCT   Published    --      --            Korea                   7011747                                                           Inc.                      Ovarian                      17                      Cancer                       Methods                      for                          27-                                  MX/a/2019/                                                    Radius Health,  Patent   Mexico     Treating                    Sep-    NP of PCT    Pending      --     --                                     003311                                                           Inc.                       Ovarian                      17                      Cancer                       Methods                      for                          27-           New                                                                                   Radius Health,  Patent              Treating     NZ 751032      Sep-    NP of PCT    Pending      --     --           Zealand                                                                                    Inc.                      Ovarian                      17                      Cancer                       Methods                      for                          27-          Russian                                                                                Radius Health,  Patent              Treating   RU 2019108382    Sep-    NP of PCT    Pending      --     --          Federation                                                                                  Inc.                      Ovarian                      17                      Cancer                       

 

                                                                                         LICENSE AGREEMENT                                                    Filing                         Patent  Issue   Type    Country      Title    Application No.          Appl. Type    Status                     Ownership                                                  Date                            No.    Date   1901 MOT OVARIAN CANCER                       Methods                      for                          27-                                      SG                                                        Radius Health,  Patent  Singapore   Treating                    Sep-    NP of PCT    Pending      --     --                                  1120190759X                                                         Inc.                      Ovarian                      17                      Cancer                       Methods                      for                          25-                                               Radius            United  Patent              Treating     16/336,358     Mar-    NP of PCT   Published     --    --    Pharmaceuticals,          States NP                      Ovarian                      19                                                 Inc.                      Cancer                                                                                               Application   Filing                         Patent   Issue  Type    Country      Title                            Appl. Type    Status                       Ownership                                      No.        Date                           No.     Date   1901 + ABEMACICLIB                     Elacestrant                    In                    Combination          United                                 30-                                                Radius                    With  Patent   States                 62/773,960    Nov-    Provisional  Expired     --       --    Pharmaceuticals,                    Abemaciclib           PRV                                    18                                                  Inc.                    In Women                    With Breast                    Cancer                    Elacestrant                    In                    Combination                                                 26-       PCT                                      Radius                    With         PCT/US2019/  Patent   PCT                                  Nov-     30-mo.     Published    --       --    Pharmaceuticals,                    Abemaciclib     063239                                                 19     30-May-21                                     Inc.                     In Women                    With Breast                    Cancer                                                                                                       

 

                                                                                         LICENSE AGREEMENT                                    Application  Filing                          Patent   Issue  Type    Country      Title                           Appl. Type    Status                        Ownership                                     No.        Date                            No.     Date   1901 RESISTANT TO CDK 4/6 INHIBITORS                     Anti-Tumor                    Activity of          United    Elacestrant                  6-                                                 Radius  Patent   States   in Models     62/776,323    Dec-   Provisional  Expired      --       --    Pharmaceuticals,           PRV      Resistant to                 18                                                   Inc.                    CDK 4/6                    Inhibitors                     Anti-Tumor                    Activity of                    Elacestrant                  6-       PCT                                       Radius                                PCT/US2019/  Patent   PCT      in Models                   Dec-    30 mo. 6-  Published     --      --     Pharmaceuticals,                                   065005                    Resistant to                 19     June-21                                       Inc.                     CDK 4/6                    Inhibitors                                                                              

 

                                                                                         LICENSE AGREEMENT                                    Application   Filing                          Patent   Issue  Type    Country      Title                            Appl. Type    Status                       Ownership                                      No.        Date                            No.     Date   1901 ESR1 MUTATIONS                     Anti-Tumor                    Activity of                    Elacestrant                    in Models          United    Harboring                     6-                                                Radius  Patent   States   ESR1           62/776,338    Dec-   Provisional  Expired      --      --    Pharmaceuticals,           PRV      Mutations                     18                                                  Inc.                    Resistant to                    Standard of                    Care                    Therapies                    Anti-Tumor                    Activity of                    Elacestrant                    in Models                    Harboring                     6-       PCT                                      Radius                                 PCT/US2019/  Patent   PCT      ESR1                         Dec-    30-mo. 6-  Published      --     --    Pharmaceuticals,                                    064980                    Mutations                     19     June-21                                      Inc.                     Resistant to                    Standard of                    Care                    Therapies                                                                              

 

                                                                                         LICENSE AGREEMENT                                     Application   Filing                        Patent   Issue  Type    Country      Title                            Appl. Type    Status                      Ownership                                      No.        Date                           No.     Date   1901 PROCESS CHEMISTRY            United    Processes                     12-                                              Radius  Patent   States   and            62/804,391    Feb-   Provisional  Expired     --       --   Pharmaceuticals,           PRV      Compounds                     19                                                 Inc.                      Processes                     11-      PCT                                     Radius                                  PCT/US2020/  Patent   PCT      and                          Feb-    30 mo. 12-  Pending     --       --   Pharmaceuticals,                                     017777                    Compounds                     20      Aug-21                                    Inc.                                                                               Application  Filing                        Patent  Issue  Type     Country       Title                            Appl. Type   Status                     Ownership                                        No.        Date                          No.    Date   1902 COMPOSITION OF MATTER                        Compounds            United                                  22-                                            Radius                      and methods  Patent    States                   62/620,441    Jan-   Provisional  Expired    --      --   Pharmaceuticals,                      of Using and            PRV                                     18                                               Inc.                      Making                        Estrogen                                                    22-                                            Radius                      Receptor-     PCT/US2019/              Non- Patent     PCT                                   Jan-                Pending    --     --    Pharmaceuticals,                      Modulating       014581             Provisional                                                    19                                               Inc.                      Compounds                        Estrogen                                                    22-                                            Radius                      Receptor- Patent   Australia                    TBD        Jul-   NP of PCT    Pending    --      --   Pharmaceuticals,                      Modulating                                                    20                                               Inc.                      Compounds                        Estrogen                                                    22-                                            Radius                      Receptor- Patent    Brazil                      TBD        Jul-   NP of PCT    Pending    --      --   Pharmaceuticals,                      Modulating                                                    20                                               Inc.                      Compounds                       

 

                                                                                         LICENSE AGREEMENT                                       Application  Filing                        Patent  Issue  Type     Country       Title                            Appl. Type   Status                     Ownership                                        No.        Date                          No.    Date   1902 COMPOSITION OF MATTER                        Estrogen                                                    22-                                            Radius                      Receptor- Patent   Canada                       TBD        Jul-   NP of PCT    Pending    --      --   Pharmaceuticals,                      Modulating                                                    20                                               Inc.                      Compounds                        Estrogen                                                    22-                                            Radius                      Receptor- Patent    China                       TBD        Jul-   NP of PCT    Pending    --      --   Pharmaceuticals,                      Modulating                                                    20                                               Inc.                      Compounds                        Estrogen                                                    22-                                            Radius                      Receptor- Patent   Europe                       TBD        Jul-   NP of PCT    Pending    --      --   Pharmaceuticals,                      Modulating                                                    20                                               Inc.                      Compounds                        Estrogen                                                    22-                                            Radius            Hong      Receptor- Patent                                TBD        Jul-   NP of PCT    Pending    --      --   Pharmaceuticals,            Kong      Modulating                                                    20                                               Inc.                      Compounds                        Estrogen                                                    22-                                            Radius                      Receptor- Patent    Israel                      TBD        Jul-   NP of PCT    Pending    --      --   Pharmaceuticals,                      Modulating                                                    20                                               Inc.                      Compounds                        Estrogen                                                    22-                                            Radius                      Receptor- Patent    Japan                       TBD        Jul-   NP of PCT    Pending    --      --   Pharmaceuticals,                      Modulating                                                    20                                               Inc.                      Compounds                        Estrogen                                                    22-                                            Radius            South     Receptor- Patent                                TBD        Jul-   NP of PCT    Pending    --      --   Pharmaceuticals,            Korea     Modulating                                                    20                                               Inc.                      Compounds                       

 

                                                                                         LICENSE AGREEMENT                                       Application  Filing                        Patent  Issue  Type     Country       Title                            Appl. Type   Status                     Ownership                                        No.        Date                          No.    Date   1902 COMPOSITION OF MATTER                        Estrogen                                                    22-                                            Radius                      Receptor- Patent   Mexico                       TBD        Jul-   NP of PCT    Pending    --      --   Pharmaceuticals,                      Modulating                                                    20                                               Inc.                      Compounds                        Estrogen                                                    22-                                            Radius            New       Receptor- Patent                                TBD        Jul-   NP of PCT    Pending    --      --   Pharmaceuticals,           Zealand    Modulating                                                    20                                               Inc.                      Compounds                        Estrogen                                                    22-                                            Radius           Russian    Receptor- Patent                                TBD        Jul-   NP of PCT    Pending    --      --   Pharmaceuticals,          Federation  Modulating                                                    20                                               Inc.                      Compounds                        Estrogen                                                    22-                                            Radius                      Receptor- Patent  Singapore                     TBD        Jul-   NP of PCT    Pending    --      --   Pharmaceuticals,                      Modulating                                                    20                                               Inc.                      Compounds                        Estrogen                                                    22-                                            Radius            United    Receptor- Patent                                TBD        Jul-   NP of PCT    Pending    --      --   Pharmaceuticals,          States NP   Modulating                                                    20                                               Inc.                      Compounds                                                                           Application   Filing                         Patent   Issue  Type    Country      Title                            Appl. Type   Status                       Ownership                                      No.        Date                           No.     Date   1902 SELECTION                      Estrogen          United                                                                                   Radius                    Receptor-                    22- Patent   States                  62/876,963           Provisional Pending      --      --    Pharmaceuticals,                    Modulating                  Jul-19           PRV                                                                                       Inc.                    Compounds                       

 

                                                                                         LICENSE AGREEMENT                                    Application   Filing                         Patent   Issue  Type    Country      Title                            Appl. Type   Status                       Ownership                                      No.        Date                           No.     Date   1902 SELECTION                      Estrogen                                                                                                   Radius                    Receptor-                    22-       Non- Patent   PCT                       TBD                            Pending      --      --    Pharmaceuticals,                    Modulating                  Jul-20  Provisional                                                                                                     Inc.                    Compounds                                                                                    

 

                                                                LICENSE AGREEMENT                                      EXHIBIT D                          TRANSITION SERVICES AGREEMENT   [*]     

 

                                                               LICENSE AGREEMENT                                     EXHIBIT E                                                                          PRESS RELEASE                                                                                    Menarini Group and Radius Health Announce Global License Agreement  for the Development and Commercialization of elacestrant       •  Menarini licenses global development and commercialization rights of elacestrant, an oral SERD        currently in late stage Phase 3 development     •  Elacestrant further strengthens Menarini’s global oncology portfolio, recently bolstered by the        acquisition of Stemline Therapeutics in the U.S.     •   Radius will receive $30M as an upfront payment and up to $320M in additional milestones along        with tiered low to mid-teen percentage royalties    WALTHAM, Mass. – Florence, Italy, July 23, 2020 – The Menarini Group and Radius Health, Inc.  (Nasdaq: RDUS) announced today that the companies have entered into an exclusive global license  agreement for development and commercialization of elacestrant.       Elacestrant is an oral SERD, a selective estrogen receptor degrader, currently being evaluated in the  EMERALD Phase 3 study as hormonal treatment for postmenopausal women and men with advanced  ER+/HER2- breast cancer.     Under the agreement, Menarini Group will be responsible for worldwide commercialization of  elacestrant, after the completion of EMERALD Phase 3 study and, assuming positive results, successful  registration of elacestrant.    Elcin Barker Ergun, Chief Executive Officer of Menarini Group, commented: “Elacestrant is a  perfect addition to our global oncology portfolio following our recent acquisition of Stemline  Therapeutics and entering the US biopharmaceuticals market. Oral SERDs can potentially lead to new  treatment paradigms in breast cancer and we look forward to advancing elacestrant’s development to  provide novel options that can help patients.”     Kelly Martin, Chief Executive Officer of Radius commented, “Menarini will be a terrific global partner  on this program and, given their recent investment and expansion in the oncology space, we are extremely  pleased to have completed this transaction with them.” Martin further commented that “this transaction is  a significant step for Radius and provides us with flexibility in moving forward.”     As part of the agreement, Radius will receive an upfront payment of $30 million and up to $320 million  in additional payments based on the successful achievement of future development and sales  milestones.  Menarini Group will make tiered, low to mid-teen percentage royalty payments to Radius  Health on global net sales.      Radius will continue to be responsible for the conduct and completion of the Phase 3 EMERALD study  through NDA filing. Costs associated with this activity will be reimbursed by Menarini Group.        

 

                                                                LICENSE AGREEMENT       About Menarini Group   Menarini Group is a leading international pharmaceutical company with a presence in 140 countries,   including a direct presence in over 70 countries. Its global platform extends throughout Europe, U.S.,   Central America, Africa, the Middle East and Asia Pacific, and generates over $4.2 billion in annual   sales. Menarini is committed to oncology, with an already commercialized product in the US and several   new investigational drugs in development for the treatment of a variety of tumors. For over 130 years,   Menarini has also been investing in the development, production and distribution of pharmaceuticals to   serve patients and physicians around the world with a full portfolio of products covering a number of   different therapeutic areas.      About Radius  Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing  and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS (abaloparatide)  injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal  women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes the  investigational use of abaloparatide injection for the treatment of men with osteoporosis, an  investigational abaloparatide-patch for potential use in osteoporosis; the investigational drug elacestrant   (RAD1901) for potential use in hormone-receptor positive breast cancer out-licensed to Menarini Group;   and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM)   under investigation for potential use in hormone-receptor positive breast cancer. For more information,   please visit www.radiuspharm.com.      About Elacestrant (RAD1901)   Elacestrant is a selective estrogen receptor degrader (SERD), which is being evaluated for potential use as   a once daily oral treatment in patients with advanced estrogen receptor positive, HER2 negative (HER2-),   breast cancer, the most common form of the disease. Fulvestrant is the only SERD that has been approved   and marketed in this indication and has generated over $1 billion worldwide revenues. Unlike fulvestrant,   which is administered as an intramuscular injection, elacestrant, if approved, has the potential to improve   the patient experience with oral dosing. In addition, preclinical data have shown elacestrant to have   greater antitumor activity than fulvestrant in in vivo models suggesting the potential for improved   efficacy in patients. In a Phase 1 study with a heavily pre-treated population (n=50), elacestrant had an   acceptable safety profile with the most commonly reported adverse events being low grade nausea and   dyspepsia, and demonstrated single-agent activity with a 19.4% objective response rate (ORR) and 4.5   months progression-free survival (PFS). Encouraging activity was seen in patients whose tumors harbored   ESR1 mutations as well as in patients whose disease had progressed after prior treatment with fulvestrant   or CDK4/6 inhibitors.      Studies completed to date indicate that elacestrant has the potential for use as a single agent or in   combination with other therapies for the treatment of breast cancer.      About EMERALD Phase 3 Study   The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant   as second- or third-line monotherapy in advanced/metastatic ER-positive (ER+)/HER2- breast cancer  patients. The study will enroll approximately 460 patients who have received prior treatment with one or  two lines of endocrine therapy, including a cyclin-dependent kinase (CDK) 4/6 inhibitor. Patients in the  study will be randomized to receive either elacestrant or the investigator’s choice of an approved  hormonal agent. The primary endpoint of the study will be progression-free survival (PFS) in the overall  patient population and in patients with estrogen receptor 1 gene (ESR1) mutations. Secondary endpoints  will include evaluation of overall survival (OS), objective response rate (ORR), and duration of response  (DOR). Top-line data from the EMERALD study is expected to be reported in the second half of 2021.     

 

                                                                LICENSE AGREEMENT       Forward-Looking Statements  This press release contains forward-looking statements within the meaning of the Private Securities  Litigation Reform Act of 1995.  All statements contained in this press release that do not relate to matters   of historical fact should be considered forward-looking statements, including without limitation   statements regarding the potential market opportunity for elacestrant, including the potential achievement   of development and sales milestones related to elacestrant; our expectations regarding the completion of,   and timing of results from, the EMERALD study; our expectations regarding an NDA filing in the U.S.   and other regulatory filings globally for elacestrant; our expectations regarding our license agreement   with Menarini for elacestrant; and the potential clinical uses and therapeutic and other benefits of   elacestrant, abaloparatide-SC, abaloparatide-patch, and RAD140.      These forward-looking statements are based on management's current expectations. These statements are   neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important   factors that may cause our actual results, performance or achievements to be materially different from any   future results, performance or achievements expressed or implied by the forward-looking statements,   including, but not limited to, the following: Our inability to ensure the timing of results from the   EMERALD trial or that its primary endpoint will be met; Menarini’s inability to ensure that elacestrant  will obtain regulatory approval or be successfully commercialized, if approved, including as a result of  risks related to coverage, pricing and reimbursement, manufacturing, supply and distribution, and  potential adverse impacts on the EMERALD trial or Menarini’s business from the ongoing COVID-19  pandemic; risks related to competitive products; risks of litigation or other challenges regarding  intellectual property rights; risks that adverse side effects of elacestrant will be identified during  commercialization, if approved, or during development activities. These and other important risks and  uncertainties discussed in our filings with the Securities and Exchange Commission, or SEC, including  under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ending December 31,  2019 and subsequent filings with the SEC, could cause actual results to differ materially from those  indicated by the forward-looking statements made in this press release.    Menarini Group Press & Media Relations  Valeria Speroni Cardi  Email: pressoffice@menarini.com  Radius Investor Relations & Media Contact:  Elhan Webb, CFA  Email: ewebb@radiuspharm.com  Phone: 617-551-4011          

 

                                                                LICENSE AGREEMENT                                      EXHIBIT F                                                                       DUKE ADDITIONAL TERMS       “Duke Patent Rights” means Duke’s legal rights under the patent laws of the United States or relevant   foreign countries for all of the following:                (a)   the following United States and foreign patent(s) and/or patent application(s),  including all divisionals, continuations, continuations-in-part arising from or claiming priority to any of the  Duke Patent Rights and containing claims covering the chemical compound known as RAD1901 or  elacestrant in any and all fields of use, and foreign counterparts of the same:               US Patent 9,421,264 (US Application No.:  14/512,061),              USSN 62/129,379,              USSN 61/971,627,              PCT/US2015/023216,              USSN 15/214,187,              USSN 15/129,197,              EPO 15769394.6 (EP 3122426),              CA 2,943,611.               (b)   United States and foreign patents issued from the applications listed in  subparagraph (a) above, including any reviewed, reissued or re-examined patents, and supplementary  protection certificates, and foreign counterparts of the same, based upon the same.               (c)   Any applications claiming priority from any of the listed applications.   The Duke Patent Rights existing as of the Effective Date are set forth in Exhibit C-1 to the Agreement.   Clause 1 - Patent Prosecution and Maintenance   1.1   Radius and Licensee shall cooperate, and Radius shall use Diligent Efforts to cause Duke to  cooperate, where needed or appropriate, in all aspects of filing, prosecuting, and maintaining all of the  patents and patent applications that form the basis for the Duke Patent Rights, including, without limitation,  (a) administrative reexaminations and reviews; and (b) disputes (including litigation) regarding  inventorship and derivation, oppositions and interferences. Upon [*] election to apply for and prosecute a  patent term extension for patents included in the Duke Patent Rights, Radius and Licensee shall cooperate,  and Radius shall use Diligent Efforts to cause Duke to cooperate, where needed or appropriate, in such  application and prosecution.   1.2   Promptly, and in any case no later than [*] days, after the Effective Date, [*] shall (i) provide [*]  with all documentation and information in [*] possession relating to the filing, prosecution and maintenance  of the Duke Patent Rights by uploading such documentation and information in an orderly fashion to a  shared virtual data room or a shared virtual ‘folder’ (such as a Google Drive ‘folder’), (ii) clearly identify  any and all prosecution matters that require immediate attention as of the Effective Date, (iii) formally  notify all patent attorneys in charge of the filing, prosecution and maintenance of the Duke Patent Rights  of [*] assumption of responsibility and full authority for such matters (or cause all such patent attorneys to  be so notified), and (iv) liaise [*] with all such patent attorneys; provided, however, that, [*]. In consultation   with [*], [*] shall develop the prosecution strategy and [*] shall draft substantive responses to the patent  offices and shall make reasonable efforts to allow [*] sufficient time to review, comment, and advise upon      

 

                                                                LICENSE AGREEMENT    such strategy and response. It is understood and agreed that in the event of any disagreement on the   prosecution strategy and/or the contents of a substantive response, as between the Parties and for so long   as [*] prosecutes the patents and patent applications that form the basis for the Duke Patent Rights, [*] shall  have the final decision-making authority with regard to the filing, prosecution and maintenance of the Duke  Patent Rights in any country in the Territory; provided that [*] may not use such final decision-making  authority in a manner inconsistent with the Duke License Agreement.    1.3   For so long as [*] prosecutes the patents and patent applications that form the basis for the Duke  Patent Rights, the out-of-pocket costs and expenses (including, but not limited to, patent attorney fees and  maintenance fees) for the filing, prosecution, maintenance and extension of all the patents and patent  applications that form the basis for the Duke Patent Rights (the “Duke Patent Prosecution and Maintenance   Costs”) incurred by [*] after the Effective Date of the Agreement and until the Second NDA Anniversary   shall be equally shared between Licensee and Radius and, upon and following Second NDA Anniversary,   [*] shall bear one hundred percent (100%) of the Duke Patent Prosecution and Maintenance Costs incurred   by [*]. [*] shall reimburse [*] for fifty (50) percent of the Duke Patent Prosecution and Maintenance Costs   incurred by Licensee prior to the Second NDA Anniversary within [*] ([*]) calendar days following receipt  of Licensee’s invoice, and [*] shall invoice [*] for such Duke Patent Prosecution and Maintenance Costs  no more frequently than once in each calendar quarter. [*] shall reimburse [*] for all reasonable and actual  documented fees and costs incurred by [*] after the Effective Date relating to the activities described in this  Clause 1. Such reimbursement shall be made within [*] ([*]) days of receipt of [*] receipt of [*] invoice  [*].    1.4   [*]    1.5   If [*] provides [*] with written notification that it will no longer support the filing, prosecution, or   maintenance of a specified patent(s) and/or patent application(s) within the Duke Patent Rights, then [*]   responsibility for fees and costs related to the filing, prosecution, and maintenance of such subject Duke   Patent Rights will terminate [*] ([*]) days after [*] receipt of such written notification. [*].      Clause 2 – Enforcement and Defense   2.1    Each Party shall promptly advise the other Party in writing of any known acts of actual or potential  infringement of the Duke Patent Rights by a Third Party. [*] has the first option (but not the obligation) to  police the Duke Patent Rights against infringement by Third Parties within the Territory. [*] shall not file   any suit without (a) first performing a thorough, diligent investigation of the merits of such suit, including   with respect to the validity and enforceability of the Duke Patent Rights, to which [*] shall promptly and   fully cooperate with all reasonable requests of [*], at [*] cost and expenses, with all reasonable requests of   [*]; (b) there being reasonable legal and economic bases for doing so; (c) notifying [*] [*] before any such   filing. This right to police includes filing, prosecuting, and settling all infringement actions at its expense,   except that [*] shall make any such settlement only with the consent of [*], not to be unreasonably withheld   or delayed. [*] has the right to file suit using counsel of its choosing, subject to [*] approval, which shall   not be unreasonably withheld or delayed. [*] may grant to third parties the right to enforce hereunder, but   only with the express written permission of [*], not to be unreasonably withheld or delayed.    2.2   Subject to Clause 2.1 above, [*] shall reasonably assist, [*], [*] in any suit brought by [*] to enforce   the Duke Patent Rights, if so requested (the assistance so provided by [*], the “Enforcement Assistance”).    [*] shall reimburse [*] for all reasonable and actual documented fees, costs and expenses incurred by [*] in  providing Enforcement Assistance to [*] that are reimbursable by [*] pursuant to Section 8.2 of the Duke   License Agreement. Such reimbursement shall be made within twenty-five (25) days of receipt of [*]     

 

                                                               LICENSE AGREEMENT   invoice. [*] shall be named in or join, [*], any action or proceeding brought by [*] to enforce the Duke  Patent Rights, if required to be named in or joined in such action or proceeding, or if requested by [*], and  [*] shall bear all of [*] related and reasonable costs and expenses; provided, however, that if [*] elect to be  represented by independent legal counsel, [*] shall bear the related fees and costs.  [*] retains the right to  participate, with counsel of its own choosing and at its own expense, in any action under this Clause 2.  Provided that if [*] is controlling enforcement activities, [*] shall defend, indemnify and hold harmless [*]  with respect to any claims asserted by an alleged infringer reasonably related to the enforcement of the  Duke Patent Rights under this Clause, including but not limited to antitrust counterclaims and claims for  recovery of attorney fees.    2.3   [*] acknowledges that Duke and its employees have a vital interest in lawsuits relating to the  validity and enforceability of the Duke Patent Rights. If a Third Party files a suit, including as a  counterclaim, alleging that any of the Duke Patent Rights is invalid or unenforceable, [*] shall have the  right (but not the obligation) to participate in such suit (if not brought against [*]) and in any case to assume  control of the defense of such claim, provided, however, that if [*] assumes control of the defense, [*] shall  consult with [*] with respect to such defense, and shall reasonably consider [*] input. In furtherance of such  defense, at the onset of such claim and as reasonable during the pendency of any such claim, the Parties  shall meet and confer in good faith to set a plan for handling the defense thereof. Notwithstanding, in the  event that the Parties cannot agree on how to proceed with respect to such claim, [*] shall have the right to  control the defense thereof. Licensee and Radius shall equally share the out-of-pocket costs and fees  associated with the activities under this Clause 2.3. The Parties shall consider reasonable controls on costs  and fees as part of an aforementioned meet and confer with respect to the handling of the defense.  Notwithstanding, if a third party asserts jurisdiction for any such action solely as the result of acts of [*],  then [*] shall be responsible for such reasonable costs and fees.   2.4   If [*] recovers damages associated with the Duke Patent Rights in patent litigation or settlement  thereof, the award shall first be divided [*].        

 

                                       EXHIBIT G                                                                      EISAI ADDITIONAL TERMS   For purposes of this Exhibit G:    “Compound” means elacestrant or any derivative or analogue thereof.    “Product” means any pharmaceutical drug in final packaged form containing the Compound or any   derivative or analogue thereof, the development, manufacture, use or sale of which, absent the licenses   granted to Licensee hereunder, would infringe the Eisai Patents or which make use of any Joint Patents.    “Affiliates” means any corporation, firm, partnership or other entity which directly or indirectly owns, is   owned by or is under common ownership with a Party to the extent of more than fifty (50) percent of the   equity having the power to vote on or direct the affairs of any such corporation, firm, partnership, or other   entity.    “Radius-Eisai Joint Invention” means any invention developed by or on behalf of Radius and disclosed by   Radius to Eisai pursuant to Section 6.3 of the Eisai License Agreement.  Any patent application claiming a   Radius-Eisai Joint Invention, and any patent stemming therefrom, shall be referred to as a “Radius-Eisai   Joint Patent”. The Radius-Eisai Joint Patents existing as of the Effective Date are set forth in Exhibit C-3.    “Radius-Invented Patents” means all patents and patent applications which are or become owned by Radius   and/or its Affiliates, or to which Radius and/or its Affiliates otherwise have, now or in the future, the right   to grant licenses, and which generically or specifically claim Compound and/or Product, a use for   Compound and/or Product, a process for manufacturing Compound and/or Product, or an intermediate used   in such process. Included within the definition of Radius-Invented Patents are all continuations,   continuations-in-part, divisions, patents of addition, reissues, re-examinations, renewals or extensions   thereof and all Supplementary Protection Certificates. Also included within the definition are all patents   and patent applications claiming any improvements on Compound and/or Product or intermediates or   manufacturing process required or useful for production of Compound and/or Product which are developed   by or for Radius and/or its Affiliates, or to which Radius and/or its Affiliates otherwise have the right to   grant licenses, now or in the future, during the term of the Agreement. Radius-Invented Patents also includes   any patent application covering an invention solely owned by Radius in accordance with Article 6.4 of the   Eisai License Agreement.  The Radius-Invented Patents existing as of the Effective Date are set forth in   Exhibit C-3.    “Licensee-Invented Patents” means [*].    Clause 1 – Patent Prosecution and Maintenance   1.1    The Agreement, including, without limitation, this Exhibit G, does not convey to Licensee any  rights in any Eisai Know-How or Eisai Patents by implication, estoppel or otherwise except for the rights  expressly granted in Section 2.1 of the Agreement. Sole and exclusive title to all Eisai Know-How and Eisai  Patents shall at all times remain vested in Eisai.  Except as expressly provided in this Exhibit G or in the  Agreement, the Agreement, including, without limitation, this Exhibit G, does not convey to Eisai and/or  Radius any rights in any Know-How developed or otherwise obtained by Licensee and/or its Affiliates,  including, but not limited to, any invention, whether patentable or not, or any information regarding the  utility or safety of Compound or Product, or any Licensee-Invented Patents by implication, estoppel or  otherwise.      

 

                                                                LICENSE AGREEMENT    1.2   Notwithstanding Clause 1.1 above, during the term of the Eisai License Agreement, Licensee shall  share with Radius all preclinical and clinical data, including safety data post-approval, provided that all   such data generated by Licensee shall be at all times solely owned by Licensee. During the term of the Eisai   License Agreement, Licensee shall promptly inform Radius of any Eisai Know-How that becomes known   to Licensee, if and to the extent Licensee is positively aware that it is Eisai Know-How, and, subject to   Clause 1.1 above and the confidentiality provision set forth in Section 9 of the Agreement, of information   that it obtains or develops regarding the utility or safety of Compound or Product.    1.3   During the term of the Eisai License Agreement, Licensee shall promptly notify Radius of any   invention made by its employees, agents or independent contractors regarding (i) Compound (including,   without limitation, intermediates and prodrugs), (ii) new form, use, manufacture, composition of   Compound (including intermediates and prodrugs), or (iii) any improvements on Compound and/or   Product.  Licensee shall not take any steps with respect to filing a patent application for such invention   before the ownership of such invention is determined by the Parties through good faith consultation in   accordance with Clause 1.4 below.    1.4   Upon Licensee notifying Radius as provided in Clause 1.3 above, the Parties (with Radius relaying   any comments of Eisai) shall promptly consult in good faith to determine the ownership of such invention.   Any invention disclosed by Licensee to Radius pursuant to Clause 1.3 above shall be [*].   1.5   Upon the request of Licensee, Radius shall request that Eisai [*].   1.6   Upon the request of Radius, Licensee shall disclose the complete texts of any Licensee-Invented  Patent. Radius shall have the right to review, with Licensee’s prior written consent, which shall not be  unreasonably withheld, all information received by Licensee concerning the institution or possible  institution of any interference, opposition, re-examination, reissue, revocation, nullification or any official  proceeding involving a Radius-Invented Patent anywhere in the world. Radius shall hold all information  disclosed to it under this Clause 1.6 as strictly confidential in accordance with the confidentiality provision  set forth in Section 9 of the Agreement.   1.7   The Parties acknowledge that [*] shall have the sole right and authority to prepare, file, prosecute,  maintain and obtain extensions of all patent applications and patents included within Eisai Patents in Japan  and the Territory. [*] shall use Diligent Efforts to cause [*] to use all commercially reasonable efforts to  prosecute and maintain all patent applications and patents included within the Eisai Patents. [*] shall  reimburse [*] for twenty-five (25) percent of [*] actual external costs and expenses incurred by [*] after the  Effective Date with respect to prosecuting and maintaining such Eisai Patents in the Territory. [*] shall  promptly furnish or have furnished to [*] copies of all patents, patent applications, substantive patent office  actions, and substantive responses received or filed in connection with any applications for the Eisai Patents  and use reasonable efforts to solicit [*] advice and review of Eisai Patents and material prosecution matters  related thereto in reasonable time prior to filing thereof, and [*] shall deliver any such comments to [*] and  shall use Diligent Efforts to cause [*] to consider in good faith [*] reasonable comments and suggestions  related thereto, which comments and suggestions shall be provided to [*] without any delay. [*] is not  required to have English translations of the records provided to [*] for that purpose but shall provide copies  of all correspondence and documents that are provided to it in English from patent officials or outside  counsel. [*] agrees to grant to [*] the right to assume responsibility for any of Eisai Patents or any part of  Eisai Patents which [*] determines in its sole discretion to abandon or otherwise cause or allow to be  forfeited, provided [*] grants [*] such right in writing.   1.8   [*] shall have the sole right and authority to file, prosecute, maintain and obtain extensions of all  patent applications and patents included within Radius-Invented Patents and Licensee-Invented Patents in  Japan and the Territory. [*] shall use all commercially reasonable efforts to prosecute and maintain all     

 

                                                                LICENSE AGREEMENT    patent applications and patents included within Radius-Invented Patents and Licensee-Invented Patents. [*]  shall promptly furnish or have furnished to [*] copies of all patents, patent applications, substantive patent  office actions, and substantive responses received or filed in connection with such applications for Radius- Invented Patents and Licensee-Invented Patents and use reasonable efforts to solicit [*] advice and review  of Radius-Invented Patents and Licensee-Invented Patents and material prosecution matters related thereto  in reasonable time prior to filing thereof; [*] shall consider in good faith [*] reasonable comments and  suggestions related thereto, which comments and suggestions shall promptly be provided to [*]. [*] is not  required to have English translations of the records provided to [*] under this Clause 1.8, but shall provide  copies of all correspondence and documents that are provided to it in English from patent officials or outside  counsel. [*] agrees to grant to [*] the right to assume responsibility for the filing, prosecution and  maintenance of any Radius-Invented Patent, Radius-Eisai Joint Patent and Licensee-Invented Patent or any   part of a Radius-Invented Patent, Radius-Eisai Joint Patent or Licensee-Invented Patent which [*] intends  to abandon or otherwise cause or allow to be forfeited. Such grant shall be made in writing and shall not be  inferred from the circumstances. [*] shall hold, and shall cause any of Affiliates to hold, all information  disclosed to it under this Clause 1.8 as confidential in accordance with the confidentiality provisions set  forth in Section 9 of the Agreement.     1.9   For so long as [*] prosecutes the Radius-Invented Patents, the out-of-pocket costs and expenses   (including, but not limited to, patent attorney fees and maintenance fees) for the filing, prosecution,   maintenance and extension of the Radius-Invented Patents (the “Radius-Invented Patent Prosecution and   Maintenance Costs”) incurred by [*] after the Effective Date and until the Second NDA Anniversary shall   be [*] prior to the [*] within [*] ([*]) calendar days following receipt of [*] invoice and [*] shall invoice  [*] for such Radius-Invented Patent Prosecution and Maintenance Costs no more frequently than [*]. [*]  shall bear all Radius-Invented Patent Prosecution and Maintenance Costs incurred by [*] after [*].  Promptly, and in any case no later than [*] days, after the Effective Date, [*] shall (i) provide [*] with all  documentation and information in Radius’ possession relating to the filing, prosecution and maintenance  of the Radius-Invented Patents and Radius-Eisai Joint Patents by uploading such documentation and  information in an orderly fashion to a shared virtual data room or a shared virtual ‘folder’ (such as a Google  Drive ‘folder’), (ii) clearly identify any and all prosecution matters that require immediate attention as of  the Effective Date, (iii) formally notify all patent attorneys in charge of the filing, prosecution and  maintenance of the Radius-Invented Patents and Radius-Eisai Joint Patents of [*] assumption of  responsibility and full authority for such matters (or cause all such patent attorneys to be so notified), and  (iv) liaise [*] with all such patent attorneys.    1.10  With respect to any potentially patentable Radius-Eisai Joint Invention or Licensee-Eisai Joint   Invention (collectively, the “Joint Inventions”), the Parties shall meet and agree in writing upon whether   and when patent applications shall be filed for such Joint Invention (any such agreement, a “Joint Patent   Agreement”; any patent application directed to a Licensee-Eisai Joint Invention, and any patent issuing   therefrom, a “Licensee-Eisai Joint Patent”; and the Radius-Eisai Joint Patents and the Licensee-Eisai Joint   Patents, collectively, the “Joint Patents”), using outside legal counsel selected by either Radius or Licensee,   as the case may be, and Eisai. The selected outside counsel shall be responsible to either Radius or Licensee,   as the case may be, and Eisai, and shall use reasonable efforts to solicit either Radius or Licensee, as the   case may be, and Eisai’s advice on material prosecution matters related thereto. Unless the applicable Joint   Patent Agreement provides otherwise, Licensee shall bear the costs and expenses incurred with respect to  the prosecution of the Licensee-Eisai Joint Patents in the Territory. If Licensee is the Prosecuting Party (as   this term is defined in this Clause 1.10) of a Radius-Eisai Joint Patent, (i) the costs and expenses for the   filing, prosecution, maintenance and extension of such Radius-Eisai Joint Patent incurred by Licensee after   the Effective Date and until [*], it being understood that [*] shall invoice [*] for such costs and expenses   no more frequently than once in each calendar quarter; and (ii) [*] shall bear all costs and expenses for the   filing, prosecution, maintenance and extension of such Radius-Eisai Joint Patent incurred after [*]. As   between Radius and Licensee, the Party that bears the costs and expenses for the prosecution of a Joint     

 

                                                                LICENSE AGREEMENT    Patent (the “Prosecuting Party”) shall have final decision-making authority in respect of the prosecution of   such Joint Patent and its maintenance in the Territory; provided, however, that such final decision making   authority may not be used in a manner inconsistent with the Eisai License Agreement. The Prosecuting   Party shall provide the other Party, and Radius shall provide Eisai, reasonable opportunity to review and   comment on such prosecution efforts regarding the applicable Joint Patent in the particular jurisdictions,   and such other Party shall provide the Prosecuting Party reasonable assistance in such efforts. The   Prosecuting Party shall provide the other Party, and Radius shall provide Eisai, with a copy of all material   communications from any patent authority in the applicable jurisdictions regarding the Joint Patent being   prosecuted by such Prosecuting Party, and shall provide drafts of any material filings or responses to be   made to such patent authorities a reasonable amount of time in advance of submitting such filings or   responses. In particular, the Prosecuting Party shall provide the other Party, and Radius shall provide Eisai,   with all information necessary or desirable to enable the other Party to comply with the duty of candor/duty  of disclosure requirements of any patent authority. Neither Party shall grant any Third Party(ies) the right  to practice the Joint Patents or any Joint Inventions without prior consent of the other Party or Eisai  anywhere in the world. Any royalty from such Third Parties shall be governed by the applicable Joint Patent  Agreement; provided that [*]. [*] may determine that it is no longer interested in supporting the continued  prosecution or maintenance of a particular Joint Patent in a country or jurisdiction, in which case, [*].    1.11  The Parties will discuss and recommend for which, if any, of the patents within the Eisai Patents,   Radius-Invented Patents, Licensee-Invented Patents and Joint Patents in the world patent term extensions   should be sought. As between the Parties, [*] shall have the final decision-making authority with respect to  applying for any such patent term extensions in the world, and will act with reasonable promptness in light  of the development stage of Products to apply for any such patent term extensions; provided that in respect  of the Eisai Patents Licensee may not use such final decision-making authority in a manner inconsistent  with the Eisai License Agreement. If in a particular country or jurisdiction in the world only one such patent  can obtain a patent term extension, then the Parties will consult in good faith to determine which such patent  should be the subject of efforts to obtain a patent term extension. As between the Parties, the Prosecuting  Party will have final decision-making authority in case of disagreement provided that in respect of the Eisai  Patents Licensee may not use such final decision-making authority in a manner inconsistent with the Eisai  License Agreement. The Party that does not apply for an extension hereunder will cooperate fully with the  other Party in making such filings or actions, for example and without limitation, making available all  required regulatory data and information and executing any required authorizations to apply for such patent  term extension.   1.12  Subject always to Section 7.3(c)(iii) of the Agreement, .in the event that a Third Party sues either  Party, its Affiliates, licensees or sublicensees for patent infringement involving the manufacture, use, sale,  distribution or marketing of Product anywhere in the world, the Party sued shall promptly notify the other  Party with regard to such action. With respect to the defense of any such action in the Territory, the Party  sued shall be wholly responsible for the defense of such action and shall bear all costs and expenses  associated therewith. In any event, the Party sued shall have the right to request, solely at its own expense,  the other Party to assist and cooperate in connection with the defense of such suit. Upon such request, the  other Party shall use [*] all reasonable efforts to assist and cooperate in connection with the defense of such  suit.    1.13  In the event that either Party becomes aware of actual or threatened infringement of Eisai Patents,   Radius-Invented Patents, Licensee-Invented Patents, or Joint Patents anywhere in the world, it shall   promptly notify the other Party thereof in writing, which notice shall include all information available to   the notifying Party regarding such alleged infringement. With respect to infringement of Eisai Patents   anywhere in the world, the Parties acknowledge that pursuant to the Eisai License Agreement, [*] has the   first right (but not the obligation) to pursue any and all injunctive, compensatory and other remedies   (collectively, “Remedies”) against the infringing third party. In the event [*] does not elect to enforce the     

 

                                                                LICENSE AGREEMENT    Eisai Patents, [*] shall notify [*] in writing promptly after [*] receives such notice from [*], and [*] shall   have the right (but not the obligation) to commence a suit or take action to enforce the applicable Eisai   Patents against such infringing third party in the Territory. In the event [*] notifies [*] that [*] has a   reasonable business basis not to enforce such Eisai Patents in the Territory, with the determination of   reasonableness taking into account the costs of such litigation, its likelihood for success, the potential   damages or settlement recovery, and the potential for exposure to counterclaims and defenses against [*]   with respect to the validity of the Eisai Patents, [*] shall provide such notice to [*] promptly following   receipt of such notice from [*], in which case [*] shall not have such enforcement right in the Territory;   provided that, the Parties will discuss in good faith whether Section 7.3(c)(ii) of the Agreement shall apply,   mutatis mutandis, with respect to the applicable country(ies) where such infringement exists as if no patent   protection or data protection clauses are in effect for such country(ies). The Party pursuing Remedies   pursuant to this Clause 1.12 in respect of Eisai Patents, Radius-Invented Patents, Licensee-Invented Patents   or Joint Patents shall bear its own costs and expenses relating to such pursuit.    [*].    With respect to infringement of Radius-Invented Patents and Licensee-Invented Patents anywhere in the   world, [*] shall have the first right (but not the obligation) to pursue any and all Remedies against the   infringing third party. [*] shall have a period of [*] to elect to so enforce such Radius-Invented Patents or   Licensee-Invented Patents. In the event [*] does not so elect, it shall so notify [*] in writing [*].   In the event that a third party infringes any Joint Patents, [*] shall have the first right (but not the obligation)   to pursue Remedies against the infringing third party if such infringement is conducted in the Territory.    In any event as set forth in this Clause 1.13, upon request from the other Party, [*] and [*] shall assist one   another and cooperate in the pursuit of Remedies, including without limitation joining such action as a party   plaintiff if required by applicable law to pursue such action, without charge to the other Party for costs and   expenses incurred thereby.    1.14  The Parties shall keep one another informed of the status of their respective activities regarding any   litigation or settlement thereof concerning the Product. Neither Party shall enter into any settlement or   consent judgment or other voluntary final disposition of any suit defended or action brought pursuant to   Clause 1.13 without the other Party's prior written consent, which consent shall not be unreasonably   withheld.exhibit102-originalv2

                                                                             Exhibit 10.2                 PARTIAL RELEASE AND ACKNOWLEDGEMENT AGREEMENT                                                            This PARTIAL  RELEASE  AND  ACKNOWLEDGEMENT  AGREEMENT                (this  “Agreement”),  dated  as  of  July  22,  2020,  is  made  by  and  among  MIDCAP  FINANCIAL  TRUST,  a  Delaware statutory trust, as agent under Term Loan Credit Agreement referred to below (in such capacity  and together its successors and assigns, the “Term Loan Agent”), MIDCAP FUNDING IV TRUST, a  Delaware statutory trust, as agent under Revolving Credit Agreement referred to below (in such capacity  and together its successors and assigns, the “Revolving Loan Agent” and, together with the Term Loan  Agent, the “Agents”) RADIUS HEALTH, INC., a Delaware corporation (“Radius Health”), and RADIUS  PHARMACEUTICALS, INC., a Delaware corporation (“Radius Pharma”, together with Radius Health,  the “Grantors” and each, a “Grantor”).                 WHEREAS, pursuant to (i) that certain Credit and Security Agreement (Term Loan), dated  as of January 10, 2020, among the Grantors, the  Term Loan Agent and the Lenders and other parties thereto  (as the same may have been amended, modified, restated, replaced or supplemented from time to time, the  “Term Loan Credit Agreement”) and that certain Intellectual Property Security Agreement, dated as of  January 10, 2020, among the Grantors and the Term Loan Agent (as the same may have been amended,  modified, restated, replaced or supplemented from time to time, the “Term Loan IP Security Agreement”)  and (ii) that certain Credit and Security Agreement (Revolving Loan), dated as of January 10, 2020, among  the Grantors, the Revolving Loan Agent and the Lenders and other parties thereto (as the same may have  been amended, modified, restated, replaced or supplemented from time to time, the “Revolving Credit  Agreement”, together with the Term Loan Credit Agreement, the “Credit Agreements”) and that certain  Intellectual  Property  Security  Agreement,  dated  as  of  January  10,  2020,  among  the  Grantors  and  the  Revolving Loan Agent (as the same may have been amended, modified, restated, replaced or supplemented  from time to time, the “Revolving IP Security Agreement”), the Grantors assigned and granted to each of  (i)  Revolving Loan Agent, for the benefit of itself and the Lenders under (and as defined in) the Revolving  Credit Agreement and (ii) Term Loan Agent, for the benefit of itself and the Lenders under (and as defined  in) the Term Loan Credit Agreement, a security interest in and to the personal property of the Grantors as  specified therein, including the property set forth on Exhibit A hereto;                WHEREAS, the Term Loan IP Security Agreement was duly filed and recorded with the  United States Patent and Trademark Office on January 15, 2020 at reel/frame 51618/200 and on January 23,  2020 at reel/frame 6838/0823, and the Revolving IP Security Agreement was duly filed and recorded with  the United States Patent and Trademark Office on January 15, 2020 at reel/frame 51618/758 and on January  23, 2020 at reel/frame 6838/0837;                 WHEREAS,  pursuant  to  that  certain  License  Agreement  (such  agreement,  as  may  be  amended or restated from time to time in accordance with the terms thereof and of the Credit Agreements,  the “License Agreement”), dated as of the date hereof, between Radius Pharma and Berlin-Chemie AG -  Menarini Group, organized under the laws of Germany having business offices at Glienicker Weg 125,  12849 Berlin, Germany (including its permitted successors and assigns, “Licensee”), Radius Pharma has  (a) granted to Licensee an exclusive, worldwide, royalty-bearing license under the Radius Elacestrant Patent  Rights and the Radius Elacestrant Know-How to research, develop, have developed, make, have made, use,  sell, offer for sale, commercialize, import and export one or more Licensed Compound(s) and Licensed  Product(s) (each as defined in Exhibit A hereto) (such license grant, as contemplated under the License  Agreement, the “License”); and (b) agreed to grant the right to use certain regulatory filings and other assets  of the Grantors that are related solely to the Licensed Compounds and Licensed Products;                WHEREAS, in connection with the License Agreement, the Grantors have requested that  each Agent release, discharge, relinquish, terminate and dissolve its security interest in and continuing lien  on, and security interest in and to, the Elacestrant Collateral (as defined in Exhibit A hereto); and     

 

                                                                                                      WHEREAS, pursuant to that certain Transition Services Agreement (such agreement, as  may  be  amended  or  restated  in  accordance  with  the  terms  thereof  and  of  the  Credit  Agreements,  the  “Transition Services Agreement”), dated as of the date hereof, between Radius Health and Licensee,  Grantor  has  agree  to  perform  certain  clinical,  regulatory  and  other  activities  relating  to  the  Licensed  Compound(s) and Licensed Products.                NOW, THEREFORE, in consideration of the foregoing, the terms and conditions set forth  in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are  hereby acknowledged, each Agent and the Grantors hereby agree as follows:                1.     Recitals.   This  Agreement  shall  constitute  a  Financing  Document  under  each  Credit Agreement and the Recitals and each reference to the Credit Agreements, unless otherwise expressly  noted, will be deemed to reference the Credit Agreements as supplemented hereby.  Capitalized terms used  but  not  otherwise  defined  herein  shall  have  the  meanings  ascribed  to  them  in  the  applicable  Credit  Agreement (including those capitalized terms used in the Recitals hereto).                2.     Release.  In reliance on the certifications set forth in Section 3(a) below, each  Agent, without recourse, representation or warranty, automatically upon the execution and delivery of the  License Agreement, and without any action required by any other Person, hereby (a) releases all of its right,  title and interest in and to the Elacestrant Collateral, and reassigns and transfers all of its right, title and  interest that such Agent may have in the Elacestrant Collateral, to the Grantors, and confirms that any Lien,  security interest or other encumbrance of any kind in favor of such Agent on or in respect of the Elacestrant  Collateral is hereby automatically discharged and released pursuant to Section 11.9 of each of the Credit  Agreements,  (b)  authorizes  Grantors  or  Grantors’  authorized  representative  (including  the  Licensee)  to  record this Agreement with the United States Patent and Trademark Office, and (c) agrees to file Uniform  Commercial Code (UCC3) financing statement amendments in a form previously agreed by the Licensee  with the Delaware Secretary of State promptly following the date hereof.  Each Agent further agrees to  execute and deliver to Grantors such further documents and instruments which any Grantor may reasonably  request (at Grantors’ sole cost and expense) in order to release or terminate any security interest in favor of  such Agent in the Elacestrant Collateral.  Except as otherwise expressly set forth herein, this Agreement  does not release any Lien granted by the Grantors in favor of either Agent, for the benefit of the applicable  Lenders, pursuant to the Credit Agreements or any other Financing Documents.  In the event the License  Agreement is terminated or all or any portion of the Elacestrant Collateral is no longer subject to the License  and the Grantors retain ownership of the Elacestrant Collateral (or such portion thereof), (i) a security  interest in the Elacestrant Collateral (or such portion thereof) shall simultaneously and automatically be  granted in favor of each Agent under Section 9 of the applicable Credit Agreement and the Elacestrant  Collateral (or such portion thereof) shall be included in the Collateral and the Agents’ Liens shall reattach  thereto and (ii) the Grantors shall promptly and duly take, execute, acknowledge and deliver all such further  acts, documents and assurances as may be necessary or as either Agent may reasonably request in order to  grant and evidence and perfect such security interests.                3.     Acknowledgement by Grantors.                         a.     The Grantors hereby certify that (i) the granting of the License pursuant to        the License Agreement is an Asset Disposition permitted pursuant to clause (i) of the definition of        Permitted Asset Dispositions in each of the Credit Agreements and (ii) no Event of Default has        occurred  and  is  continuing  at  the  time  such  License  is  granted or  would  immediately  result        therefrom.  Without limiting the foregoing, Grantors represent, warrant and covenant to each Agent        that, at all times, the Elacestrant Collateral, including all assets set forth on Exhibit A, are Oncology        Assets and that no other assets of any Credit Party (other than the Oncology Assets) are included        in the definition of Elascestrant Collateral.          

 

                                                                                                             b.     The Grantors hereby acknowledge that the License Agreement and any         and  all  proceeds  and products  (other  than  any  products  that  themselves  constitute  Elascestrant         Collateral) thereof (including all Payment Rights (as defined below) thereunder) shall constitute         Collateral and that all references to “Collateral” contained in the Credit Agreement or the other         Financing Documents are hereby deemed for all purposes to include the License Agreement and         the proceeds thereof (including all Payment Rights thereunder) as part of the Collateral.  For the         avoidance of doubt, in no event shall the License Agreement or the proceeds and products (other         than any products that themselves constitute Elascestrant Collateral) thereof (including all Payment         Rights  thereunder)  constitute  Excluded  Property.  The  term  “Payment  Rights”  as  used  herein         means, collectively: (i) all proceeds received by or on behalf of Radius Pharma under the License         Agreement, (ii) all rights to payment of Radius Pharma under the License Agreement and (iii) all         rights of Radius Pharma related, ancillary or incidental to the foregoing clauses (i) and (ii).  For         purposes of this clause (b), the term “proceeds” shall have the meaning set forth in the UCC.                       c.     The Grantors agree, on behalf of themselves and the other Credit Parties,         that  they  will  not,  without  Agents’  prior  consent,  amend,  supplement  or  otherwise  modify  the         License Agreement, or any other material agreement related thereto, or enter into any agreement or         other document related to the License Agreement or the Elascestrant Collateral, in each case, to the         extent  such  amendment,  supplement  or  modification  or  new  agreement  or  document  would  be         materially adverse to either Agent or the Lenders or their Collateral.                4.     Acknowledgement by Each Agent.  Each Agent (a) acknowledges and agrees on  behalf  of  itself  and  (b)  confirms  that  the  Required  Lenders  under  each  of  the  Credit  Agreements  has  acknowledged and agreed that, in each case, pursuant to Section 10.1(g) of the License Agreement, Radius  Pharma has covenanted that it will not, nor will it permit any of its Affiliates to, directly or indirectly, create,  assume or suffer to exist any Lien on or security interest in all or any portion of the Elacestrant Collateral  for so long and during the period that the License Agreement remains in full force and effect or that the  Elacestrant Collateral remains subject to the License (in accordance with its terms).                 5. Miscellaneous.                       a.     The agreements of each Agent hereunder are made without recourse to or         warranty by such Agent.  It is expressly agreed and understood that this is a partial release and that it         shall in no manner release, affect or otherwise impair the liens and security interest in favor of either         Agent, under the Credit Agreements or otherwise, against any Collateral other than the Elacestrant         Collateral.   Other  than  the  Liens  expressly  released  pursuant  to  Section  2  above,  each  Grantor         confirms and agrees that all security interests and Liens granted to each Agent continue in full force         and effect, and that all Collateral remains free and clear of any Liens, other than Permitted Liens.                          b.     GOVERNING LAW.  THIS AGREEMENT AND ALL DISPUTES AND        OTHER  MATTERS  RELATING  HERETO  OR  THERETO  OR  ARISING  THEREFROM        (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL BE         GOVERNED  BY,  AND  SHALL  BE  CONSTRUED  AND  ENFORCED  IN  ACCORDANCE         WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS         OF  LAWS  PRINCIPLES  (OTHER  THAN  SECTION  5-1401  OF  THE  GENERAL         OBLIGATIONS LAW).                       c.     WAIVER OF JURY TRIAL.   EACH PARTY HERETO HEREBY        IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL         ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR         THE  TRANSACTIONS  CONTEMPLATED  HEREBY  AND  AGREES  THAT  ANY  SUCH          

 

                                                                                   ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A  JURY.  EACH PARTY HERETO ACKNOWLEDGES THAT THIS WAIVER IS A MATERIAL  INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS RELIED  ON  THE  WAIVER  IN  ENTERING  INTO  THIS  AGREEMENT,  AND  THAT  EACH  WILL   CONTINUE  TO  RELY  ON  THIS  WAIVER  IN  THEIR  RELATED  FUTURE  DEALINGS.    EACH PARTY WARRANTS AND REPRESENTS THAT IT HAS HAD THE OPPORTUNITY   OF  REVIEWING  THIS  JURY  WAIVER  WITH  LEGAL  COUNSEL,  AND  THAT  IT   KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS.                 d.     Counterparts.   This  Agreement  may  be  signed  in  any  number  of  counterparts, each of which shall be deemed an original and all of which when taken together shall  constitute one and the same instrument.  Delivery of an executed counterpart of this Agreement by  facsimile or by electronic mail delivery of an electronic version (e.g., .pdf or .tif file) of an executed  signature page shall be effective as delivery of an original executed counterpart hereof and shall  bind the parties hereto.                 e.     Successors  and  Assigns.  This  Agreement  shall  be  binding  upon  the  successors and assigns of each Agent, and shall be binding upon each Grantor and its successors  and assigns.  No Person other than the parties hereto shall have any rights hereunder or be entitled   to rely on this Agreement and all third-party beneficiary rights are hereby expressly disclaimed;   provided  that,  notwithstanding  the  foregoing,  the  Licensee  shall  be  an  express  third-party  beneficiary solely of clause (b) of Section 2 hereof, and such clause shall expressly inure to the  benefit of the Licensee and the Licensee shall be entitled to rely on and enforce the provisions of  such clause but not in respect of any other provision of this Agreement.                      [remainder of this page intentionally left blank]                                                    

 

                                                                                                      IN WITNESS WHEREOF, intending to be legally bound, each of the parties have caused  this Agreement to be executed as of the day and year first above mentioned.   GRANTORS:                          RADIUS HEALTH, INC.                                                                            By:/s/ Jose Carmona                                      Name: Jose Carmona                                     Title: Chief Financial Officer                                          RADIUS PHARMACEUTICALS, INC.                                                                           By: /s/ Jose Carmona                                      Name: Jose Carmona                                     Title: Chief Financial Officer           1      

 

                                                                                                                           MIDCAP FINANCIAL TRUST, as Term Loan Agent                                                     By: Apollo Capital Management, L.P.,                                       its investment manager                                                                          By: Apollo Capital Management GP, LLC,                                           its general partner                                                                                                                     By: /s/ Maurice Amsellem                                                  Name: Maurice Amsellem                                          Title:   Authorized Signatory                                                                                                                                          MIDCAP FUNDING IV TRUST, as Revolving Loan           Agent                                                     By: Apollo Capital Management, L.P.,                                       its investment manager                                                                          By: Apollo Capital Management GP, LLC,                                           its general partner                                                                                                                     By: /s/ Maurice Amsellem                                                  Name: Maurice Amsellem                                          Title:   Authorized Signatory                                                                                                      2                                  

 

                                                                                                                                Exhibit A    “Elacestrant Collateral” means all term loan credit Collateral (as such term is defined in the Term Loan  Credit Agreement) and all revolving credit Collateral (as such term is defined in the Revolving Credit  Agreement), as applicable, that, in each case, is related solely to the Licensed Compounds or Licensed  Products,  specifically  including  (without  limitation)  the  Radius  Elacestrant  Patent  Rights,  Radius  Elacestrant  Know-How,  Elacestrant  Contracts,  Elacestrant  Upstream  Licenses  and  TSA  Inventions;  provided that Elacestrant Collateral shall not include any of the following assets or property: (i) cash or  cash equivalents, (ii) deposit accounts or securities accounts, (iii) accounts or accounts receivable, (iv) the  License Agreement (or any payments or rights to payment thereunder), (v) any other contract or agreement  (or any payments or rights to payment thereunder) that provides for any payments to, or received by or on  behalf of, any Grantor (or any of its Affiliates) by Licensee or any Affiliate thereof or any of their respective  successors or assigns, (vi) any payments or rights to payment of any Grantor, or any Affiliate thereof, under  any other contract or agreement related to the License Agreement or the Licensed Product or Licensed  Compounds or (vii) any proceeds in respect of any of the foregoing.     For purposes of the foregoing, the following terms shall have the following meanings:   1.1    “Affiliate”  of  a  Person  means  any  other  Person  which  (directly or  indirectly)  is  controlled  by,        controls or is under common control with such Person.  For the purposes of this definition, the        term “control”  (including,  with  correlative  meanings,  the  terms “controlled  by”  and “under        common control with”) as used with respect to any Person means (a) in the case of a corporate        entity, direct or indirect ownership of voting securities entitled to cast at least fifty percent (50%)        of the votes in the election of directors, (b) in the case of a non-corporate entity, direct or indirect        ownership of at least fifty percent (50%), including ownership by trusts with substantially the same        beneficial interest, of the equity interests with the power to direct the management and policies of        such Person, provided that if local law restricts foreign ownership, control will be established by        direct or indirect ownership of the maximum ownership percentage that may, under such local law,        be owned by foreign interests, or (c) the power to direct the management or policies of a Person,        whether through ownership of voting securities, by contract or otherwise.   1.2   “Combination” means a Combination Product or Combination Therapy.   1.3    “Combination Product” means a Licensed Product that includes at least one additional active        ingredient other than Licensed Compound.  Drug delivery vehicles, adjuvants, and excipients will        not be deemed to be “active ingredients”, except in the case where such delivery vehicle, adjuvant,        or excipient is recognized as an active ingredient in accordance with 21 C.F.R. § 210.3(b)(7) (as        amended), or any foreign counterpart.    1.4   “Combination Therapy” means a therapy comprised of a Licensed Product and one or more other        therapeutically or prophylactically active ingredients, whether priced and sold in a single package        containing such multiple products, packaged separately but sold together for a single price, or sold        under separate price points but labeled for use together, including all dosage forms, formulations,        presentations, and package configurations.  Drug delivery vehicles, adjuvants, and excipients will        not be deemed to be “active ingredients”, except in the case where such delivery vehicle, adjuvant,        or excipient is recognized as an active ingredient in accordance with 21 C.F.R. § 210.3(b)(7) (as        amended), or any foreign counterpart.   1.5   “Confidential Information” means all Radius Elacestrant Know-How, marketing plans, strategies        and  customer  lists,  and  other  information  or  material  that  are disclosed  or  provided  by  Radius        Health or its Affiliates to Licensee or its Affiliates pursuant to the terms of the Transition Services    

 

                                                                                               Agreement, regardless of whether any of the foregoing are marked “confidential” or “proprietary”        or  communicated  to  the  other  by  Radius  Health  or  its  Affiliates  in  oral,  written,  graphic,  or        electronic form.   1.6   “Duke License Agreement” means that certain Patent License Agreement dated as of December        8, 2017, by and between Radius Pharma and Duke University (“Duke”) as such agreement may be        amended or restated from time to time in a manner that is not prohibited  under the Financing        Documents.   1.7   “Duke Patent Rights” means Duke’s legal rights under the patent laws of the United States or        relevant foreign countries for all of the following:                (a)    the  following  United  States  and  foreign  patent(s)  and/or  patent  application(s),  including all divisionals, continuations, continuations-in-part arising from or claiming priority to any of the  Duke  Patent  Rights  and  containing  claims  covering  the  chemical compound  known  as  RAD1901  or  elacestrant in any and all fields of use, and foreign counterparts of the same:                              US Patent 9,421,264 (US Application No.:  14/512,061),                             USSN 62/129,379,                             USSN 61/971,627,                             PCT/US2015/023216,                             USSN 15/214,187,                             USSN 15/129,197,                             EPO 15769394.6 (EP 3122426),                             CA 2,943,611.                (b)    United  States  and  foreign  patents issued  from  the  applications listed  in  subparagraph  (a)  above,  including  any  reviewed,  reissued  or  re-examined  patents,  and  supplementary  protection certificates, and foreign counterparts of the same, based upon the same.                (c)    Any applications claiming priority from any of the listed applications.    The Duke Patent Rights existing as of the Effective Date are set forth on Appendix 6 to this Exhibit A.    1.8    “Effective Date” means July 22, 2020.     1.9    “Eisai License Agreement” means that certain License Agreement, dated as of June 29, 2006, by        and between Radius Pharma and Eisai Co., Ltd. (“Eisai”), as such agreement may be amended or        restated from time to time in a manner that is not prohibited  under the Financing Documents.    1.10  “Eisai Patents” means all patents and patent applications which are or become owned by Eisai        and/or its Affiliates, or to which Eisai and/or its Affiliates, otherwise have, now or in the future,        the right to grant licenses, and which generically or specifically claim Compound and/or Product,        a use for Compound and/or Product, a process for manufacturing Compound and/or Product, or an        intermediate  use  in  such  process.   Included  within  the  definition of Eisai Patents are all        continuations,  continuations-in-part,  divisions,  patents  of  addition,  reissues,  re-examinations,        renewals or extensions thereof and all Supplementary Protection Certificates. Also included within        the  definition  are  any  improvements  on  Compound  and/or  Product or  intermediates  or         manufacturing process required or useful for production of Compound and/or Product which are         developed by or for Eisai and/or its Affiliates, or to which Eisai and/or its Affiliates otherwise has         the right to grant licenses, now or in the future, during the term of the License Agreement. Eisai    

 

                                                                                               Patents  also  includes  any  patent  application  covering  an  invention  solely  owned  by  Eisai  in        accordance  with  Article  6.4  of  the  Eisai  License  Agreement.  For  purposes  of  this  clause 1.10         (“Eisai Patents”), clause 1.17 (“Radius-Eisai Joint Invention”), clause 1.18 (“Radius-Eisai Joint        Patents”),  and  clause  1.20  (“Radius  Elacestrant  Invented  Patent”),  (i)  “Compound”  means        elacestrant or any derivative or analogue thereof, (ii) “Product” means any pharmaceutical drug in        final  packaged  form  containing  the  Compound  or  any  derivative  or  analogue  thereof,  the        development, manufacture, use or sale of which, absent the licenses granted to Licensee under the        License Agreement, would infringe the Eisai Patents or which make use of any Radius-Eisai Joint        Patents,  and  (iii)  “Affiliates”  means  any  corporation,  firm,  partnership  or  other  entity  which        directly or indirectly owns, is owned by or is under common ownership with Eisai to the extent of        more than fifty (50) percent of the equity having the power to vote on or direct the affairs of any        such corporation, firm, partnership, or other entity The Eisai Patents existing as of the Effective        Date as set forth on Appendix 6 to this Exhibit A.   1.11   “Elacestrant Contracts” means (a) the contracts listed on Appendix 4 to this Exhibit A, solely to        the extent that such contracts are solely related to the Licensed Compounds or Licensed Products,         and (b) any contracts that Radius Health or its Affiliates enter into after the Effective Date, solely         for the purpose of carrying out the Services on behalf of Radius Health.   1.12   “Elacestrant  Upstream  Licenses”  means  the  Duke  License  Agreement  and  Eisai  License        Agreement.   1.13  “Know-How” means all know-how, trade secrets, chemical and biological materials, formulations,        information,  documents,  studies,  results,  data  and  regulatory  approvals,  data  (including  from        clinical studies), filings and correspondence (including drug master files), including biological,        chemical,  pharmacological,  toxicological,  pre-clinical,  clinical  and  assay  data,  manufacturing        processes and data, specifications, sourcing information, assays, and quality control and testing        procedures, whether or not patented or patentable.   1.14  “Licensed  Compound”  means  the  compound  known  as  elacestrant  (RAD1901),  as  further        described on Appendix 1 to this Exhibit A, the backup compounds listed on Appendix 2 to this        Exhibit  A,  and  in  each  case,  any  modification,  improvement,  derivative  or  Structural  Analog        thereof,  including  any  metabolite,  salt,  ester,  free  acid  form,  free  base  form,  crystalline  form,        amorphous form, pro-drug form, racemate, chelate, polymorph, tautomer, solvate, or optical isomer        thereof.   1.15  “Licensed  Product”  means  any  pharmaceutical  product  containing  any  Licensed  Compound        (alone or with other active ingredients), in all forms, presentations, formulations and dosage forms.         For clarification, Licensed Product will include any Combination.   1.16  “Person”  means  an  individual,  sole  proprietorship,  partnership,  limited  partnership,  limited        liability partnership, corporation, limited liability company, business trust, joint stock company,        trust, beneficiary or trustee of any trust, incorporated association, joint venture, or similar entity or        organization,  including  a  government  or  political  subdivision  or  department  or  agency  of  a        government.   1.17  “Radius-Eisai Joint Invention” means any invention developed by or on behalf of Radius Pharma        and disclosed by Radius Pharma to Eisai pursuant to Section 6.3 of the Eisai License Agreement.     

 

                                                                                         1.18   “Radius-Eisai  Joint  Patents”  means  any  patent  application claiming  a  Radius-Eisai  Joint        Invention, and any patent stemming therefrom.  The Radius-Eisai Joint Patents existing as of the        Effective Date are set forth in Appendix 6 to this Exhibit A.   1.19   “Radius Elacestrant Know-How” means (a) all Know-How that is related solely to the Licensed        Compounds or Licensed Products and is controlled by Radius Pharma or any of its Affiliates as of        the Effective Date, and (b) all Know-How within the TSA Inventions.   1.20  “Radius Elacestrant Invented Patents” means all patents and patent applications which are or        become  owned  by  Radius  Pharma   and/or  its  Affiliates,  to  which Radius  Pharma  and/or  its        Affiliates otherwise have, now or in the future, the right to grant licenses, and which generically or         specifically claim Compound and/or Product, a use for Compound and/or Product, a process for         manufacturing Compound and/or Product, or an intermediate used in such process. Included within         the definition of Radius Elacestrant Invented Patents are all continuations, continuations-in-part,         divisions,  patents  of  addition,  reissues,  re-examinations,  renewals  or  extensions  thereof  and  all         Supplementary Protection Certificates. Also included within the definition are all patents and patent         applications any improvements on Compound and/or Product or intermediates or manufacturing         process required or useful for production of Compound and/or Product which are developed by or        for Radius Pharma and/or its Affiliates, or to which Radius Pharma and/or its Affiliates otherwise        have the right to grant licenses, now or in the future, during the term of the License Agreement.        Radius  Elacestrant  Invented  Patents  also  includes  any  patent  application  covering  an  invention        solely owned by Radius in accordance with Article 6.4 of the Eisai License Agreement. The Radius        Elacestrant Invented Patents existing as of the Effective Date are set forth in in Appendix 5 to this        Exhibit A.   1.21   “Radius  Elacestrant  Patent  Rights”  means  (a)  the  patents  and  patent  applications  listed  in        Appendix  5  and  Appendix  6  to  this  Exhibit  A,  plus  any  conversion,  continuation,  division  or        substitution thereon, any reissues, reexaminations or extensions thereof, any continuation-in-part         application or patent that is entitled to the priority date of, and is directed specifically to subject         matter specifically described in, at least one of the patents or patent applications described above,         and any foreign counterparts of any of the foregoing, and (b) all patents and patent applications that         specifically  claim  or  cover  the  TSA  Inventions,  plus  any  conversion,  continuation,  division  or         substitution thereon, any reissues, reexaminations or extensions thereof, any continuation-in-part         application or patent that is entitled to the priority date of, and is directed specifically to subject         matter specifically described in, at least one of the patents or patent applications described above,         and any foreign counterparts of any of the foregoing.  For the sake of clarity, the Radius Elacestrant         Patent Rights include the Duke Patent Rights, the Eisai Patents, the Radius-Eisai Joint Patents, and         the Radius Elacestrant Invented Patents.   1.22   “Services” means the services to be performed by or on behalf of Radius Health in the interest of        Licensee pursuant to the Transition Services Agreement.   1.23  “Structural Analog” means a compound covered by the chemical structure set forth on Appendix        3 to this Exhibit A.   1.24   “TSA  Inventions”  means  any  materials,  data,  processes,  documents,  deliverables,  information        (including Confidential Information), discoveries, inventions, know-how and the like developed or        generated by or on behalf of Radius Health after the Effective Date during the course of performing        the  Services,  whether  or  not  patentable,  and  all  related  patent,  copyright  and  other  intellectual        property rights in any of the foregoing.      

 

                                                                                                Appendix 1 to Exhibit A                                                       Licensed Compound                                  Elacestrant (RAD1901)                                                                                                                                     

 

                                                                                       Appendix 2 to Exhibit A                                                    Backup Compounds                                 1902 genus:                                                        1902 Selection Case genus:                                                                  

 

                                                                    1902 lead compounds:                                                                                                                                             

 

                                                                                                                                                                                                                                                                                                                                                   

 

                                                                                                                                                                                                                                                                                                                                    

 

                                                                                                                                                                              

 

                                                                                                                    Appendix 3 to Exhibit A                                         Structural Analog    1.    A compound represented by the following formula (I);                                                                              wherein                                               f g’               f’    g’  Z represents a bond, a C1-C4 alkylene group or –CR ’R -CH2-O- wherein R  and R  independently represent a C1-C6 alkyl group;       -T-NRaRb represents -NRaRb,                                      , or                                                         ;     A represents a 5- to 14-membered heteroarylene group which may have one or more substituents   or a C6-C14 arylene group which may have one or more substituents;                                              c         c  Y represents a C1-C4 alkylene group or –CH2-NR - wherein R  represents a C1-C6 alkyl group  which may have a substituent;     ring G is a ring or a fused ring system selected from the group consisting of;         

 

                                                                                                 ,            ,             ,             ,               ,                   ,             ,            ,            ,             ,                   ,                ,             ,                        ,                 ,             ,             ,              ,               ,                 ,            ,            ,             ,               ,                   ,              ,             ,            ,               , and                   ;    wherein each Rh is independently selected from hydrogen or CH3; Rg is hydrogen, C1-C3 alkyl, C1- C3 fluoroalkyl, CN, fluorine, chlorine or bromine; and each Re is independently selected from  hydrogen,  halogen,  OH,  O(CO)R,  O(CO)NR1R2,  OPO3,  OSO3,O(SO2)NR1R2,  or  wherein  two  adjacent Re together form:                            ,                 ,         , or                  ;          

 

                                                                                   wherein  each  R3  is  hydrogen,  C1-C12  acyl,  or  C1-C12  acyloxy;  and  each  R4  is  independently  hydrogen, C1-C3 alkyl, fluorine or chlorine;   R’ represents 1 to 4 substituents independently selected from a hydrogen and a C1-C6 alkoxy  group;    a partial structure in formula (I) represented by the following formula:                                                                                      or       R’’ represents a hydroxyl group that may be further protected by a protecting group or a C1-C6  alkoxy group which may have a substituent; U and V are each independently selected from CRa’        

 

                                                                                   or N; each Ra’ is independently selected from:  H, C1-C3 alkyl, C1-C3 fluoroalkyl, phenyl   (optionally substituted with 1-3 groups selected from fluorine, chlorine, C1-C3 alkyl, CN, OC1-C3   alkyl, OH), OH, OC1-3alkyl, CN, fluorine, or chlorine; and       Ra and Rb are the same as or different from each other and each represents a hydrogen atom, a   C1-C6 alkyl group which may have one or more substituents, or a C3-C8 cycloalkyl group which   may have one or more substituents, or when Ra and Rb are bonded together, they may form,  together with the nitrogen atom that is adjacent to a Ra and Rb, a 4- to 10-membered single ring   which may have one or more substituents; and       L represents a single bond,      or a salt thereof.                                       

 

                                                                                                                                                             Appendix 4 to Exhibit A                                                               Elacestrant Contracts as of the Effective Date                                  1. Companion Diagnostics Master Collaboration Agreement, by and between Guardant Health, Inc.      and Radius Pharmaceuticals, Inc., dated as of July 8, 2020  2. Master Services Agreement, by and between Radius Health, Inc. and Guardant Health, Inc., dated     as of September 14, 2016 and amended October 22, 2018  3. Patient Referral Agreement, by and between Radius Health, Inc. and Guardant Health, Inc., dated as     of February 7, 2020  4. Master Services Agreement, by and between Radius Health, Inc. and Mayne Pharma Inc., d/b/a     Metrics Contract Services, dated as of October 30, 2015 and amended August 12, 2019  5. Master Services Agreement, by and between Radius Health, Inc. and Sambi Pharma PVT Ltd, dated     as of January 7, 2020  6. Professional Services Agreement, by and between Radius Health, Inc. and Link2Trials B.V., dated     as of May 1, 2019  7. Development and Manufacturing Services Agreement, by and between Radius Pharmaceuticals,      Inc. and Asymchem, Inc., dated as of October 17, 2018  8. Master Services Agreement, by and between Radius Health, Inc. and Sai Life Sciences Limited,     dated as of May 13, 2016  9. Master Services Agreement, by and between Radius Health, Inc. and ARC Trinova Limited trading     as “Arcinova”, dated as of October 16, 2018  10. Master Services Agreement, by and between Radius Health, Inc. and CRF Health Management     Limited, dated as of May 8, 2018  11. Master Agreement for Pharmaceutical Development and Technology Transfer Services, by and     between Patheon, Inc. and Radius Pharmaceuticals, Inc., dated as of March 27, 2017  12. Master Clinical Contract Services Agreement, by and between Radius Health, Inc. and Parexel     International (IRL) Limited, dated as of April 24, 2015 and amended April 24, 2018, but only with     respect to Statement of Work RAD1901-308 dated as of December 14, 2017                                                    

 

                                                                                                                                                                                                                                                       Appendix 5 to Exhibit A                                                                                                                       Patents                                                                                                                                  Filing                           Patent    Issue   Type   Country     Title        Application No.          Appl. Type    Status                          Ownership                                                     Date                              No.      Date    1901 THERAPEUTIC REGIMENS           United                                      12-                  Therapeutic                                                                          Radius Health,  Patent  States                    61/334,095       May-   Provisional   Expired       --        --                   Regimens                                                                                  Inc.           PRV                                        10                                                       12-                  Therapeutic                                 Non-                                     Radius Health,  Patent   PCT                  PCT/US2011/036311    May-                 Expired       --        --                   Regimens                                 Provisional                                      Inc.                                                      10                                                        9-      Nat’l          United   Therapeutic                                                                          Radius Health,  Patent                            13/697,230       Nov-    Phase of   Abandoned       --        --          States   Regimens                                                                                  Inc.                                                      12       PCT           United                                      19-                                        31-        Radius                   Therapeutic                              CON of US  Patent  States                    14/281,475       May-                 Issued     9,555,014  Jan-   Pharmaceuticals,                   Regimens                                 13/697,230          CON                                        14                                         17          Inc.                                                       12-      Nat’l                   Therapeutic                                                                          Radius Health,  Patent  Canada                     2799183         May-    Phase of   Abandoned       --        --                   Regimens                                                                                  Inc.                                                      11       PCT                                   

 

                                                                                                                                                                             Filing                           Patent    Issue   Type   Country     Title        Application No.          Appl. Type    Status                          Ownership                                                     Date                              No.      Date    1901 THERAPEUTIC REGIMENS                                                                         Abandoned                                                     12-      Nat’l                             20-                  Therapeutic                                              all                         Radius Health,  Patent  Europe                    11781299.0       May-    Phase of                2568806    Mar-                  Regimens                                              Validation                          Inc.                                                      11       PCT                               13                                                                         countries                                                       12-                                        18-        Radius          Europe   Therapeutic                               DIV of EP  Patent                            16163037.1       May-               Abandoned    3106159    Nov-   Pharmaceuticals,            DIV    Regimens                                    ‘299                                                      11                                         16          Inc.                                                       12-      Nat’l                             8-                  Therapeutic                                                                          Radius Health,  Patent  Mexico                 MX/a/2012/013014    May-    Phase of     Issued      342898    Nov-                  Regimens                                                                                  Inc.                                                      11       PCT                               12                                                                                                           Filing                        Patent   Issue   Type    Country       Title         Application No.           Appl. Type   Status                       Ownership                                                          Date                           No.      Date   1901 HF: MOT HOT FLASHES                     Treatment of                    vasomotor           United   symptoms with                          22-                                               Radius  Patent   States   Selective            60/816,191       Jun-   Provisional Expired      --       --   Pharmaceuticals,            PRV     estrogen                               06                                                 Inc.                    receptor                    modulators                                   

 

                                                                                                                                                                                  Filing                        Patent   Issue   Type    Country       Title         Application No.           Appl. Type   Status                       Ownership                                                          Date                           No.      Date   1901 HF: MOT HOT FLASHES                     Treatment of                    vasomotor                    symptoms with                          22-                                               Radius                                                                    Non- Patent    PCT     Selective       PCT/US2007/014598     Jun-               Expired      --       --   Pharmaceuticals,                                                                 Provisional                    estrogen                               07                                                 Inc.                    receptor                    modulators                    Treatment of                    vasomotor                    symptoms with                          22-      Nat'l                          2-        Radius  Patent   Canada   Selective            2,656,067        Jun-    Phase of    Issued  2,656,067   Jan-  Pharmaceuticals,                    estrogen                               07     '598 PCT                         14         Inc.                    receptor                    modulators                    Treatment of                    vasomotor                                                                  Validation                    symptoms with                          22-                                     1-        Radius                                                                     of  Patent Switzerland Selective          07796378.3        Jun-                Issued   2037905   May-   Pharmaceuticals,                                                                  2037905                    estrogen                               07                                      13         Inc.                                                                   Patent                    receptor                    modulators                    Treatment of                    vasomotor                                                                  Validation                    symptoms with                          22-                                     1-        Radius                                                                     of  Patent  Germany   Selective           07796378.3        Jun-                Issued   2037905   May-   Pharmaceuticals,                                                                  2037905                    estrogen                               07                                      13         Inc.                                                                   Patent                    receptor                    modulators                                   

 

                                                                                                                                                                                  Filing                        Patent   Issue   Type    Country       Title         Application No.           Appl. Type   Status                       Ownership                                                          Date                           No.      Date   1901 HF: MOT HOT FLASHES                     Treatment of                    vasomotor                    symptoms with                          22-      Nat'l                          1-        Radius  Patent   Europe   Selective           07796378.3        Jun-    Phase of    Issued   2037905   May-   Pharmaceuticals,                    estrogen                               07     '598 PCT                         13         Inc.                    receptor                    modulators                    Treatment of                    vasomotor                                                                  Validation                    symptoms with                          22-                                     1-        Radius                                                                     of  Patent    Spain   Selective           07796378.3        Jun-                Issued   2037905   May-   Pharmaceuticals,                                                                  2037905                    estrogen                               07                                      13         Inc.                                                                   Patent                    receptor                    modulators                    Treatment of                    vasomotor                                                                  Validation                    symptoms with                          22-                                     1-        Radius                                                                     of  Patent   France   Selective           07796378.3        Jun-                Issued   2037905   May-   Pharmaceuticals,                                                                  2037905                    estrogen                               07                                      13         Inc.                                                                   Patent                    receptor                    modulators                    Treatment of                    vasomotor                                                                  Validation                    symptoms with                          22-                                     1-        Radius            Great                                                    of  Patent            Selective           07796378.3        Jun-                Issued   2037905   May-   Pharmaceuticals,           Britain                                                2037905                    estrogen                               07                                      13         Inc.                                                                   Patent                    receptor                    modulators                                   

 

                                                                                                                                                                                  Filing                        Patent   Issue   Type    Country       Title         Application No.           Appl. Type   Status                       Ownership                                                          Date                           No.      Date   1901 HF: MOT HOT FLASHES                     Treatment of                    vasomotor                                                                  Validation                    symptoms with                          22-                                     1-        Radius                                                                     of  Patent   Ireland  Selective           07796378.3        Jun-                Issued   2037905   May-   Pharmaceuticals,                                                                  2037905                    estrogen                               07                                      13         Inc.                                                                   Patent                    receptor                    modulators                    Treatment of                    vasomotor                                                                  Validation                    symptoms with                          22-                                     1-        Radius                                                                     of  Patent    Italy   Selective           07796378.3        Jun-                Issued   2037905   May-   Pharmaceuticals,                                                                  2037905                    estrogen                               07                                      13         Inc.                                                                   Patent                    receptor                    modulators                    Treatment of                    vasomotor           United   symptoms with                          27-      Nat'l                         13-        Radius  Patent   States   Selective            12/308,640       Oct-    Phase of    Issued  8,933,130   Jan-  Pharmaceuticals,             NP     estrogen                               09     '598 PCT                         15         Inc.                    receptor                    modulators                                                                   

 

                                                                                                                                                                            Filing                               Patent  Issue   Type    Country      Title     Application No.             Appl. Type       Status                      Ownership                                                    Date                                   No.    Date   1901 ER MUTANTS                      Methods           United                                    29-                                                     Radius                     of  Patent    States                  62/154,699       Apr-     Provisional      Expired      --     --   Pharmaceuticals,                     Treating            PRV                                      15                                                       Inc.                     Cancer                      Methods           United                                    30-                                                     Radius                     of  Patent    States                  62/155,451       Apr-     Provisional      Expired      --     --   Pharmaceuticals,                     Treating            PRV                                      15                                                       Inc.                     Cancer                      Methods           United                                     6-                                                     Radius                     of  Patent    States                  62/252,085      Nov-      Provisional      Expired      --     --   Pharmaceuticals,                     Treating            PRV                                      15                                                       Inc.                     Cancer                      Methods           United                                    10-                                                     Radius                     of  Patent    States                  62/265,696      Dec-      Provisional      Expired      --     --   Pharmaceuticals,                     Treating            PRV                                      15                                                       Inc.                     Cancer                      Methods                                                     29-                                                     Radius                     of  Patent    PCT                 PCT/US2016/30317     Apr-   Non-Provisional    Expired      --     --   Pharmaceuticals,                     Treating                                                     16                                                       Inc.                     Cancer                                   

 

                                                                                                                                                                            Filing                               Patent  Issue   Type    Country      Title     Application No.             Appl. Type       Status                      Ownership                                                    Date                                   No.    Date   1901 ER MUTANTS                      Methods                                                     29-     Nat'l phase of                                  Radius                     of  Patent  Australia                2016256470        Apr-     PCT/US16/       Pending       --     --   Pharmaceuticals,                     Treating                                                     16         30317                                         Inc.                     Cancer                      Methods                                                     29-     Nat'l phase of                                  Radius                     of         BR 112017023233- Patent    Brazil                                   Apr-     PCT/US16/       Published     --     --   Pharmaceuticals,                     Treating           2                                                     16         30317                                         Inc.                     Cancer                      Methods                                                     29-     Nat'l phase of                                  Radius                     of  Patent   Canada                   2,984,195        Apr-     PCT/US16/       Pending       --     --   Pharmaceuticals,                     Treating                                                     16         30317                                         Inc.                     Cancer                      Methods                                                     29-     Nat'l phase of                                  Radius                     of  Patent    China                201680038908.9      Apr-     PCT/US16/       Published     --     --   Pharmaceuticals,                     Treating                                                     16         30317                                         Inc.                     Cancer                      Methods                                                     29-     Nat'l phase of                                  Radius                     of  Patent   Europe                   16787290.2       Apr-     PCT/US16/       Published     --     --   Pharmaceuticals,                     Treating                                                     16         30317                                         Inc.                     Cancer                                   

 

                                                                                                                                                                            Filing                               Patent  Issue   Type    Country      Title     Application No.             Appl. Type       Status                      Ownership                                                    Date                                   No.    Date   1901 ER MUTANTS                      Methods                                                     29-                                                     Radius            Hong     of                                        OFF EP  Patent                            18110956.1       Apr-                     Published     --     --   Pharmaceuticals,            Kong     Treating                                 16787290.2                                                     16                                                       Inc.                     Cancer                      Methods                                                     29-     Nat'l phase of                                  Radius                     of  Patent    Israel                    255148         Apr-     PCT/US16/       Published     --     --   Pharmaceuticals,                     Treating                                                     16         30317                                         Inc.                     Cancer                      Methods                                                     29-                                                     Radius                     of                                      Nat'l phase of  Patent    Japan                  2018-509731       Apr-                     Published     --     --   Pharmaceuticals,                     Treating                              PCT/US16/30317                                                     16                                                       Inc.                     Cancer                      Methods                                                     29-     Nat'l phase of                                  Radius            South    of  Patent                         10-2017-7034603     Apr-     PCT/US16/       Published     --     --   Pharmaceuticals,            Korea    Treating                                                     16         30317                                         Inc.                     Cancer                      Methods                                                     29-     Nat'l phase of                                  Radius                     of  Patent   Mexico               MX/a/2017/013801     Apr-     PCT/US16/       Pending       --     --   Pharmaceuticals,                     Treating                                                     16         30317                                         Inc.                     Cancer                                   

 

                                                                                                                                                                            Filing                               Patent  Issue   Type    Country      Title     Application No.             Appl. Type       Status                      Ownership                                                    Date                                   No.    Date   1901 ER MUTANTS                      Methods                                                     29-     Nat'l phase of                                  Radius            New      of  Patent                              737825         Apr-     PCT/US16/       Pending       --     --   Pharmaceuticals,           Zealand   Treating                                                     16         30317                                         Inc.                     Cancer                      Methods                                                     29-     Nat'l phase of                                  Radius           Russian   of  Patent                           2017140674        Apr-     PCT/US16/       Pending       --     --   Pharmaceuticals,          Federation Treating                                                     16         30317                                         Inc.                     Cancer                      Methods                                                     29-     Nat'l phase of                                  Radius                     of  Patent  Singapore               11201708858W       Apr-     PCT/US16/      Abandoned      --     --   Pharmaceuticals,                     Treating                                                     16         30317                                         Inc.                     Cancer                      Methods                                                     29-                                                     Radius          Singapore  of  Patent                          10201903993U       Apr-      Divisional     Published                 Pharmaceuticals,          Divisional Treating                                                     16                                                       Inc.                     Cancer            United                     Methods            States                                   26-        CON of                                       Radius                     of  Patent    CON                     15/794,774       Oct-     PCT/US16/       Published     --     --   Pharmaceuticals,                     Treating           CON of                                    17         30317                                         Inc.                     Cancer            PCT                                                  

 

                                                                                                                                                                                                Filing                           Patent  Issue  Type     Country        Title       Application No.           Appl. Type    Status                       Ownership                                                         Date                             No.    Date   1901 COMBINATION W/ CDK 4/6 INHIBITOR              United    Methods for                        15-                                                 Radius  Patent    States    Treating          62/192,940       Jul-   Provisional   Expired      --      --   Pharmaceuticals,             PRV      Cancer                              15                                                   Inc.              United    Methods for                        10-                                                 Radius  Patent    States    Treating          62/265,658       Dec-   Provisional   Expired      --      --   Pharmaceuticals,             PRV      Cancer                              15                                                   Inc.              United    Methods for                        15-                                                 Radius  Patent    States    Treating          62/323,572       Apr-   Provisional   Expired      --      --   Pharmaceuticals,             PRV      Cancer                              16                                                   Inc.                        Methods for                        29-                                                 Radius                                                                   Non- Patent     PCT      Treating      PCT/US2016/30321     Apr-                 Expired      --      --   Pharmaceuticals,                                                                Provisional                      Cancer                              16                                                   Inc.                                                                 Nat'l Phase                      Methods for                        29-                                                 Radius                                                                    of  Patent   Australia  Treating         2016256471        Apr-                 Pending      --      --   Pharmaceuticals,                                                                PCT/US16/                      Cancer                              16                                                   Inc.                                                                  30321                                   

 

                                                                                                                                                                                Filing                           Patent  Issue  Type     Country        Title       Application No.           Appl. Type    Status                       Ownership                                                         Date                             No.    Date   1901 COMBINATION W/ CDK 4/6 INHIBITOR                                                                  Nat'l Phase                      Methods for                        29-                                                 Radius                                            BR                      of  Patent    Brazil    Treating                           Apr-                Published     --      --   Pharmaceuticals,                                     112017023269-3             PCT/US16/                      Cancer                              16                                                   Inc.                                                                  30321                                                                 Nat'l Phase                      Methods for                        29-                                                 Radius                                                                    of  Patent   Canada     Treating          2,984,200        Apr-                 Pending      --      --   Pharmaceuticals,                                                                PCT/US16/                      Cancer                              16                                                   Inc.                                                                  30321                                                                 Nat'l Phase                      Methods for                        29-                                                 Radius                                                                    of  Patent    China     Treating       201680039059.9      Apr-                Published     --      --   Pharmaceuticals,                                                                PCT/US16/                      Cancer                              16                                                   Inc.                                                                  30321                                                                 Nat'l Phase                      Methods for                        29-                                                 Radius                                                                    of  Patent   Europe     Treating          16787291.0       Apr-                Published     --      --   Pharmaceuticals,                                                                PCT/US16/                      Cancer                              16                                                   Inc.                                                                  30321                       Methods for                        29-                                                 Radius            Hong                                                 OFF EP  Patent              Treating          18110957.0       Apr-                Published     --      --   Pharmaceuticals,            Kong                                               16787291.0                      Cancer                              16                                                   Inc.                                   

 

                                                                                                                                                                                Filing                           Patent  Issue  Type     Country        Title       Application No.           Appl. Type    Status                       Ownership                                                         Date                             No.    Date   1901 COMBINATION W/ CDK 4/6 INHIBITOR                                                                  Nat'l Phase                      Methods for                        29-                                                 Radius                                                                    of  Patent    Israel    Treating            255189         Apr-                 Pending      --      --   Pharmaceuticals,                                                                PCT/US16/                      Cancer                              16                                                   Inc.                                                                  30321                                                                 Nat'l Phase                      Methods for                        29-                                                 Radius                                                                    of  Patent    Japan     Treating         2018-509732       Apr-                Published     --      --   Pharmaceuticals,                                                                PCT/US16/                      Cancer                              16                                                   Inc.                                                                  30321                                                                 Nat'l Phase                      Methods for                        29-                                                 Radius            South                                                   of  Patent              Treating       10-2017-7034606     Apr-                Published     --      --   Pharmaceuticals,            Korea                                               PCT/US16/                      Cancer                              16                                                   Inc.                                                                  30321                                                                 Nat'l Phase                      Methods for                        29-                                                 Radius                                                                    of  Patent   Mexico     Treating      MX/a/2017/013802     Apr-                 Pending      --      --   Pharmaceuticals,                                                                PCT/US16/                      Cancer                              16                                                   Inc.                                                                  30321                                                                 Nat'l Phase                      Methods for                        29-                                                 Radius             New                                                    of  Patent              Treating            737822         Apr-                 Pending      --      --   Pharmaceuticals,           Zealand                                              PCT/US16/                      Cancer                              16                                                   Inc.                                                                  30321                                   

 

                                                                                                                                                                                Filing                           Patent  Issue  Type     Country        Title       Application No.           Appl. Type    Status                       Ownership                                                         Date                             No.    Date   1901 COMBINATION W/ CDK 4/6 INHIBITOR                                                                  Nat'l Phase                      Methods for                        29-                                                 Radius           Russian                                                  of  Patent              Treating         2017140675        Apr-                 Pending      --      --   Pharmaceuticals,          Federation                                            PCT/US16/                      Cancer                              16                                                   Inc.                                                                  30321                                                                 Nat'l Phase                      Methods for                        29-                                                 Radius                                                                    of  Patent  Singapore   Treating        11201708860S       Apr-                 Pending      --      --   Pharmaceuticals,                                                                PCT/US16/                      Cancer                              16                                                   Inc.                                                                  30321             United    Methods for                        24-                                                 Radius                                                                CON of US  Patent    States    Treating          16/580,914       Sep-                Published     --      --   Pharmaceuticals,                                                                15/794,861            CON 2     Cancer                              19                                                   Inc.             United                      Methods for                        26-     CON of                                      Radius            States  Patent              Treating          15/794,861       Oct-   PCT/US16/   Abandoned      --      ..   Pharmaceuticals,            CON                      Cancer                              17      30321                                        Inc.           of PCT                                                                    

 

                                                                                                                                                                                Filing                          Patent   Issue  Type     Country        Title       Application No.           Appl. Type    Status                       Ownership                                                        Date                              No.    Date   1901 COMBINATION W/ M-TOR INHIBITORS             United    Methods for                        15-                                                 Radius  Patent    States    Treating          62/192,944       Jul-  Provisional    Expired      --     --    Pharmaceuticals,             PRV      Cancer                              15                                                  Inc.              United    Methods for                        10-                                                 Radius  Patent    States    Treating          62/265,663      Dec-   Provisional    Expired      --     --    Pharmaceuticals,             PRV      Cancer                              15                                                  Inc.              United    Methods for                        15-                                                 Radius  Patent    States    Treating          62/323,576       Apr-  Provisional    Expired      --     --    Pharmaceuticals,             PRV      Cancer                              16                                                  Inc.                        Methods for                        29-                                                 Radius                                                                  Non- Patent     PCT      Treating      PCT/US2016/30316     Apr-                 Expired      --     --    Pharmaceuticals,                                                               Provisional                      Cancer                              16                                                  Inc.                                                                Nat'l phase                      Methods for                        29-                                                 Radius                                                                    of  Patent   Australia  Treating         2016256469        Apr-                Pending       --     --    Pharmaceuticals,                                                               PCT/US16/                      Cancer                              16                                                  Inc.                                                                  30316                                   

 

                                                                                                                                                                                Filing                          Patent   Issue  Type     Country        Title       Application No.           Appl. Type    Status                       Ownership                                                        Date                              No.    Date   1901 COMBINATION W/ M-TOR INHIBITORS                                                                Nat'l phase                      Methods for                        29-                                                 Radius                                            BR                      of  Patent    Brazil    Treating                           Apr-                Published     --     --    Pharmaceuticals,                                     112017023228-6            PCT/US16/                      Cancer                              16                                                  Inc.                                                                  30316                                                                Nat'l phase                      Methods for                        29-                                                 Radius                                                                    of  Patent   Canada     Treating           2,984,357       Apr-                Pending       --     --    Pharmaceuticals,                                                               PCT/US16/                      Cancer                              16                                                  Inc.                                                                  30316                                                                Nat'l phase                      Methods for                        29-                                                 Radius                                                                    of  Patent    China     Treating       201680038907.4      Apr-                Published     --     --    Pharmaceuticals,                                                               PCT/US16/                      Cancer                              16                                                  Inc.                                                                  30316                                                                Nat'l phase                      Methods for                        29-                                                 Radius                                                                    of  Patent   Europe     Treating          16787289.4       Apr-                Published     --     --    Pharmaceuticals,                                                               PCT/US16/                      Cancer                              16                                                  Inc.                                                                  30316                       Methods for                        29-                                                 Radius            Hong                                                 OFF EP  Patent              Treating          18110955.2       Apr-                Published     --     --    Pharmaceuticals,            Kong                                               16787289.4                      Cancer                              16                                                  Inc.                                   

 

                                                                                                                                                                                Filing                          Patent   Issue  Type     Country        Title       Application No.           Appl. Type    Status                       Ownership                                                        Date                              No.    Date   1901 COMBINATION W/ M-TOR INHIBITORS                                                                Nat'l phase                      Methods for                        29-                                                 Radius                                                                    of  Patent    Israel    Treating            255261         Apr-                Pending       --     --    Pharmaceuticals,                                                               PCT/US16/                      Cancer                              16                                                  Inc.                                                                  30316                                                                Nat'l phase                      Methods for                        29-                                                 Radius                                                                    of  Patent    Japan     Treating         2017-556627       Apr-                Published     --     --    Pharmaceuticals,                                                               PCT/US16/                      Cancer                              16                                                  Inc.                                                                  30316                                                                Nat'l phase                      Methods for                        29-                                                 Radius            South                                                   of  Patent              Treating       10-2017-7034608     Apr-                Published     --     --    Pharmaceuticals,            Korea                                              PCT/US16/                      Cancer                              16                                                  Inc.                                                                  30316                                                                Nat'l phase                      Methods for                        29-                                                 Radius                                                                    of  Patent   Mexico     Treating      MX/a/2017/013794     Apr-                Pending       --     --    Pharmaceuticals,                                                               PCT/US16/                      Cancer                              16                                                  Inc.                                                                  30316                                                                Nat'l phase                      Methods for                        29-                                                 Radius             New                                                    of  Patent              Treating            737819         Apr-                Pending       --     --    Pharmaceuticals,           Zealand                                             PCT/US16/                      Cancer                              16                                                  Inc.                                                                  30316                                   

 

                                                                                                                                                                                Filing                          Patent   Issue  Type     Country        Title       Application No.           Appl. Type    Status                       Ownership                                                        Date                              No.    Date   1901 COMBINATION W/ M-TOR INHIBITORS                                                                Nat'l phase                      Methods for                        29-                                                 Radius           Russian                                                  of  Patent              Treating         2017140676        Apr-                Pending       --     --    Pharmaceuticals,          Federation                                           PCT/US16/                      Cancer                              16                                                  Inc.                                                                  30316                                                                Nat'l phase                      Methods for                        29-                                                 Radius                                                                    of  Patent  Singapore   Treating        11201708861V       Apr-                Pending       --     --    Pharmaceuticals,                                                               PCT/US16/                      Cancer                              16                                                  Inc.                                                                  30316             United                                             Nat'l phase                      Methods for                        26-                                                 Radius            States                                                  of  Patent              Treating          15/794,910       Oct-               Abandoned                   Pharmaceuticals,            CON                                                PCT/US16/                      Cancer                            2017                                                  Inc.           of PCT                                                 30316             United                      Methods For                        20-                                                 Radius            States                                               CON of  Patent              Treating          16/545,859      Aug-                 Published     --      --   Pharmaceuticals,            CON                                                15/794,910                      Cancer                              19                                                  Inc.          of 439320                                                                    

 

                                                                                                                                                                              Filing                          Patent      Issue   Type   Country      Title        Application No.           Appl. Type    Status                            Ownership                                                       Date                             No.       Date  1901 POLYMORPHS                      Polymorphic           United                                       5-                                                      Radius                    Forms of  Patent   States                    62/442,921        Jan-   Provisional  Expired       --         --     Pharmaceuticals,                    RAD1901-           PRV                                         17                                                       Inc.                    2HCL                     Polymorphic                                                        5-                                                      Radius           United   Forms of                                     Non  Patent                             15/863,850        Jan-                Issued    10385008   8/20/2019  Pharmaceuticals,           States   RAD1901-                                  Provisional                                                        18                                                       Inc.                    2HCL                     Polymorphic                                                       28-                                                      Radius           United   Forms of  Patent                             16/456,314        Jun-   Divisional   Allowed       --         --     Pharmaceuticals,           States   RAD1901-                                                       19                                                       Inc.                    2HCL                     Polymorphic                                                        6-                                                      Radius           United   Forms of  Patent                             16/921,684        July-  Divisional   Pending       --         --     Pharmaceuticals,          States   RAD1901-                                                       20                                                       Inc.                    2HCL                     Polymorphic                                                        5-                                                      Radius                    Forms of                                    Non- Patent    PCT                  PCT/US2018/012714     Jan-                Expired       --         --     Pharmaceuticals,                    RAD1901-                                  Provisional                                                        18                                                       Inc.                    2HCL                                   

 

                                                                                                                                                                              Filing                          Patent      Issue   Type   Country      Title        Application No.           Appl. Type    Status                            Ownership                                                       Date                             No.       Date  1901 POLYMORPHS                      Polymorphic                                                        5-                                                      Radius                    Forms of  Patent  Australia                AU 2018205285       Jan-   NP of PCT    Pending      --          --     Pharmaceuticals,                    RAD1901-                                                       18                                                       Inc.                    2HCL                     Polymorphic                                                        5-                                                      Radius                    Forms of  Patent  Canada                       3047411         Jan-   NP of PCT    Pending       --         --     Pharmaceuticals,                    RAD1901-                                                       18                                                       Inc.                    2HCL                     Polymorphic                                                        5-                                                      Radius                    Forms of  Patent   China                   201880006119.6      Jan-   NP of PCT   Published      --         --     Pharmaceuticals,                    RAD1901-                                                       18                                                       Inc.                     2HCL                     Polymorphic                                                        5-                                                      Radius                    Forms of        EP 18736577.0  Patent  Europe                                       Jan-   NP of PCT   Published      --         --     Pharmaceuticals,                    RAD1901-           3565542                                                        18                                                       Inc.                    2HCL                     Polymorphic                                                        5-     OFF EP                                           Radius           Hong     Forms of  Patent                            62020005942.1      Jan-      EP        Pending       --         --     Pharmaceuticals,           Kong     RAD1901-                                                       18   18736577.0                                          Inc.                    2HCL                                   

 

                                                                                                                                                                              Filing                          Patent      Issue   Type   Country      Title        Application No.           Appl. Type    Status                            Ownership                                                       Date                             No.       Date  1901 POLYMORPHS                      Polymorphic                                                        5-                                                      Radius                    Forms of  Patent   Israel                     IL 267772        Jan-   NP of PCT   Published     --          --     Pharmaceuticals,                    RAD1901-                                                       18                                                       Inc.                    2HCL                     Polymorphic                                                        5-                                                      Radius                    Forms of  Patent   Japan                   JP 2019-536266      Jan-   NP of PCT   Published      --         --     Pharmaceuticals,                    RAD1901-                                                       18                                                       Inc.                     2HCL                     Polymorphic                                                        5-                                                      Radius           South    Forms of         KR 10-2019- Patent                                               Jan-   NP of PCT   Published      --         --     Pharmaceuticals,           Korea    RAD1901-           7022624                                                        18                                                       Inc.                    2HCL                     Polymorphic                                                        5-                                                      Radius                    Forms of  Patent   Mexico                 MX/a/2019/007748     Jan-   NP of PCT    Pending       --         --     Pharmaceuticals,                    RAD1901-                                                       18                                                       Inc.                    2HCL                                                                      

 

                                                                                                                                                                            Filing                          Patent     Issue   Type   Country       Title      Application No.          Appl. Type    Status                           Ownership                                                     Date                             No.       Date   1901 POLYMORPHS (PATTERN B)                    Polymorphic           United                                                                                            Radius                   Forms of                         4-Jul- Patent   States                    62/694,003             Provisional  Expired       --        --     Pharmaceuticals,                   RAD1901-                           18           PRV                                                                                                Inc.                   2HCL                    Polymorphic                                                               PCT                                            Radius                   Forms of         PCT/US2019/     3-Jul- Patent   PCT                                                30 mo.    Published      --        --     Pharmaceuticals,                   RAD1901-            040527         19                                                             4-Jan-21                                         Inc.                   2HCL                                                      

 

                                                                                                                                                                              Filing                          Patent    Issue   Type    Country        Title      Application No.          Appl. Type    Status                         Ownership                                                      Date                             No.      Date   1901 MOT OVARIAN CANCER                       Methods for            United                                     27-                                                    Radius                      Treating  Patent    States                     62/400,495     Sep-    Provisional  Expired      --        --    Pharmaceuticals,                      Ovarian             PRV                                       16                                                     Inc.                      Cancer                       Methods for                                                       27-                     Treating        PCT/US2017/                Non-                                     Radius Health,  Patent     PCT                                      Sep-                 Expired      --        --                      Ovarian           053834                Provisional                                     Inc.                                                       17                      Cancer                       Methods for                                                       27-                     Treating                                                                            Radius Health,  Patent   Australia                 AU 2017336564    Sep-    NP of PCT    Pending       --      --                       Ovarian                                                                                 Inc.                                                       17                      Cancer                       Methods for                                          BR           27-                     Treating                                                                            Radius Health,  Patent    Brazil                      11 2019       Sep-    NP of PCT   Published      --       --                      Ovarian                                                                                 Inc.                                        004276-8       17                      Cancer                       Methods for                                                       27-                     Treating                                                                            Radius Health,  Patent   Canada                     CA 3036568      Sep-    NP of PCT    Pending       --      --                       Ovarian                                                                                 Inc.                                                       17                      Cancer                                   

 

                                                                                                                                                                              Filing                          Patent    Issue   Type    Country        Title      Application No.          Appl. Type    Status                         Ownership                                                      Date                             No.      Date   1901 MOT OVARIAN CANCER                       Methods for                                                       27-                     Treating            CN                                                              Radius Health,  Patent    China                                     Sep-    NP of PCT   Published      --       --                      Ovarian       201780058319.1                                                            Inc.                                                       17                      Cancer                       Methods for                                                       27-                     Treating                                                                           Radius Health,  Patent   Europe                    EP 17857371.3    Sep-    NP of PCT   Published      --       --                      Ovarian                                                                                 Inc.                                                        17                      Cancer                       Methods for                                                       27-           Hong      Treating                                 OFF EP                                     Radius Health,  Patent                               19129832.2     Sep-                 Pending       --       --            Kong      Ovarian                                 17857371.3                                      Inc.                                                       17                      Cancer                       Methods for                                                       27-                     Treating                                                                            Radius Health,  Patent    Israel                     IL 265537      Sep-    NP of PCT    Pending       --       --                      Ovarian                                                                                 Inc.                                                       17                      Cancer                       Methods for                                                       27-                     Treating                                                                            Radius Health,  Patent    Japan                   JP 2019-515854    Sep-    NP of PCT   Published      --       --                      Ovarian                                                                                 Inc.                                                       17                      Cancer                                   

 

                                                                                                                                                                              Filing                          Patent    Issue   Type    Country        Title      Application No.          Appl. Type    Status                         Ownership                                                      Date                             No.      Date   1901 MOT OVARIAN CANCER                       Methods for                                                       27-           South     Treating        KR 10-2019-                                                         Radius Health,  Patent                                              Sep-    NP of PCT   Published     --        --            Korea     Ovarian           7011747                                                               Inc.                                                       17                      Cancer                       Methods for                                                       27-                     Treating         MX/a/2019/                                                        Radius Health,  Patent   Mexico                                     Sep-    NP of PCT    Pending       --       --                      Ovarian           003311                                                                Inc.                                                        17                      Cancer                       Methods for                                                       27-            New      Treating                                                                            Radius Health,  Patent                               NZ 751032      Sep-    NP of PCT    Pending       --       --           Zealand    Ovarian                                                                                 Inc.                                                       17                      Cancer                       Methods for                                                       27-          Russian    Treating                                                                            Radius Health,  Patent                            RU 2019108382     Sep-    NP of PCT    Pending       --       --          Federation  Ovarian                                                                                 Inc.                                                       17                      Cancer                       Methods for                                                       27-                     Treating            SG                                                             Radius Health,  Patent  Singapore                                   Sep-    NP of PCT    Pending       --       --                      Ovarian         1120190759X                                                             Inc.                                                       17                      Cancer                                   

 

                                                                                                                                                                              Filing                          Patent    Issue   Type    Country        Title      Application No.          Appl. Type    Status                         Ownership                                                      Date                             No.      Date   1901 MOT OVARIAN CANCER                       Methods for                                                       25-                                                    Radius            United    Treating  Patent                               16/336,358     Mar-    NP of PCT   Published      --      --     Pharmaceuticals,          States NP   Ovarian                                                       19                                                     Inc.                      Cancer                                                                                                     Filing                          Patent     Issue  Type    Country        Title     Application No.          Appl. Type    Status                           Ownership                                                    Date                              No.       Date   1901 + ABEMACICLIB                     Elacestrant In                    Combination           United                                                                                            Radius                    With                             30- Patent   States                    62/773,960             Provisional  Expired       --        --     Pharmaceuticals,                    Abemaciclib In                 Nov-18            PRV                                                                                               Inc.                    Women With                    Breast Cancer                    Elacestrant In                    Combination                                                               PCT                                           Radius                    With            PCT/US2019/      26- Patent    PCT                                               30-mo.    Published      --        --     Pharmaceuticals,                    Abemaciclib In     063239      Nov-19                                                            30-May-21                                         Inc.                     Women With                    Breast Cancer                                                                                                   

 

                                                                                                                                                                            Filing                          Patent     Issue  Type    Country        Title     Application No.          Appl. Type    Status                           Ownership                                                    Date                              No.       Date   1901 RESISTANT TO CDK 4/6 INHIBITORS                     Anti-Tumor                    Activity of           United   Elacestrant in                                                                           Radius                                                    6-Dec- Patent   States   Models           62/776,323             Provisional  Expired       --        --     Pharmaceuticals,                                                     18            PRV     Resistant to                                                                              Inc.                    CDK 4/6                    Inhibitors                    Anti-Tumor                    Activity of                    Elacestrant in                             PCT                                           Radius                                    PCT/US2019/     6-Dec- Patent    PCT     Models                                   30 mo. 6-  Published      --        --     Pharmaceuticals,                                       065005        19                    Resistant to                             June-21                                          Inc.                     CDK 4/6                    Inhibitors                                                     

 

                                                                                                                                                              Application    Filing                          Patent     Issue  Type     Country        Title                              Appl. Type   Status                           Ownership                                          No.        Date                             No.       Date   1901 ESR1 MUTATIONS                     Anti-Tumor                    Activity of                    Elacestrant in                    Models           United                                                                                            Radius                    Harboring                       6-Dec- Patent   States                     62/776,338             Provisional  Expired      --        --     Pharmaceuticals,                    ESR1                              18            PRV                                                                                               Inc.                    Mutations                    Resistant to                    Standard of                    Care Therapies                   Anti-Tumor                    Activity of                    Elacestrant in                    Models                                                               PCT                                           Radius                    Harboring        PCT/US2019/    6-Dec- Patent    PCT                                              30-mo. 6-   Published     --        --     Pharmaceuticals,                    ESR1                064980        19                                                              June-21                                         Inc.                     Mutations                    Resistant to                    Standard of                    Care Therapies                                                    

 

                                                                                                                                                                              Filing                                    Issue  Type    Country         Title      Application No.          Appl. Type   Status   Patent No.            Ownership                                                      Date                                      Date   1901 PROCESS CHEMISTRY            United                                                                                           Radius                    Processes and                    12-Feb- Patent   States                     62/804,391              Provisional  Expired      --        --   Pharmaceuticals,                    Compounds                          19            PRV                                                                                              Inc.                                                                   PCT                                        Radius                    Processes and    PCT/US2020/     11-Feb- Patent    PCT                                               30 mo. 12-  Pending       --        --   Pharmaceuticals,                    Compounds           017777         20                                                                Aug-21                                       Inc.                                                                         Application    Filing                                    Issue  Type     Country         Title                               Appl. Type   Status  Patent No.            Ownership                                           No.         Date                                     Date   1902 COMPOSITION OF MATTER                       Compounds            United                                                                                          Radius                      and methods of                 22-Jan- Patent    States                     62/620,441              Provisional Expired       --       --   Pharmaceuticals,                      Using and                         18             PRV                                                                                             Inc.                      Making                       Estrogen                                                                                                            Radius                      Receptor-       PCT/US2019/    22-Jan-     Non- Patent     PCT                                                           Pending       --       --   Pharmaceuticals,                      Modulating         014581         19     Provisional                                                                                                             Inc.                      Compounds                                   

 

                                                                                                                                                               Application    Filing                                    Issue  Type     Country         Title                               Appl. Type   Status  Patent No.            Ownership                                           No.         Date                                     Date   1902 COMPOSITION OF MATTER                       Estrogen                                                                                                            Radius                      Receptor-                       22-Jul- Patent   Australia                      TBD                  NP of PCT  Pending        --       --   Pharmaceuticals,                     Modulating                        20                                                                                                             Inc.                      Compounds                       Estrogen                                                                                                            Radius                      Receptor-                       22-Jul- Patent    Brazil                        TBD                  NP of PCT  Pending        --       --   Pharmaceuticals,                     Modulating                        20                                                                                                             Inc.                      Compounds                       Estrogen                                                                                                            Radius                      Receptor-                       22-Jul- Patent   Canada                         TBD                  NP of PCT  Pending        --       --   Pharmaceuticals,                     Modulating                        20                                                                                                             Inc.                      Compounds                       Estrogen                                                                                                            Radius                      Receptor-                       22-Jul- Patent    China                         TBD                  NP of PCT  Pending        --       --   Pharmaceuticals,                     Modulating                        20                                                                                                             Inc.                      Compounds                       Estrogen                                                                                                            Radius                      Receptor-                       22-Jul- Patent   Europe                         TBD                  NP of PCT  Pending        --       --   Pharmaceuticals,                     Modulating                        20                                                                                                             Inc.                      Compounds                                   

 

                                                                                                                                                               Application    Filing                                    Issue  Type     Country         Title                               Appl. Type   Status  Patent No.            Ownership                                           No.         Date                                     Date   1902 COMPOSITION OF MATTER                       Estrogen                                                                                                            Radius            Hong      Receptor-                       22-Jul- Patent                                  TBD                  NP of PCT  Pending        --       --   Pharmaceuticals,           Kong      Modulating                        20                                                                                                             Inc.                      Compounds                       Estrogen                                                                                                            Radius                      Receptor-                       22-Jul- Patent    Israel                        TBD                  NP of PCT  Pending        --       --   Pharmaceuticals,                     Modulating                        20                                                                                                             Inc.                      Compounds                       Estrogen                                                                                                            Radius                      Receptor-                       22-Jul- Patent    Japan                         TBD                  NP of PCT  Pending        --       --   Pharmaceuticals,                     Modulating                        20                                                                                                             Inc.                      Compounds                       Estrogen                                                                                                            Radius            South     Receptor-                       22-Jul- Patent                                  TBD                  NP of PCT  Pending        --       --   Pharmaceuticals,           Korea     Modulating                        20                                                                                                             Inc.                      Compounds                       Estrogen                                                                                                            Radius                      Receptor-                       22-Jul- Patent   Mexico                         TBD                  NP of PCT  Pending        --       --   Pharmaceuticals,                     Modulating                        20                                                                                                             Inc.                      Compounds                                   

 

                                                                                                                                                               Application    Filing                                    Issue  Type     Country         Title                               Appl. Type   Status  Patent No.            Ownership                                           No.         Date                                     Date   1902 COMPOSITION OF MATTER                       Estrogen                                                                                                            Radius             New      Receptor-                       22-Jul- Patent                                  TBD                  NP of PCT  Pending        --       --   Pharmaceuticals,          Zealand    Modulating                        20                                                                                                             Inc.                      Compounds                       Estrogen                                                                                                            Radius           Russian    Receptor-                       22-Jul- Patent                                  TBD                  NP of PCT  Pending        --       --   Pharmaceuticals,         Federation  Modulating                        20                                                                                                             Inc.                      Compounds                       Estrogen                                                                                                            Radius                      Receptor-                       22-Jul- Patent  Singapore                       TBD                  NP of PCT  Pending        --       --   Pharmaceuticals,                     Modulating                        20                                                                                                             Inc.                      Compounds                       Estrogen                                                                                                            Radius            United    Receptor-                       22-Jul- Patent                                  TBD                  NP of PCT  Pending        --       --   Pharmaceuticals,         States NP   Modulating                        20                                                                                                             Inc.                      Compounds                                                                    

 

                                                                                                                                                              Application    Filing                                    Issue  Type    Country        Title                               Appl. Type   Status   Patent No.             Ownership                                         No.         Date                                       Date   1902 SELECTION                     Estrogen           United                                                                                           Radius                    Receptor-                       22-Jul- Patent   States                     62/876,963             Provisional Pending       --        --    Pharmaceuticals,                    Modulating                        19            PRV                                                                                              Inc.                    Compounds                     Estrogen                                                                                                            Radius                    Receptor-                       22-Jul-     Non- Patent    PCT                          TBD                             Pending       --        --    Pharmaceuticals,                   Modulating                        20     Provisional                                                                                                            Inc.                    Compounds                                                                                                                                                                                                                                                                                

 

                                                                                                                                                                                                                                                                                                    Appendix 6 to Exhibit A                                                                                                                    Patent Rights                                                                         Application                                          Patent  Type     Country         Title                        Filing Date   Appl. Type    Status               Issue Date  Ownership                                            No.                                                No.   1901 EISAI COM   Patent  Australia      Selective      2003292625      25-Dec-03     Nat'l Phase  Issued    20032926    20-Nov-08    Eisai R&D                         Estrogen                                       of PCT                  25                   Manageme                        Receptor                                                                                    nt Co., Ltd.                        Modulator   Patent   Canada        Selective        2512000       25-Dec-03     Nat'l Phase  Issued    2512000     9-Aug-11     Eisai R&D                         Estrogen                                       of PCT                                       Manageme                        Receptor                                                                                    nt Co., Ltd.                        Modulator   Patent   Europe        Selective      03782904.1      25-Dec-03     Nat'l Phase  Issued    1577288     23-Jul-14    Eisai R&D                         Estrogen                                       of PCT      in CH,                           Manageme                        Receptor                                                  DE, GB,                           nt Co., Ltd.                        Modulator                                                  FR, LI,                                                                                     NL                                                                                  11/30/18 Patent   Poland        Selective           --             --            --       Issued     186710         --       Eisai R&D                         Estrogen                                                                                    Manageme                        Receptor                                                                                    nt Co., Ltd.                        Modulator                                   

 

                                                                                                                                                                 Application                                          Patent  Type     Country         Title                        Filing Date   Appl. Type    Status               Issue Date  Ownership                                            No.                                                No.   1901 EISAI COM   Patent    India        Selective      2829/DELNP      25-Dec-03     Nat'l Phase  Issued     323625     24-Oct-19    Eisai R&D                         Estrogen          /2005                        of PCT                                       Manageme                        Receptor                                                                                    nt Co., Ltd.                        Modulator   Patent    Japan        Selective      2004562947      25-Dec-03     Nat'l Phase  Issued    4500689     23-Apr-10    Eisai R&D                         Estrogen                                       of PCT                                       Manageme                        Receptor                                                                                    nt Co., Ltd.                        Modulator   Patent   United        Selective      11/158,245      22-Jun-05     CIP of PCT   Issued    7,612,114   3-Nov-09     Eisai R&D           States        Estrogen                                                                                    Manageme                        Receptor                                                                                    nt Co., Ltd.                        Modulator   Patent   United        Selective      12/544,965      20-Aug-09     DIV of '245  Issued    7,960,412   14-Jun-11    Eisai R&D           States        Estrogen                                                                                    Manageme                        Receptor                                                                                    nt Co., Ltd.                        Modulator   Patent   United        Selective      13/048,391      15-Mar-11     DIV of '965  Issued    8,399,520   19-Mar-13    Eisai R&D           States        Estrogen                                                                                    Manageme                        Receptor                                                                                    nt Co., Ltd.                        Modulator                                   

 

                                                                                                                                                                 Application                                          Patent  Type     Country         Title                        Filing Date   Appl. Type    Status               Issue Date  Ownership                                            No.                                                No.   1901 EISAI COM   Patent    PCT          Selective     PCT/JP03/16      25-Dec-03        PCT       Expired      --           --       Eisai Co.,                         Estrogen           808                                                                          Ltd.                         Receptor                        Modulator                                                                                                                                                                                Application     Filing                            Patent     Issue   Type   Country        Title                                Appl. Type   Status                           Ownership                                         No.         Date                               No.       Date   1901 DUKE   Patent  United   Method of         61/971,627      3-28-   Provisional   Expired       --        --         Duke          States   Treating Cancer                   2017                                                   University                   Using Selective                   Estrogen                   Receptor                   Modulators  Patent  United   Method of         14/512,061     10-10-      Non-       Issued    9421264      8-23-       Duke          States   Treating Cancer                   2014    Provisional                          2016      University                   Using Selective                   Estrogen                   Receptor                   Modulators                                   

 

                                                                                                                                                             Application     Filing                            Patent     Issue   Type   Country        Title                                Appl. Type   Status                           Ownership                                         No.         Date                               No.       Date   1901 DUKE   Patent  United   Method of         62/129,379    3-6-2015  Provisional   Expired       --        --         Duke          States   Treating Cancer                                                                          University                   Using Selective                   Estrogen                   Receptor                   Modulators  Patent   PCT     Method of        PCT/US2015/      3-28-      PCT        Expired       --        --         Duke                   Treating Cancer     023216        2015                                                   University                   Using Selective                   Estrogen                   Receptor                   Modulators  Patent  United   Method of         15/214,187      7-19-      Non-       Issued    10071066     9-11-       Duke          States   Treating Cancer                   2016    Provisional                          2018      University                   Using Selective                   Estrogen                   Receptor                   Modulators  Patent  United   Method of         15/129,197    26-Sep-      Non-       Issued    10420734    24-Sep-      Duke          States   Treating Cancer                    16     Provisional                           19       University            NP     Using Selective                   Estrogen                   Receptor                   Modulators  Patent  Canada  Method of           2943611        3-28-     CA NP      Pending        --        --         Duke                   Treating Cancer                   2015                                                   University                   Using Selective                 National                   Estrogen                          Entry                   Receptor                          9-22-                  Modulators                        2016                                  

 

                                                                                                                                                             Application     Filing                            Patent     Issue   Type   Country        Title                                Appl. Type   Status                           Ownership                                         No.         Date                               No.       Date   1901 DUKE   Patent  Europe  Method of          15769394.6      3-28-     EP NP      Published      --        --         Duke                   Treating Cancer                   2015                                                   University                   Using Selective                 National                   Estrogen                          Entry                   Receptor                           10-                  Modulators                      27/2016 Patent  Europe   Method of          Proposed     Proposed    EP Div     Proposed       --        --         Duke            DIV    Treating Cancer                                                                          University                   Using Selective                   Estrogen                   Receptor                   Modulators  Patent  United   Method of         16/041,416    20-Jul-18    Non-     Abandoned       --        --         Duke          States   Treating Cancer                           Provisional                                    University          CON 2    Using Selective                   Estrogen                   Receptor                   Modulators  Patent  United   Method of         16/549,828    23-Aug-      Non-      Published      --        --         Duke          States   Treating Cancer                    19     Provisional                                    University          CON 3    Using Selective                   Estrogen                   Receptor                   Modulators  Patent  United   Method of         16/721,329    19-Dec-      Non-      Published      --        --         Duke          States   Treating Cancer                    19     Provisional                                    University          CON 4    Using Selective                   Estrogen                   Receptor                   Modulators

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]